Document:

Corporate Integrity Agreement

 Exhibit 10.2 
  
 CORPORATE INTEGRITY AGREEMENT 
 BETWEEN THE 
 OFFICE OF INSPECTOR
GENERAL 
 OF THE 
 DEPARTMENT OF HEALTH AND HUMAN SERVICES 
 AND 
 AMEDISYS, INC.

 AND 
 AMEDISYS SPECIALIZED MEDICAL SERVICES, INC. 
  

	I.	PREAMBLE 

  
 Amedisys, Inc. and Amedisys Specialized Medical Services, Inc. (“Specialized”) (collectively “Amedisys”) hereby enter into this
Corporate Integrity Agreement (“CIA”) with the Office of Inspector General (“OIG”) of the United States Department of Health and Human Services (“HHS”) to promote compliance by its officers, directors, employees,
contractors, and agents with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f)) (“Federal health care program requirements”).
Contemporaneously with this CIA, Amedisys is entering into a Settlement Agreement with the United States, and this CIA is incorporated by reference into the Settlement Agreement. 
  
 Prior to the execution of this CIA, Amedisys voluntarily established a Corporate Compliance Program (“CCP”) applicable to all its
subsidiaries inclusive of Specialized. The CCP, among other things, includes written policies and procedures, staff training, mechanisms for individuals to report incidents of noncompliance, and oversight by a Corporate Compliance Officer and
Corporate Compliance Committee. Amedisys and OIG agree that Amedisys has elements of its compliance program that may conform to the requirements of the CIA, and, if necessary, Amedisys may utilize and adapt any components of the CCP existing at the
time of the execution of the CIA as necessary to be in compliance with the obligations assumed by Amedisys pursuant to this CIA. To the extent that Amedisys’ existing CCP cannot be adapted or maintained to meet the obligations of this CIA,
Amedisys shall adopt new components to its CCP or create a new compliance program, so that Amedisys shall meet the obligations assumed pursuant to this CIA. 
  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	1	  	 

	II.	TERM AND SCOPE OF THE CIA 

  
 A. The period of the compliance obligations assumed by Amedisys under this
CIA shall be three years from the effective date of this CIA (“Effective Date”). The Effective Date shall be the date on which the final signatory of this CIA executes this CIA. Each one-year period, beginning with the one-year period
following the Effective Date, shall be referred to as a “Reporting Period.” 
  
 B. Sections VII, VIII, IX, X, and XI shall expire no later than 120 days after OIG’s receipt of: (1) Amedisys’ final annual report; or (2) any additional materials submitted by Amedisys pursuant to
OIG’s request, whichever is later. 
  
 C. The scope of this
CIA shall be governed by the following definitions: 
  

	 	1.	“Covered Persons” includes: 

  

	 	    	a. all officers, directors, and employees of Amedisys; and 

  

	 	    	b. all contractors and agents that provide patient care items or services or that perform billing or coding functions on behalf of Amedisys; 

  

	 	2.	“Relevant Covered Persons” includes all individuals who are directly involved in the billing or coding functions on behalf of Amedisys. 

  

	III.	CORPORATE INTEGRITY OBLIGATIONS 

  
 Amedisys shall maintain a Compliance Program that includes the following
elements: 
  
 A. Compliance Officer and Committee.

  
 1. Corporate Compliance Officer. Amedisys represents
that it has appointed a Corporate Compliance Officer. The Corporate Compliance Officer shall be responsible for developing and implementing policies, procedures, and practices designed to ensure compliance with the requirements set forth in this CIA
and with Federal health 
  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	2	  	 

 care program requirements. The Corporate Compliance Officer shall be a member of senior management of Amedisys, shall
make periodic (at least quarterly) reports regarding compliance matters directly to the Board of Directors of Amedisys, and shall be authorized to report on such matters to the Board of Directors at any time. The Corporate Compliance Officer
shall be responsible for monitoring the day-to-day compliance activities engaged in by Amedisys as well as for any reporting obligations created under this CIA. 
  

Amedisys shall report to OIG, in writing, any changes in the identity or position description of the Corporate Compliance Officer, or any actions or
changes that would affect the Corporate Compliance Officer’s ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change. 
  
 2. Compliance Committee. Amedisys shall maintain its existing Compliance Committee. The Compliance Committee shall
include the Corporate Compliance Officer and other members of senior management necessary to meet the requirements of this CIA (e.g., senior executives of relevant departments, such as billing, clinical, human resources, audit, and
operations). The Corporate Compliance Officer shall chair the Compliance Committee and the Committee shall support the Corporate Compliance Officer in fulfilling his/her responsibilities (e.g., shall assist in the analysis of the
organization’s risk areas and shall oversee monitoring of internal and external audits and investigations). 
  
 Amedisys shall report to OIG, in writing, any changes in the composition of the Compliance Committee, or any actions or changes that would affect the
Compliance Committee’s ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change. 
  
 B. Written Standards. 
  
 1. Code of Conduct. Amedisys shall maintain its written “Standards of Conduct.” The “Standards of Conduct” shall be distributed
to any Covered Persons within 90 days after the Effective Date. Amedisys shall make the promotion of, and adherence to, the “Standards of Conduct” an element in evaluating the performance of all employees. The “Standards of
Conduct” shall, at a minimum, set forth: 
  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	3	  	 

	 	    	a. Amedisys’ commitment to full compliance with all Federal health care program requirements, including its commitment to prepare and submit accurate claims consistent with
such requirements; 

  

	 	    	b. Amedisys’ requirement that all of its Covered Persons shall be expected to comply with all Federal health care program requirements and with Amedisys’ own Policies and
Procedures as implemented pursuant to Section III.B.2 (including the requirements of this CIA); 

  

	 	    	c. the requirement that all of Amedisys’ Covered Persons shall be expected to report to the Compliance Officer, or other appropriate individual designated by Amedisys,
suspected violations of any Federal health care program requirements or of Amedisys’ own Policies and Procedures; 

  

	 	    	d. the possible consequences to both Amedisys and Covered Persons of failure to comply with Federal health care program requirements and with Amedisys’ own Policies and
Procedures and the failure to report such noncompliance; and 

  

	 	    	e. the right of all individuals to use the Disclosure Program described in Section III.E, and Amedisys’ commitment to maintain confidentiality, as appropriate, and
nonretaliation with respect to such disclosures. 

  
 Within 90 days after the Effective Date, each Covered Person shall certify, in writing, that he or she has received, read, understood, and shall abide by Amedisys’ “Standards of Conduct.” New Covered Persons shall receive the
“Standards of Conduct” and shall complete the required certification within 30 days after becoming a Covered Person or within 90 days after the Effective Date, whichever is later. 
  
 Amedisys shall periodically review the “Standards of Conduct” to
determine if revisions are appropriate and shall make any necessary revisions based on such a review. Any such revised Code of Conduct shall be distributed within 30 days after finalizing such changes. Each Covered Person shall certify that he or
she has received, read, 
  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	4	  	 

 understood, and shall abide by the revised “Standards of Conduct” within 30 days after the distribution of such
revisions. 
  
 2. Policies and Procedures. Amedisys shall
maintain, and update as necessary, its written Policies and Procedures regarding the operation of Amedisys’ compliance program and its compliance with Federal health care program requirements. At a minimum, the Policies and Procedures shall:

  

	 	    	a. address the subjects relating to the Code of Conduct identified in Section III.B.1; and 

  

	 	    	b. require that all claims submitted for payment to any Federal health care program be properly supported by documentation, including, but not limited to: 

 
 i. documentation that the billed for services have been rendered;

  
 ii. documentation that patients who received services were
homebound; 
  
 iii. documentation supporting cost report
deductions; 
  
 iv. valid physician and patient signatures; and

  
 v. valid physician and nurses’ documentation regarding
medical necessity and reasonableness of care, plans of care and actual care provided. 
  
 Within 90 days after the Effective Date, the relevant portions of the Policies and Procedures shall be distributed to all individuals whose job functions relate to those Policies and Procedures. Appropriate and
knowledgeable staff shall be available to explain the Policies and Procedures. 
  
 At least annually (and more frequently, if appropriate), Amedisys shall assess and update as necessary the Policies and Procedures. Within 30 days after the effective date of any revisions, the relevant portions of
any such revised Policies and Procedures shall 
  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	5	  	 

 be distributed to all individuals whose job functions relate to those Policies and Procedures. 
  
 C. Training and Education. 
  
 1. General Training. Withing 120 days after the Effective Date,
Amedisys shall provide general compliance training to each Covered Person. This training, at a minimum, shall explain Amedisys’: 
  

	 	    	a. CIA requirements; and 

  

	 	    	b. Amedisys’ Compliance Program (including the Code of Conduct and the Policies and Procedures as they pertain to general compliance issues). 

  
 New Covered Persons shall receive the general training described above within
60 days after becoming a Covered Person or within 120 days after the Effective Date, whichever is later. After receiving the initial training described above, each Covered Person shall receive at least one hours of general compliance training
annually. 
  
 2. Specific Training. Within 120 days after
the Effective Date, each Relevant Covered Person shall receive at least two hours of specific training in addition to the general training required above. This specific training shall include a discussion of: 
  

	 	    	a. the submission of accurate claims for services rendered to Federal health care program beneficiaries; 

  

	 	    	b. policies, procedures, and other requirements applicable to the documentation of medical records; 

  

	 	    	c. the personal obligation of each individual involved in the claims submission process to ensure that such claims are accurate; 

  

	 	    	d. applicable reimbursement statutes, regulations, and program requirements and directives; 

  

	 	    	e. the legal sanctions for improper claims; and 

  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	6	  	 

	 	    	f. examples of proper and improper claims submission practices. 

  
 Persons providing the training shall be knowledgeable about the submission of claims for home health services. 
  
 Relevant Covered Persons shall receive this training within 30 days after the
beginning of their employment or becoming Relevant Covered Persons, or within 120 days after the Effective Date, whichever is later. An Amedisys employee who has completed the specific training shall review a new Relevant Covered Person’s work,
to the extent that the work relates to the delivery of patient care items or services preparation or to the submission of claims for reimbursement from any Federal health care program, until such time as the new Relevant Covered Person completes his
or her applicable training. 
  
 After receiving the initial
training described in this Section, each Relevant Covered Person shall receive at least two hours of specific training annually. Amedisys shall annually review the training, and, where appropriate, update the training to reflect changes in
Federal health care program requirements, any issues discovered during internal audits or IRO audits, and any other relevant information. 
  
 3. Certification. Each individual who is required to attend training shall certify, in writing, that he or she has received the required training.
The certification shall specify the type of training received and the date received. The Compliance Officer shall retain the certifications, along with all course materials. These shall be made available to OIG, upon request. 
  
 D. Review Procedures. 
  
 1. General Description. 
  

	 	    	a. Retention of Independent Review Organization. Within 90 days after the Effective Date, Amedisys shall retain an entity (or entities), such as an accounting, auditing, or
consulting firm (hereinafter “Independent Review Organization” or “IRO”), to perform reviews at Specialized to assist Amedisys in assessing and evaluating its billing and coding practices and certain other obligations pursuant to

  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	7	  	 

	 	    	this CIA and the Settlement Agreement. The OIG must approve Amedisys’ selection of each IRO prior to its engagement. Each IRO retained by Amedisys shall have expertise in the
billing, coding, reporting, and other requirements of the home health care industry pertaining to this CIA and in the general requirements of the Federal health care program(s) from which Specialized seeks reimbursement. Each IRO shall assess, along
with Amedisys, whether it can perform the IRO review in a professionally independent and/or objective fashion, as appropriate to the nature of the engagement, taking into account any other business relationships or engagements that may exist. The
IRO(s) review shall address and analyze Specialized’s billing and coding to the Federal health care programs (“Claims Review”) and shall analyze whether Amedisys sought payment for certain unallowable costs (“Unallowable Cost
Review”). 

  

	 	    	b. Frequency of Claims Review. The Claims Review shall be performed annually and shall cover each of the Reporting Periods. The IRO(s) shall perform all components of each
annual Claims Review. 

  

	 	    	c. Frequency of Unallowable Cost Review. The IRO shall perform the Unallowable Cost Review for the first Reporting Period.  

  

	 	    	d. Retention of Records. The IRO and Amedisys shall retain and make available to OIG, upon request, all work papers, supporting documentation, correspondence, and draft
reports (those exchanged between the IRO and Amedisys) related to the reviews. 

  
 2. Claims Review. The Claims Review shall include a Discovery Sample and, if necessary, a Full Sample. The applicable definitions, procedures, and reporting requirements are outlined in Appendix A to this CIA,
which is incorporated by reference. 
  

	 	    	a. Discovery Sample. The IRO shall randomly select and review a sample of 50 Units (each unit shall consist of the file of a unique Medicare beneficiary as it
represents a paid claim for services submitted under the Home Health Prospective Payment System). The claims shall be reviewed based on the supporting documentation 

  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	8	  	 

	 	    	available at Amedisys or under Amedisys’ control and applicable billing and coding regulations and guidance to determine whether the claim submitted was correctly coded,
submitted, and reimbursed. 

  
 i. If the Error
Rate (as defined in Appendix A) for the Discovery Sample is less than 5%, no additional sampling is required, nor is the Systems Review required. (Note: The threshold listed above does not imply that this is an acceptable error rate. Accordingly,
Amedisys should, as appropriate, further analyze any errors identified in the Discovery Sample. Amedisys recognizes that OIG or other HHS component, in its discretion and as authorized by statute, regulation, or other appropriate authority, may also
analyze or review Paid Claims included, or errors identified, in the Discovery Sample.) 
  
 ii. If the Discovery Sample indicates that the Error Rate is 5% or greater, the IRO shall perform a Full Sample and a Systems Review, as described below, for Amedisys’ Monroe, Louisiana facility. 
  

	 	    	b. Full Sample. If necessary, as determined by procedures set forth in Section III.D.2.a, the IRO shall perform an additional sample of Units for Specialized using commonly
accepted sampling methods and in accordance with Appendix A. The Full Sample shall be designed to (i) estimate the actual Overpayment in the population with a 90% confidence level and with a maximum relative precision of 25% of the point estimate;
and (ii) conform with the Centers for Medicare and Medicaid Services’ statistical sampling for overpayment estimation guidelines. The Paid Claims shall be reviewed based on supporting documentation available at Amedisys or under Amedisys’
control and applicable billing and coding regulations and guidance to determine whether the claim submitted was correctly coded, submitted, and reimbursed. For purposes of calculating the size of the Full Sample, the Discovery Sample may serve as
the probe sample, if statistically appropriate. Additionally, Amedisys may use the Items sampled as part of the Discovery Sample, and the corresponding findings for those 50 Units, as part of 

  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	9	  	 

	 	    	its Full Sample. OIG, in its full discretion, may refer the findings of the Full Sample (and any related workpapers) received from Amedisys to the appropriate Federal health care
program payor, including the Medicare contractor (e.g., carrier, fiscal intermediary, or DMERC), for appropriate follow-up by that payor. 

  

	 	    	c. Systems Review. If Amedisys’ Discovery Sample identifies an Error Rate of 5% or greater, Amedisys’ IRO shall also conduct a Systems Review. Specifically, for
each claim in the Discovery Sample and Full Sample that resulted in an Overpayment, the IRO shall perform a “walk through” of the system(s) and process(es) that generated the claim to identify any problems or weaknesses that may have
resulted in the identified Overpayments. The IRO shall provide its observations and recommendations on suggested improvements to the system(s) and process(es) that generated the claim. 

  

	 	    	d. Repayment of Identified Overpayments. In accordance with Section III.H.1, Amedisys shall repay any Overpayment(s) identified in the Discovery Sample or the Full Sample (if
applicable), regardless of the Error Rate, to the appropriate payor and in accordance with payor refund policies. Amedisys shall make available to OIG any and all documentation that reflects the refund of the Overpayment(s) to the payor.

  
 3. Claims Review Report. The IRO shall
prepare a report based upon the Claims Review performed (the “Claims Review Report”). Information to be included in the Claims Review Report is detailed in Appendix A. 
  
 4. Unallowable Cost Review. The IRO shall conduct a review of compliance with the unallowable cost provisions of the
Settlement Agreement for Amedisys’ Monroe, Louisiana facility. The IRO shall determine whether Amedisys has complied with its obligations not to charge to, or otherwise seek payment from, Federal or State payors for unallowable costs (as
defined in the Settlement Agreement) and its obligation to identify to applicable Federal or State payors any unallowable costs included in payments previously sought from the United States, or any State Medicaid program. This unallowable cost
analysis shall include, but not be limited to, payments sought in any cost reports, cost statements, information reports, or payment requests already submitted 
  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	10	  	 

 by Amedisys or any of its subsidiaries on behalf of its Monroe, Louisiana facility. To the extent that such cost reports,
cost statements, information reports, or payment requests, even if already settled, have been adjusted to account for the effect of the inclusion of the unallowable costs, the IRO shall determine if such adjustments were proper. In making this
determination, the IRO may need to review cost reports and/or financial statements from the year in which the Settlement Agreement was executed, as well as from previous years. 
  
 5. Unallowable Cost Review Report. The IRO shall prepare a report based upon the Unallowable Cost Review performed.
The Unallowable Cost Review Report shall include the IRO’s findings and supporting rationale regarding the Unallowable Costs Review and whether Amedisys has complied with its obligation not to charge to, or otherwise seek payment from, Federal
or State payors for unallowable costs (as defined in the Settlement Agreement) and its obligation to identify to applicable Federal or State payors any unallowable costs included in payments previously sought from such payor. 
  
 6. Validation Review. In the event OIG has reason to believe that: (a)
Specialized’s Claims Review or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to
determine whether the Claims Review or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (“Validation Review”). 
  
 Prior to initiating a Validation Review, OIG shall notify Amedisys of its
intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Amedisys may request a meeting with OIG to discuss the results of any Claims Review or Unallowable Cost Review
submissions or findings; present any additional or relevant information to clarify the results of the Claims Review or Unallowable Cost Review or to correct the inaccuracy of the Claims Review; or propose alternatives to the proposed Validation
Review. Amedisys shall provide any additional information as may be requested by OIG under this Section in an expedited manner. OIG will attempt in good faith to resolve any Claims Review or Unallowable Cost Review with Amedisys prior to conducting
a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG. Amedisys shall pay for the reasonable cost of any such review performed by OIG or any of its
designated agents so 
  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	11	  	 

 long as it is initiated within one year after Amedisys’ final submission (as described in Section II) is received by
OIG. 
  
 7. Independence/Objectivity Certification. The IRO
shall include in its report(s) to Amedisys a certification or sworn affidavit that it has evaluated its professional independence and/or objectivity, as appropriate to the nature of the engagement, with regard to the Claims Review or Unallowable
Cost Review and that it has concluded that it is, in fact, independent and/or objective. 
  
 8. Internal Billing Review Option. Subject to approval from OIG and subject to the conditions set forth below, after the second complete Claims Review period in which the IRO has performed the Claims Review as
required in section III.D.2, Amedisys may, at its option, conduct an internal review of its billings to the Federal health care programs for Claims Review the third Reporting Period in lieu of having the IRO conduct the Claims Review. This internal
review shall comply with all of the requirements outlined herein and in section III.D.2 above. 
  
 Prior to conducting its internal billing review, Amedisys agrees: i) to develop and adopt a written formal internal audit work plan consistent with the terms of this CIA; ii) to devote sufficient resources and staff
to enable it to accomplish an internal billing review based on its internal work plan; and iii) that its internal billing review staff shall at all times include persons qualified and experienced in accepted auditing and control processes, who
possess expertise in billing, coding and Medicare program requirements. In addition, Amedisys agrees that its internal billing review staff shall not include persons who were involved in the submission of bills or claims to the Medicare programs
during the period to be audited and shall not include persons who are presently involved in such submissions. 
  
 If, in its sole discretion, OIG determines that such internal review satisfactorily establishes the adequacy of Amedisys’ billing and compliance
practices pursuant to this CIA, the OIG will allow Amedisys to perform an internal review in lieu of the IRO conducting the Claims review for the third Reporting Period. Consistent with the requirements of section III.D.2, the internal billing
review shall include a Claims Review and the required respective reports of Amedisys’ findings. 
  
 In the event Amedisys is unable to satisfactorily implement an audit work plan, devote sufficient resources and appropriate qualified staff, or conduct a
satisfactory 

  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	12	  	 

 
internal review, Amedisys agrees, at OIG’s discretion, to engage the IRO to complete Claims Review during the third Reporting Period. To the extent that
OIG permits Amedisys to perform internal billing reviews, Amedisys shall submit all the information required in section III.D.2 as well as the results of the IRO’s verification. If Amedisys decides not to exercise its internal review option,
the requirements of the IRO Claims Review shall remain in effect for the term of this CIA. 
  
 E. Disclosure Program. 
  
 Amedisys shall maintain its existing Disclosure Program, including its toll-free compliance telephone line to enable individuals to disclose, to the Corporate Compliance Officer or some other person who is not in the disclosing
individual’s chain of command, any identified issues or questions associated with Amedisys’ policies, conduct, practices, or procedures with respect to a Federal health care program, believed by the individual to be a potential violation
of criminal, civil, or administrative law. Amedisys shall appropriately publicize the existence of the disclosure mechanism (e.g., via periodic e-mails to employees or by posting the information in prominent common areas) to all Covered
Persons. 
  
 The Disclosure Program shall emphasize Amedisys’
nonretribution, nonretaliation policy, and shall include a reporting mechanism for anonymous communications for which appropriate confidentiality shall be maintained. Upon receipt of a disclosure, the Corporate Compliance Officer (or designee) shall
gather all relevant information from the disclosing individual. The Corporate Compliance Officer (or designee) shall make a preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that he or she has obtained all
of the information necessary to determine whether a further review should be conducted. For any disclosure that is sufficiently specific so that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and
(2) provides an opportunity for taking corrective action, Amedisys shall conduct an internal review of the allegations set forth in such a disclosure and ensure that proper follow-up is conducted. 
  
 The Compliance Officer (or designee) shall maintain a disclosure log, which
shall include a record and summary of each disclosure received (whether anonymous or not), the status of the respective internal reviews, and any corrective action taken in response to the internal reviews. The disclosure log shall be available to
OIG, upon request. 

  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	13	  	 

 F. Ineligible Persons. 
  

1. Definition. For purposes of this CIA, an “Ineligible Person” shall be an individual or entity who: (a) is currently excluded,
debarred, suspended, or otherwise ineligible to participate in the Federal health care programs or in Federal procurement or nonprocurement programs; or (b) has been convicted of a criminal offense that falls within the ambit of 42 U.S.C. §
1320a-7(a), but has not yet been excluded, debarred, suspended, or otherwise declared ineligible. 
  
 2. Screening Requirements. Amedisys shall ensure that all owners, officers, directors, employees, contractors and agents of Amedisys are not
Ineligible Persons. To ensure that such persons are not Ineligible Persons, Amedisys shall screen such persons prior to engaging their services by: (a) requiring such persons to disclose whether they are Ineligible Persons; and (b) appropriately
querying the General Services Administration’s List of Parties Excluded from Federal Programs (available through the Internet at http://epls.arnet.gov) and the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at
http://oig.hhs.gov) (these lists shall hereinafter be referred to as the “Exclusion Lists”). Nothing in this Section affects the responsibility of (or liability for) Amedisys to refrain from billing Federal health care programs for
services of the Ineligible Person. 
  
 3. Review and Removal
Requirement. Within 120 days after the Effective Date, Amedisys shall review its list of the persons identified in Section F.2 against the Exclusion Lists. Thereafter, Amedisys shall review its list of such persons against the Exclusion Lists
annually. In addition, Amedisys shall require such persons to disclose immediately any debarment, exclusion, suspension, or other event that makes such person an Ineligible Person. 
  
 If Amedisys has actual notice that such person has become an Ineligible Person, Amedisys shall remove such person from
responsibility for, or involvement with, Amedisys’ business operations related to the Federal health care programs and shall remove such person from any position for which the person’s compensation or the items or services rendered,
ordered, or prescribed by the person are paid in whole or part, directly or indirectly, by Federal health care programs or otherwise with Federal funds at least until such time as the person is reinstated into participation in the Federal health
care programs. 
  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	14	  	 

 4. Pending Charges and Proposed Exclusions. If Amedisys has actual notice that a person identified
in Section F.2 is charged with a criminal offense related to any Federal health care program, or is proposed for exclusion during his or her employment, involvement, or contract term, Amedisys shall take all appropriate actions to ensure that the
responsibilities of that person have not and shall not adversely affect the quality of care rendered to any beneficiary, patient, or resident, or the accuracy of any claims submitted to any Federal health care program. 
  
 G. Notification of Government Investigation or Legal Proceedings.

  
 Within 30 days after discovery, Amedisys shall notify OIG, in
writing, of any ongoing investigation known to Amedisys or legal proceeding conducted or brought by a governmental entity or its agents involving an allegation that Amedisys has committed a crime or has engaged in fraudulent activities. This
notification shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding. Amedisys shall also provide written notice to OIG within 30 days after the
resolution of the matter, and shall provide OIG with a description of the findings and/or results of the proceedings, if any. 
  
 H. Reporting. 
  
 1. Overpayments 
  

	 	    	a. Definition of Overpayments. For purposes of this CIA, an “Overpayment” shall mean the amount of money Amedisys has received in excess of the amount due
and payable under any Federal health care program requirements. 

  

	 	    	 b. Reporting of Overpayments. If, at any time, Amedisys identifies or learns of any Overpayment, Amedisys shall notify the payor (e.g., Medicare
fiscal intermediary or carrier) within 30 days after identification of the Overpayment and take remedial steps within 60 days after identification (or such additional time as may be agreed to by the payor) to correct the problem, including
preventing the underlying problem and the Overpayment from recurring. Also, within 30 days after identification of the Overpayment, Amedisys shall repay the Overpayment to the appropriate payor to the extent 

  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	15	  	 

	 	    	such Overpayment has been quantified. If not yet quantified, within 30 days after identification, Amedisys shall notify the payor of its efforts to quantify the Overpayment amount
along with a schedule of when such work is expected to be completed. Notification and repayment to the payor shall be done in accordance with the payor’s policies, and for Medicare contractors, shall include the information contained on the
Overpayment Refund Form, provided as Appendix B to this CIA. Notwithstanding the above, notification and repayment of any Overpayment amount that routinely is reconciled or adjusted pursuant to policies and procedures established by the payor should
be handled in accordance with such policies and procedures inclusive of repayment plans. 

  
 2. Material Deficiencies. 
  

	 	    	a. Definition of Material Deficiency. For purposes of this CIA, a “Material Deficiency” means anything that involves: 

  
 i. a substantial Overpayment; or 
  
 ii. a matter that a reasonable person would consider a probable violation
of criminal, civil, or administrative laws applicable to any Federal health care program for which penalties or exclusion may be authorized. 
  

	 	    	A Material Deficiency may be the result of an isolated event or a series of occurrences. 

  

	 	    	b. Reporting of Material Deficiencies. If Amedisys determines through any means that there is a Material Deficiency, Amedisys shall notify OIG, in writing, within 30 days
after making the determination that the Material Deficiency exists. The report to OIG shall include the following information: 

  
 i. If the Material Deficiency results in an Overpayment, the report to OIG shall be made at the same time as the notification to the payor required in
Section III.H.1, and shall 
  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	16	  	 

 include all of the information on the Overpayment Refund Form, as well as: 
  
 (A) the payor’s name, address, and contact person to whom the
Overpayment was sent; and 
  
 (B) the date of the check and
identification number (or electronic transaction number) by which the Overpayment was repaid/refunded; 
  
 ii. a complete description of the Material Deficiency, including the relevant facts, persons involved, and legal and Federal health care program
authorities implicated; 
  
 iii. a description of Amedisys’
actions taken to correct the Material Deficiency; and 
  
 iv.
any further steps Amedisys plans to take to address the Material Deficiency and prevent it from recurring. 
  

	IV.	NEW BUSINESS UNITS OR LOCATIONS 

  
 In the event that, after the Effective Date, Amedisys changes locations or
sells, closes, purchases, or establishes a new business unit or location related to the furnishing of items or services that may be reimbursed by Federal health care programs, Amedisys shall notify OIG of this fact as soon as possible, but no later
than within 30 days after the date of change of location, sale, closure, purchase, or establishment. This notification shall include the address of the new business unit or location, phone number, fax number, Medicare provider number (if any), and
the corresponding contractor’s name and address that has issued each Medicare provider number. All Covered Persons at each such business unit or location shall be subject to the applicable requirements in this CIA (e.g., completing
certifications and undergoing training). 
  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	17	  	 

	V.	IMPLEMENTATION AND ANNUAL REPORTS 

  
 A. Implementation Report. Within 150 days after the Effective Date,
Amedisys shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA. This Implementation Report shall include: 
  
 1. the name, address, phone number, and position description of the Corporate Compliance Officer required by Section III.A,
and a summary of other noncompliance job responsibilities the Corporate Compliance Officer may have; 
  
 2. the names and positions of the members of the Compliance Committee required by Section III.A; 
  
 3. a copy of Amedisys’ Code of Conduct required by Section III.B.1;

  
 4. a copy of all Policies and Procedures required by Section
III.B.2; 
  
 5. a copy of all training materials used for the
training required by Section III.C, a description of such training, including a description of the targeted audiences, length of sessions, which sessions were mandatory and for whom, percentage of attendance, and a schedule of when the training
sessions were held; 
  
 6. a certification by the Compliance
Officer that: 
  

	 	    	a. the Policies and Procedures required by Section III.B have been developed, are being implemented, and have been distributed to all appropriate Covered Persons;

  

	 	    	b. all Covered Persons have completed the Code of Conduct certification required by Section III.B.1; and 

  

	 	    	c. all Covered Persons have completed the applicable training and executed the certification(s) required by Section III.C. 

  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	18	  	 

 The documentation supporting this certification shall be available to OIG, upon request. 
  
 7. a description of the Disclosure Program required by Section III.E;

  
 8. the identity of the IRO(s), a summary/description of all
engagements between Amedisys and the IRO, including, but not limited to, any outside financial audits or reimbursement consulting, and the proposed start and completion dates of the Claims Review, Unallowable Cost Review, or Systems Review;

  
 9. a certification from the IRO regarding its professional
independence and/or objectivity with respect to Amedisys; 
  
 10.
a summary of personnel actions (other than hiring) taken pursuant to Section III.F.; 
  
 11. a list of all of Amedisys’ locations (including locations and mailing addresses), the corresponding name under which each location is doing business, the corresponding phone numbers and fax numbers, each
location’s Medicare provider identification number(s), and the name and address of the Medicare contractor to which Amedisys currently submits claims; 
  
 12. a description of Amedisys’ corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective
lines of business; and 
  
 13. the certification required by
Section V.C. 
  
 B. Annual Reports. Amedisys shall submit
to OIG Annual Reports with respect to the status of, and findings regarding, Amedisys’ compliance activities for each of the three Reporting Periods. 
  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	19	  	 

 Each Annual Report shall include: 
  
 1. any change in the identity, position description, or other noncompliance job responsibilities of the Compliance Officer
and any change in the membership of the Compliance Committee described in Section III.A; 
  
 2. a certification by the Corporate Compliance Officer that: 
  

	 	    	a. all Covered Persons have completed any Code of Conduct certifications required by Section III.B.1; 

  

	 	    	b. all Covered Persons have completed the applicable training and executed the certification(s) required by Section III.C; 

  

	 	    	c. Amedisys has complied with its obligations under the Settlement Agreement: (i) not to resubmit to any Federal health care program payors any previously denied claims related to
the Covered Conduct addressed in the Settlement Agreement, and not to appeal any such denials of claims; (ii) not to charge to or otherwise seek payment from Federal or State payors for unallowable costs (as defined in the Settlement Agreement); and
(iii) to identify and adjust any past charges or claims for unallowable costs; 

  
 The documentation supporting this certification shall be available to OIG, upon request. 
  
 3. a summary of any significant changes or amendments to the Policies and Procedures required by Section III.B and the reasons for such changes
(e.g., change in contractor policy) and copies of any compliance-related Policies and Procedures; 
  
 4. a copy of all training materials used for the training required by Section III.C (to the extent it has not already been provided as part of the
Implementation Report), a description of such training conducted during the Reporting Period, including a description of the targeted audiences, length of sessions, which sessions were mandatory and for whom, percentage of attendance, and a schedule
of when the training sessions were held; 
  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	20	  	 

 5. a complete copy of all reports prepared pursuant to the IRO or internal claims review, unallowable
cost review, and systems review, if applicable, including a copy of the methodology used, along with a copy of the IRO’s engagement letter; 
  
 6. Amedisys and/or Specialized’s response and corrective action plan(s) related to any issues raised by the IRO(s); 
  
 7. a revised summary/description of all engagements between Amedisys and the
IRO, including, but not limited to, any outside financial audits, compliance program engagements, or reimbursement consulting, if different from what was submitted as part of the Implementation Report; 
  
 8. a certification from the IRO regarding its professional independence
and/or objectivity with respect to Amedisys; 
  
 9. a summary of
Material Deficiencies (as defined in Section III.H) identified during the Reporting Period and the status of any corrective and preventative action relating to all such Material Deficiencies; 
  
 10. a report of the aggregate Overpayments that have been returned to the
Federal health care programs. Overpayment amounts that are routinely reconciled or adjusted pursuant to policies and procedures established by the payor do not need to be included in this aggregate Overpayment report; 
  
 11. a summary of the disclosures in the disclosure log required by Section
III.E that: (a) relate to Federal health care programs; or (b) allege abuse or neglect of patients; 
  
 12. a description of any personnel actions (other than hiring) taken by Amedisys as a result of the obligations in Section III.F, and the name, title, and
responsibilities of any person who is determined to be an Ineligible Person under Section III.F., and the actions taken in response to the obligations set forth in that Section; 
  
 13. a summary describing any ongoing investigation or legal proceeding required to have been reported pursuant to Section
III.G. The summary 

  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	21	  	 

 
shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal
proceeding; 
  
 14. a description of all changes to the most
recently provided list (as updated) of Amedisys’ locations (including addresses) as required by Section V.A.11, the corresponding name under which each location is doing business, the corresponding phone numbers and fax numbers, each
location’s Medicare provider identification number(s), and the contractor name and address that issued each Medicare provider number; and 
  
 15. the certification required by Section V.C. 
  
 The first Annual Report shall be received by OIG no later than 60 days after the end of the first Reporting Period. Subsequent Annual Reports shall be
received by OIG no later than the anniversary date of the due date of the first Annual Report. 
  
 C. Certifications. The Implementation Report and Annual Reports shall include a certification by the Corporate Compliance Officer that: (1) to the best of his or her knowledge, except as otherwise described in
the applicable report, Amedisys is in compliance with all of the requirements of this CIA; and (2) the Corporate Compliance Officer has reviewed the Report and has made reasonable inquiry regarding its content and believes that the information is
accurate and truthful. 
  
 D. Designation of Information.
Amedisys shall clearly identify any portions of its submissions that it believes are trade secrets, or information that is commercial or financial and privileged or confidential, and therefore potentially exempt from disclosure under the Freedom of
Information Act (“FOIA”), 5 U.S.C. § 552. Amedisys shall refrain from identifying any information as exempt from disclosure if that information does not meet the criteria for exemption from disclosure under FOIA. 
  

	VI.	NOTIFICATIONS AND SUBMISSION OF REPORTS 

  
 Unless otherwise stated in writing after the Effective Date, all
notifications and reports required under this CIA shall be submitted to the following entities: 
  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	22	  	 

	OIG:	Administrative and Civil Remedies Branch 

	    	Office of Counsel to the Inspector General 

	    	Office of Inspector General 

	    	U.S. Department of Health and Human Services 

	    	Cohen Building, Room 5527 

	    	330 Independence Avenue, S.W. 

	    	Washington, D.C. 20201 

	    	Telephone: 202.619.2078 

	    	Facsimile: 202.205.0604 

  

	Amedisys:	Corporate Compliance Officer 

	    	Amedisys, Inc. 

	    	11100 Mead Road, Suite 300 

	    	Baton Rouge, LA 70816 

	    	Telephone: 225-292-2031 

	    	Facsimile: 225-295-9624 

  
 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other
means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. 
  

	VII.	OIG INSPECTION, AUDIT AND REVIEW RIGHTS 

  
 In addition to any other rights OIG may have by statute, regulation, or
contract, OIG or its duly authorized representative(s) may examine or request copies of Amedisys’ books, records, and other documents and supporting materials and/or conduct on-site reviews of any of Amedisys’ locations for the purpose of
verifying and evaluating: (a) Amedisys’ compliance with the terms of this CIA; and (b) Amedisys’ compliance with the requirements of the Federal health care programs in which it participates. This CIA does not require Amedisys to provide
to the OIG or its duly authorized representative(s) or agents any legally-privileged documents nor shall this CIA be construed as constituting a present or future waiver by Amedisys of any legal privileges. Notwithstanding that fact, the existence
of any such privilege shall not be used by Amedisys to avoid its obligations to comply with the provisions of this CIA. The documentation described above shall be made available by Amedisys to OIG or its duly authorized representative(s) at all
reasonable times for inspection, audit, or reproduction. Furthermore, for purposes of this 
  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	23	  	 

 provision, OIG or its duly authorized representative(s) may interview any of Amedisys’ employees, contractors, or
agents who consent to be interviewed at the individual’s place of business during normal business hours or at such other place and time as may be mutually agreed upon between the individual and OIG. Prior to exercising its rights under this
Section, OIG shall notify the Corporate Compliance Officer. Amedisys shall assist OIG or its duly authorized representative(s) in contacting and arranging interviews with such individuals upon OIG’s request. Amedisys’ employees may elect
to be interviewed with or without a representative of Amedisys present. 
  

	VIII.	DOCUMENT AND RECORD RETENTION 

  
 Amedisys shall maintain for inspection all documents and records relating to
reimbursement from the Federal health care programs, or to compliance with this CIA, for four years (or longer if otherwise required by law). 
  

	IX.	DISCLOSURES 

  
 Consistent with HHS’s FOIA procedures, set forth in 45 C.F.R. Part 5, OIG shall make a reasonable effort to notify Amedisys prior to any release by
OIG of information submitted by Amedisys pursuant to its obligations under this CIA and identified upon submission by Amedisys as trade secrets, or information that is commercial or financial and privileged or confidential, under the FOIA rules.
With respect to such releases, Amedisys shall have the rights set forth at 45 C.F.R. § 5.65(d). 
  

	X.	BREACH AND DEFAULT PROVISIONS 

  
 Amedisys is expected to fully and timely comply with all of its CIA
obligations. 
  
 A. Stipulated Penalties for Failure to Comply
with Certain Obligations. As a contractual remedy, Amedisys and OIG hereby agree that failure to comply with certain obligations set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as
“Stipulated Penalties”) in accordance with the following provisions. 
  
 1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Amedisys fails to have in place any of the obligations described in Section III:

  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	24	  	 

	 	    	a. a Compliance Officer; 

  

	 	    	b. a Compliance Committee;; 

  

	 	    	c. a written Code of Conduct; 

  

	 	    	d. written Policies and Procedures; 

  

	 	    	e. a requirement that Covered Persons be trained; and 

  

	 	    	f. a Disclosure Program. 

  
 2. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Amedisys fails to retain
an IRO, as required in Section III.D. 
  
 3. A Stipulated Penalty
of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Amedisys fails to meet any of the deadlines for the submission of the Implementation Report or the Annual Reports to OIG. 
  
 4. A Stipulated Penalty of $2,000 (which shall begin to accrue on the date
the failure to comply began) for each day Amedisys employs or contracts with an Ineligible Person and that person: (a) has responsibility for, or involvement with, Amedisys’ business operations related to the Federal health care programs; or
(b) is in a position for which the person’s salary or the items or services rendered, ordered, or prescribed by the person are paid in whole or part, directly or indirectly, by Federal health care programs or otherwise with Federal funds (the
Stipulated Penalty described in this Subsection shall not be demanded for any time period during which Amedisys can demonstrate that it did not discover the person’s exclusion or other ineligibility after making a reasonable inquiry (as
described in Section III.F) as to the status of the person). 
  
 5. A Stipulated Penalty of $1,500 for each day Amedisys fails to grant access to the information or documentation as required in Section VII. (This Stipulated Penalty shall begin to accrue on the date Amedisys fails to grant access.)

  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	25	  	 

 6. A Stipulated Penalty of $5,000 for each false certification submitted by or on behalf of Amedisys as
part of its Implementation Report, Annual Report, additional documentation to a report (as requested by the OIG) or otherwise required by this CIA. 
  
 7. A Stipulated Penalty of $1,000 for each day Amedisys fails to comply fully and adequately with any obligation of this CIA. In its notice to Amedisys,
OIG shall state the specific grounds for its determination that Amedisys has failed to comply fully and adequately with the CIA obligation(s) at issue and steps Amedisys shall take to comply with the CIA. (This Stipulated Penalty shall begin to
accrue 10 days after Amedisys receives notice from OIG of the failure to comply.) A Stipulated Penalty as described in this Subsection shall not be demanded for any violation for which OIG has sought a Stipulated Penalty under Subsections 1-6 of
this Section. 
  
 B. Timely Written Requests for
Extensions. Amedisys may, in advance of the due date, submit a timely written request for an extension of time to perform any act or file any notification or report required by this CIA. Notwithstanding any other provision in this Section, if
OIG grants the timely written request with respect to an act, notification, or report, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until one day after Amedisys fails to meet the
revised deadline set by OIG. Notwithstanding any other provision in this Section, if OIG denies such a timely written request, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until
three business days after Amedisys receives OIG’s written denial of such request or the original due date, whichever is later. A “timely written request” is defined as a request in writing received by OIG at least five business days
prior to the date by which any act is due to be performed or any notification or report is due to be filed. 
  
 C. Payment of Stipulated Penalties. 
  
 1. Demand Letter. Upon a finding that Amedisys has failed to comply with any of the obligations described in Section X.A and after determining that
Stipulated Penalties are appropriate, OIG shall notify Amedisys of: (a) Amedisys’ failure to comply; and (b) OIG’s exercise of its contractual right to demand payment of the Stipulated Penalties (this notification is hereinafter referred
to as the “Demand Letter”). 
  
 2. Response to Demand
Letter. Within 10 days after the receipt of the Demand Letter, Amedisys shall either: (a) cure the breach to OIG’s satisfaction and pay 
  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	26	  	 

 the applicable Stipulated Penalties; or (b) request a hearing before an HHS administrative law judge (“ALJ”) to
dispute OIG’s determination of noncompliance, pursuant to the agreed upon provisions set forth below in Section X.E. In the event Amedisys elects to request an ALJ hearing, the Stipulated Penalties shall continue to accrue until Amedisys cures,
to OIG’s satisfaction, the alleged breach in dispute. Failure to respond to the Demand Letter in one of these two manners within the allowed time period shall be considered a material breach of this CIA and shall be grounds for exclusion under
Section X.D. 
  
 3. Form of Payment. Payment of the
Stipulated Penalties shall be made by certified or cashier’s check, payable to: “Secretary of the Department of Health and Human Services,” and submitted to OIG at the address set forth in Section VI. 
  
 4. Independence from Material Breach Determination. Except as set
forth in Section X.D.1.c, these provisions for payment of Stipulated Penalties shall not affect or otherwise set a standard for OIG’s decision that Amedisys has materially breached this CIA, which decision shall be made at OIG’s discretion
and shall be governed by the provisions in Section X.D, below. 
  
 D. Exclusion for Material Breach of this CIA. 
  
 1. Definition of Material Breach. A material breach of this CIA means: 
  

	 	    	a. a failure by Amedisys to report a Material Deficiency, take corrective action, and make the appropriate refunds, as required in Section III.H; 

  

	 	    	b. a repeated or flagrant violation of the obligations under this CIA, including, but not limited to, the obligations addressed in Section X.A; 

  

	 	    	c. a failure to respond to a Demand Letter concerning the payment of Stipulated Penalties in accordance with Section X.C; or 

  

	 	    	d. a failure to retain and use an IRO in accordance with Section III.D. 

  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	27	  	 

 2. Notice of Material Breach and Intent to Exclude. The parties agree that a material breach of
this CIA by Amedisys constitutes an independent basis for Amedisys’ exclusion from participation in the Federal health care programs. Upon a determination by OIG that Amedisys has materially breached this CIA and that exclusion is the
appropriate remedy, OIG shall notify Amedisys of: (a) Amedisys’ material breach; and (b) OIG’s intent to exercise its contractual right to impose exclusion (this notification is hereinafter referred to as the “Notice of Material
Breach and Intent to Exclude”). 
  
 3. Opportunity to
Cure. Amedisys shall have 30 days from the date of receipt of the Notice of Material Breach and Intent to Exclude to demonstrate to OIG’s satisfaction that: 
  

	 	    	a. Amedisys is in compliance with the obligations of the CIA cited by OIG as being the basis for the material breach; 

  

	 	    	b. the alleged material breach has been cured; or 

  

	 	    	c. the alleged material breach cannot be cured within the 30-day period, but that: (i) Amedisys has begun to take action to cure the material breach; (ii) Amedisys is pursuing such
action with due diligence; and (iii) Amedisys has provided to OIG a reasonable timetable for curing the material breach. 

  
 4. Exclusion Letter. If, at the conclusion of the 30-day period, Amedisys fails to satisfy the requirements of Section X.D.3, OIG may exclude
Amedisys from participation in the Federal health care programs. OIG shall notify Amedisys in writing of its determination to exclude Amedisys (this letter shall be referred to hereinafter as the “Exclusion Letter”). Subject to the Dispute
Resolution provisions in Section X.E, below, the exclusion shall go into effect 30 days after the date of the Exclusion Letter. The exclusion shall have national effect and shall also apply to all other Federal procurement and nonprocurement
programs. Reinstatement to program participation is not automatic. After the end of the period of exclusion, Amedisys may apply for reinstatement by submitting a written request for reinstatement in accordance with the provisions at 42 C.F.R.
§§ 1001.3001-.3004. 
  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	28	  	 

 E. Dispute Resolution 
  
 1. Review Rights. Upon OIG’s delivery to Amedisys of its Demand Letter or of its Exclusion Letter, and as an
agreed-upon contractual remedy for the resolution of disputes arising under this CIA, Amedisys shall be afforded certain review rights comparable to the ones that are provided in 42 U.S.C. § 1320a-7(f) and 42 C.F.R. Part 1005 as if they applied
to the Stipulated Penalties or exclusion sought pursuant to this CIA. Specifically, OIG’s determination to demand payment of Stipulated Penalties or to seek exclusion shall be subject to review by an HHS ALJ and, in the event of an appeal, the
HHS Departmental Appeals Board (“DAB”), in a manner consistent with the provisions in 42 C.F.R. §§ 1005.2-1005.21. Notwithstanding the language in 42 C.F.R. § 1005.2(c), the request for a hearing involving Stipulated
Penalties shall be made within 10 days after receipt of the Demand Letter and the request for a hearing involving exclusion shall be made within 25 days after receipt of the Exclusion Letter. 
  
 2. Stipulated Penalties Review. Notwithstanding any provision of Title
42 of the United States Code or Chapter 42 of the Code of Federal Regulations, the only issues in a proceeding for Stipulated Penalties under this CIA shall be: (a) whether Amedisys was in full and timely compliance with the obligations of this CIA
for which OIG demands payment; and (b) the period of noncompliance. Amedisys shall have the burden of proving its full and timely compliance and the steps taken to cure the noncompliance, if any. OIG shall not have the right to appeal to the DAB an
adverse ALJ decision related to Stipulated Penalties. If the ALJ agrees with OIG with regard to a finding of a breach of this CIA and orders Amedisys to pay Stipulated Penalties, such Stipulated Penalties shall become due and payable 20 days after
the ALJ issues such a decision unless Amedisys requests review of the ALJ decision by the DAB. If the ALJ decision is properly appealed to the DAB and the DAB upholds the determination of OIG, the Stipulated Penalties shall become due and payable 20
days after the DAB issues its decision. 
  
 3. Exclusion
Review. Notwithstanding any provision of Title 42 of the United States Code or Chapter 42 of the Code of Federal Regulations, the only issues in a proceeding for exclusion based on a material breach of this CIA shall be: 
  

	 	    	a. whether Amedisys was in material breach of this CIA; 

  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	29	  	 

	 	    	b. whether such breach was continuing on the date of the Exclusion Letter; and 

  

	 	    	c. whether the alleged material breach could not have been cured within the 30-day period, but that: (i) Amedisys had begun to take action to cure the material breach within that
period; (ii) Amedisys has pursued and is pursuing such action with due diligence; and (iii) Amedisys provided to OIG within that period a reasonable timetable for curing the material breach and Amedisys has followed the timetable.

  
 For purposes of the exclusion herein, exclusion shall take
effect only after an ALJ decision favorable to OIG, or, if the ALJ rules for Amedisys, only after a DAB decision in favor of OIG. Amedisys’ election of its contractual right to appeal to the DAB shall not abrogate OIG’s authority to
exclude Amedisys upon the issuance of an ALJ’s decision in favor of OIG. If the ALJ sustains the determination of OIG and determines that exclusion is authorized, such exclusion shall take effect 20 days after the ALJ issues such a decision,
notwithstanding that Amedisys may request review of the ALJ decision by the DAB. If the DAB finds in favor of OIG after an ALJ decision adverse to OIG, the exclusion shall take effect 20 days after the DAB decision. Amedisys shall waive its right to
any notice of such an exclusion if a decision upholding the exclusion is rendered by the ALJ or DAB. If the DAB finds in favor of Amedisys, Amedisys shall be reinstated effective on the date of the original exclusion. 
  

	XI.	EFFECTIVE AND BINDING AGREEMENT 

  
 Consistent with the provisions in the Settlement Agreement pursuant to which
this CIA is entered, and into which this CIA is incorporated, Amedisys and OIG agree as follows: 
  
 A. This CIA in its entirety shall be binding on the successors, assigns, and transferees of Amedisys; 
  
 B. The specific obligations expressly imposed herein on Amedisys shall be
binding on the successors, assigns and transferees of Amedisys. 
  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	30	  	 

 C. This CIA shall become final and binding on the date the final signature is obtained on the CIA;

  
 D. Any modifications to this CIA shall be made with the prior
written consent of the parties to this CIA; 
  
 E. OIG may agree
to a suspension of Amedisys’ obligations under the CIA in the event of Amedisys’ cessation of participation in Federal health care programs. If Amedisys withdraws from participation in Federal health care programs and is relieved of its
CIA obligations by OIG, Amedisys shall notify OIG at least 30 days in advance of Amedisys’ intent to reapply as a participating provider or supplier with the Federal health care programs. Upon receipt of such notification, OIG shall evaluate
whether the CIA should be reactivated or modified. 
  
 F. The
undersigned Amedisys signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatory represents that he is signing this CIA in his official capacity and that he is authorized to execute this CIA.

  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	31	  	 

 ON BEHALF OF AMEDISYS, INC.
AND 
 AMEDISYS SPECIALIZED MEDICAL SERVICES,
INC. 
  

	  
 /s/ William F. Borne

	    	  
 November 10, 2003

	 William F. Borne
	    	 DATE

	 Chief Executive Officer, Amedisys, Inc.
	    	 
	 Vice-President, Amedisys Specialized Medical Services, Inc.
	    	 
		
	  
 /s/ Jeffrey D. Jeter, Esq.

	    	 November 10, 2003

	 Jeffrey D. Jeter, Esq.
	    	 DATE

	 Vice President of Corporate Compliance
and Corporate Counsel
	    	 

  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	32	  	 

 ON BEHALF OF THE OFFICE
OF INSPECTOR GENERAL 
 OF THE DEPARTMENT
OF HEALTH AND HUMAN SERVICES 
  

		
	 /s/ Larry J. Goldberg

	    	 November 10, 2003

	 Larry J. Goldberg
	    	 DATE

	 Assistant Inspector General for Legal Affairs
 Office of Inspector General
 U. S. Department of Health and Human Services
	    	 

  

	 Amedisys, Inc. and
 Amedisys Specialized Medical Services, Inc.
 Corporate Integrity Agreement
	  	33INDENTURE, BY AND BETWEEN TRANSWITCH CORPORATION AND U.S. BANCORP PIPER JAFFRAY

 Exhibit 4.1 
  

  
 TRANSWITCH CORPORATION

  
 And 
  
 U.S. BANK NATIONAL ASSOCIATION 
  
 as Trustee 
  
 INDENTURE 
  

  
 Dated as of September 30, 2003 
  

  
 5.45% Convertible Plus Cash NotesSM due 2007 
  

 TRANSWITCH CORPORATION 
  
 Reconciliation and tie between Trust Indenture Act 
 of 1939 and Indenture, dated as of September 30, 2003 
  

	 Trust Indenture
 Act Section

	  	 	  	Indenture Section

	 Section 310
	  	 (a)(1)
	  	 	  	 5.10

	 	  	 (a)(2)
	  	 	  	 5.10

	 	  	 (b)
	  	 	  	 5.03,5.06

	 Section 311
	  	 	  	 	  	 5.12

	 Section 312
	  	 (a)
	  	 	  	 6.04

	 Section 312
	  	 (c)
	  	 	  	 6.01

	 Section 313
	  	 (a)
	  	 	  	 6.02

	 Section 313
	  	 (c)
	  	 	  	 1.01 “Outstanding”,

	 	  	 	  	 	  	 5.05, 6.02, 6.03(c)

	 Section 314
	  	 (a)(1-3)
	  	 	  	 6.03

	 	  	 (a)(4)
	  	 	  	 9.06

	 	  	 (c)(1)
	  	 	  	 1.02

	 	  	 (c)(2)
	  	 	  	 1.02

	 	  	 (e)
	  	 	  	 1.02

	 Section 315
	  	 (a)(2)
	  	 	  	 5.02

	 	  	 (b)
	  	 	  	 5.02(h), 5.05

	 	  	 (c)
	  	 	  	 5.01

	 	  	 (d)
	  	 	  	 5.01

	 	  	 (e)
	  	 	  	 4.15

	 Section 316
	  	 (a) (last
	  	 	  	 
	 	  	 sentence)
	  	 	  	 1.01 “Outstanding”

	 	  	 (a)(1)(A)
	  	 	  	 4.12

	 	  	 (a)(1)(B)
	  	 	  	 4.13

	 	  	 (b)
	  	 	  	 4.08

	 	  	 (c)
	  	 	  	 1.04(d)(i)

	 Section 317
	  	 (a)(1)
	  	 	  	 4.03

	 	  	 (a)(2)
	  	 	  	 4.04

	 	  	 (b)
	  	 	  	 9.03

	 Section 318
	  	 (a)
	  	 	  	 1.11

 Note: This reconciliation and tie shall not, for any
purpose, be deemed to be a part of the Indenture. 

 TABLE OF CONTENTS 
  

	 	  	 	  	 	  	Page

	 ARTICLE 1            Definitions and Other Provisions of
General Application
	  	1
				
	 	  	SECTION 1.01.	  	 Definitions
	  	1
	 	  	SECTION 1.02.	  	 Compliance Certificates and Opinions
	  	9
	 	  	SECTION 1.03.	  	 Form of Documents Delivered to Trustee
	  	10
	 	  	SECTION 1.04.	  	 Acts of Holders
	  	10
	 	  	SECTION 1.05.	  	 Notices, Etc. to Trustee and Company
	  	12
	 	  	SECTION 1.06.	  	 Notice to Holders; Waiver
	  	12
	 	  	SECTION 1.07.	  	 Effect of Headings and Table of Contents
	  	13
	 	  	SECTION 1.08.	  	 Successors and Assigns
	  	13
	 	  	SECTION 1.09.	  	 Separability Clause
	  	13
	 	  	SECTION 1.10.	  	 Benefits of Indenture
	  	13
	 	  	SECTION 1.11.	  	 Governing Law
	  	13
	 	  	SECTION 1.12.	  	 Legal Holiday
	  	13
	 	  	SECTION 1.13.	  	 Personal Immunity from Liability for Incorporators, Stockholders, Etc
	  	14
	 	  	SECTION 1.14.	  	 Conflict with Trust Indenture Act
	  	14
	 	  	SECTION 1.15.	  	 Execution in Counterparts
	  	14
		
	 ARTICLE 2            Note Forms
	  	14
				
	 	  	SECTION 2.01.	  	 Forms of Notes
	  	14
	 	  	SECTION 2.02.	  	 Form of Trustee’s Certificate of Authentication
	  	15
	 	  	SECTION 2.03.	  	 Notes Issuable in Global Form
	  	15
		
	 ARTICLE 3            The Notes
	  	16
				
	 	  	SECTION 3.01.	  	 Title and Term
	  	16
	 	  	SECTION 3.02.	  	 Denominations
	  	16
	 	  	SECTION 3.03.	  	 Execution, Authentication, Delivery and Dating
	  	16
	 	  	SECTION 3.04.	  	 Registration, Registration of Transfer and Exchange
	  	17
	 	  	SECTION 3.05.	  	 Mutilated, Destroyed, Lost and Stolen Notes
	  	19
	 	  	SECTION 3.06.	  	 Payment of Interest; Interest Rights Preserved
	  	20
	 	  	SECTION 3.07.	  	 Persons Deemed Owners
	  	22
	 	  	SECTION 3.08.	  	 Cancellation
	  	22
	 	  	SECTION 3.09.	  	 Computation of Interest
	  	23
	 	  	SECTION 3.10.	  	 CUSIP Numbers
	  	23
		
	 ARTICLE 4            Remedies
	  	23
				
	 	  	SECTION 4.01.	  	 Events of Default
	  	23
	 	  	SECTION 4.02.	  	 Acceleration of Maturity; Rescission and Annulment
	  	25
	 	  	SECTION 4.03.	  	 Collection of Indebtedness and Suits for Enforcement by Trustee
	  	26
	 	  	SECTION 4.04.	  	 Trustee May File Proofs of Claim
	  	26
	 	  	SECTION 4.05.	  	 Trustee May Enforce Claims Without Possession of Notes
	  	27
	 	  	SECTION 4.06.	  	 Application of Money Collected
	  	27
	 	  	SECTION 4.07.	  	 Limitation on Suits
	  	28
	 	  	SECTION 4.08.	  	 Unconditional Right of Holders to Receive Principal, Premium, If Any, and Interest
	  	28
	 	  	SECTION 4.09.	  	 Restoration of Rights and Remedies
	  	28
	 	  	SECTION 4.10.	  	 Rights and Remedies Cumulative
	  	28
	 	  	SECTION 4.11.	  	 Delay or Omission Not Waiver
	  	29
	 	  	SECTION 4.12.	  	 Control by Holders of Notes
	  	29
	 	  	SECTION 4.13.	  	 Waiver of Past Defaults
	  	29
	 	  	SECTION 4.14.	  	 Waiver of Usury, Stay or Extension Laws
	  	30
	 	  	SECTION 4.15.	  	 Undertaking for Costs
	  	30

  

 -ii- 

	 ARTICLE 5            The Trustee
	  	30
				
	 	  	SECTION 5.01.	  	General	  	31
	 	  	SECTION 5.02.	  	Certain Rights of Trustee	  	32
	 	  	SECTION 5.03.	  	Individual Rights of Trustee	  	32
	 	  	SECTION 5.04.	  	Trustee’s Disclaimer	  	32
	 	  	SECTION 5.05.	  	Notice of Default	  	33
	 	  	SECTION 5.06.	  	Conflicting Interests of Trustee	  	33
	 	  	SECTION 5.07.	  	Compensation and Indemnity	  	33
	 	  	SECTION 5.08.	  	Replacement of Trustee	  	34
	 	  	SECTION 5.09.	  	Successor Trustee by Merger, Etc	  	34
	 	  	SECTION 5.10.	  	Eligibility	  	35
	 	  	SECTION 5.11.	  	Money Held in Trust	  	35
	 	  	SECTION 5.12.	  	Preferential Collection of Claims	  	35
	 	  	SECTION 5.13.	  	Trustee’s Application for Instructions from the Company	  	35
		
	 ARTICLE 6            Holders’ Lists And Reports By
Trustee And Company
	  	35
				
	 	  	SECTION 6.01.	  	Disclosure of Names and Addresses of Holders	  	35
	 	  	SECTION 6.02.	  	Reports by Trustee	  	35
	 	  	SECTION 6.03.	  	Reports by Company	  	36
	 	  	SECTION 6.04.	  	Company to Furnish Trustee Names and Addresses of Holders	  	36
		
	 ARTICLE 7            Consolidation, Merger, Sale, Lease Or
Conveyance
	  	37
				
	 	  	SECTION 7.01.	  	Consolidations and Mergers of Company and Sales, Leases and Conveyances Permitted Subject to Certain Conditions	  	37
	 	  	SECTION 7.02.	  	Rights and Duties of Successor Corporation	  	37
	 	  	SECTION 7.03.	  	Officers’ Certificate and Opinion of Counsel	  	38
		
	 ARTICLE 8            Supplemental
Indentures
	  	38
				
	 	  	SECTION 8.01.	  	Supplemental Indentures Without Consent of Holders	  	38
	 	  	SECTION 8.02.	  	Supplemental Indentures with Consent of Holders	  	39
	 	  	SECTION 8.03.	  	Execution of Supplemental Indenture	  	40
	 	  	SECTION 8.04.	  	Effect of Supplemental Indentures	  	40
	 	  	SECTION 8.05.	  	Conformity with Trust Indenture Act	  	40
	 	  	SECTION 8.06.	  	Reference in Notes to Supplemental Indentures	  	40
		
	 ARTICLE 9            Covenants
	  	40
				
	 	  	SECTION 9.01.	  	Payment of Principal, Premium, If Any, and Interest	  	40
	 	  	SECTION 9.02.	  	Maintenance of Office or Agency	  	40
	 	  	SECTION 9.03.	  	Money for Notes Payments to Be Held in Trust	  	41
	 	  	SECTION 9.04.	  	Existence	  	42
	 	  	SECTION 9.05.	  	Payment of Taxes and Other Claims	  	42
	 	  	SECTION 9.06.	  	Statement as to Compliance; Notice of Default	  	43
	 	  	SECTION 9.07.	  	Prohibition on Private Transactions Involving Existing Notes	  	43
	 	  	SECTION 9.08.	  	Waiver of Certain Covenants	  	43
		
	 ARTICLE 10        Redemption Of Notes
	  	43
				
	 	  	SECTION 10.01.	  	Optional Redemption by the Company	  	43
	 	  	SECTION 10.02.	  	Election to Redeem; Notice to Trustee	  	43
	 	  	SECTION 10.03.	  	Selection by Trustee of Notes to Be Redeemed	  	44
	 	  	SECTION 10.04.	  	Notice of Redemption	  	44
	 	  	SECTION 10.05.	  	Deposit of Redemption Price	  	45
	 	  	SECTION 10.06.	  	Notes Payable on Redemption Date	  	46
	 	  	SECTION 10.07.	  	Notes Redeemed in Part	  	46

  

 -iii- 

		
	 ARTICLE 11        Repurchase At Option Of Holders Upon Change In
Control
	  	46
				
	 	  	SECTION 11.01.	  	Right to Require Repurchase	  	46
	 	  	SECTION 11.02.	  	Notices; Method of Exercising Repurchase Right, Etc	  	46
	 	  	SECTION 11.03.	  	Certain Definitions	  	49
	 	  	SECTION 11.04.	  	Change in Control	  	49
	
	 
		
	 ARTICLE 12        Conversion
	  	50
				
	 	  	SECTION 12.01.	  	Voluntary Conversion Privilege and Conversion Consideration	  	50
	 	  	SECTION 12.02.	  	Exercise of Conversion Privilege	  	52
	 	  	SECTION 12.03.	  	Fractional Shares	  	54
	 	  	SECTION 12.04.	  	Adjustment of Conversion Consideration	  	55
	 	  	SECTION 12.05.	  	Notice of Adjustments	  	65
	 	  	SECTION 12.06.	  	Notice of Certain Corporate Action	  	65
	 	  	SECTION 12.07.	  	Company’s Obligation Regarding Common Stock	  	66
	 	  	SECTION 12.08.	  	Taxes on Conversions	  	66
	 	  	SECTION 12.09.	  	Covenant as to Common Stock	  	67
	 	  	SECTION 12.10.	  	Cancellation of Converted Notes	  	67
	 	  	SECTION 12.11.	  	Provisions in Case of Reclassification, Consolidation, Merger or Sale of Assets	  	67
	 	  	SECTION 12.12.	  	Auto-Conversion by the Company	  	68
	 	  	SECTION 12.13.	  	Notification to Trustee	  	71
	 	  	SECTION 12.14.	  	Company’s Obligation	  	71
				
	 	  	       SIGNATURES
	  	 	  	 
			
	 	  	       EXHIBIT A - FORM OF NOTE
	  	 

  

 -iv- 

 INDENTURE, dated as of September 30, 2003, between TRANSWITCH CORPORATION, a Delaware corporation
(the “Company”), having its principal office at Three Enterprise Drive, Shelton, Connecticut 06484 and U.S. Bank National Association, a national banking association, as Trustee hereunder (the “Trustee”). 
  
 RECITALS OF THE COMPANY 
  
 The Company has duly authorized the issue of its 5.45% Convertible Plus Cash
NotesSM due 2007 (the “Notes”) in an aggregate original principal amount not to exceed $114,143,000, and
to provide for such issuance, the Company has duly authorized the execution and delivery of this Indenture. 
  
 Upon qualification of this Indenture under the Trust Indenture Act of 1939, as amended (the “TIA”), it shall be subject to the provisions of the
TIA that are deemed to be incorporated into this Indenture and shall, to the extent applicable, be governed by such provisions. 
  
 All things necessary to make this Indenture a valid agreement of the Company, in accordance with its terms, have been done. 
  
 NOW, THEREFORE, THIS INDENTURE WITNESSETH: 
  
 For and in consideration of the premises and the purchase of the Notes by
the holders thereof, it is mutually covenanted and agreed, for the equal and proportionate benefit of all the holders of the Notes, as follows: 
  
 ARTICLE 1 
 Definitions and Other
Provisions of General Application 
  
 SECTION 1.01.
Definitions. For all purposes of this Indenture, except as otherwise expressly provided or unless the context otherwise requires: 
  
 (1) the terms defined in this Article have the meanings assigned to them in this Article and include the plural as well as the singular, and references to
he or him or she or her are intended to be gender neutral; 
  
 (2)
all other terms used herein which are defined in the TIA, either directly or by reference therein, have the meanings assigned to them therein; 
  
 (3) the word “including” means “including without limitation,” and 
  
 (4) the words “herein,” “hereof” and “hereunder” and other words of similar import refer to
this Indenture as a whole and not to any particular Article, Section or other subdivision. 
  
 “Act,” when used with respect to any Holder, has the meaning specified in Section 1.04. 

 “Affiliate” of any specified Person means any other Person directly or indirectly controlling
or controlled by or under direct or indirect common control with such specified Person. For the purposes of this definition, “control” when used with respect to any specified Person means the power to direct the management and policies of
such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise; and the terms “controlling” and “controlled” have meanings correlative to the foregoing. 
  
 “Agent Members” has the meaning specified in Section 2.03.

  
 “Authorized Newspaper” means a newspaper, printed in
the English language or in an official language of the country of publication, customarily published on each Business Day, whether or not published on Saturdays, Sundays or holidays, and of general circulation in each place in connection with which
the term is used or in the financial community of each such place. Whenever successive publications are required to be made in Authorized Newspapers, the successive publications may be made in the same or in different Authorized Newspapers in the
same city meeting the foregoing requirements and in each case on any Business Day. “Auto-Conversion” means either a Cash Auto-Conversion as defined in 12.12(a) or a Stock Auto-Conversion as defined in 12.12(d), as applicable. 

 
 “Auto-Conversion Date” has the meaning specified in Section
12.12(a). 
  
 “Auto-Conversion Notice” means either a
Cash Auto-Conversion Notice as defined in Section 12.12(a) or a Stock Auto-Conversion Notice as defined in Section 12.12(f). 
  
 “Auto-Conversion Price” has the meaning specified in Section 12.12(a). The Auto-Conversion Price is subject to appropriate adjustment upon
certain events as described in Section 12.04. 
  
 “Average
Sale Price” has the meaning specified in Section 12.04. 
  
 “Bankruptcy Law” has the meaning specified in Section 4.01. 
  
 “Base Shares” has the meaning specified in Section 12.01. 
  
 “Board of Directors” means the board of directors of the Company, the executive committee of that board or any committee of that board duly
authorized to act hereunder. 
  
 “Board Resolution”
means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to have been duly adopted by the Board of Directors and to be in full force and effect on the date of such certification, and delivered to the Trustee.

  
 “Business Day” means each Monday, Tuesday,
Wednesday, Thursday and Friday which is not a day on which banking institutions in the City of New York or a city in which the Corporate Trust Office is located or, when used with respect to any Place of Payment, such Place of Payment, are
authorized or obligated by law, regulation or executive order to close. 
  

 -2- 

 “Cash Auto-Conversion” has the meaning specified in Section 12.12(a). 
  
 “Cash Auto-Conversion Notice” has the meaning specified in Section
12.12(b). 
  
 “Change in Control” has the meaning
specified in Section 11.04. 
  
 “Change in Control Purchase
Notice” has the meaning specified in Section 11.02. 
  
 “close of business” means 5:00 p.m. (New York City time). 
  
 “Closing Price” has the meaning specified in Section 12.03. 
  
 “Commencement Date” has the meaning specified in Section 12.04. 
  
 “Commission” means the Securities and Exchange Commission, as from time to time constituted, created under the
Securities Exchange Act of 1934, or, if at any time after execution of this instrument such Commission is not existing and performing substantially the duties now assigned to it under the TIA, then the body performing such duties on such date.

  
 “Common Stock” means the common stock of the
Company, $0.001 par value, as it exists on the date of this Indenture and any shares of any class or classes of capital stock of the Company resulting from any reclassification or reclassifications thereof. 
  
 “Company” means the Person named as the “Company” in the
first paragraph of this Indenture until a successor corporation shall have become such pursuant to the applicable provisions of this Indenture, and thereafter “Company” shall mean such successor corporation. 
  
 “Company Notice” has the meaning specified in Section 11.02.

  
 “Company Request” and “Company Order”
mean, respectively, a written request or order signed in the name of the Company by the Chairman of the Board of Directors, the Chief Executive Officer, the President, the Chief Financial Officer or a Vice President of the Company and any of the
foregoing or any Assistant Vice President, the Treasurer, an Assistant Treasurer, the Secretary or an Assistant Secretary of the Company, and delivered to the Trustee. 
  
 “conversion,” when used with reference to the Notes, shall mean and include each of a voluntary conversion or an
Auto-Conversion. 
  
 “Conversion Agent” means any Person
authorized by the Company pursuant to Section 9.02 to convert Notes in accordance with Article 12. 
  
 “Conversion Consideration” has the meaning specified in Section 12.01. 
  
 “Conversion Date” has the meaning specified in Section 12.02. 
  

 -3- 

 “Corporate Trust Office” means the office of the Trustee at which, at any particular time, its
corporate trust business as it relates to this Indenture shall be principally administered and as to which notice to that effect has been delivered to the Company and the Holders in accordance with the provisions hereof, which office at the date
hereof is located at U.S. Bank National Association, One Federal Street, Third Floor, Boston, MA 02110 Attention: Corporate Trust Services/Chi C. Ma. 
  
 “Current Event” has the meaning specified in Section 12.04. 
  
 “Custodian” means U.S. Bank National Association with respect to the Notes in global form, or any successor entity
thereto. 
  
 “corporation” means a corporation,
association, partnership, company (including limited liability company), joint-stock company or business trust. 
  
 “daily volume-weighted average price” has the meaning specified in Section 12.03. 
  
 “Default” means any event that is, or after notice or passage of time or both would be, an Event of Default.

  
 “Defaulted Interest” has the meaning specified in
Section 3.06. 
  
 “Dollar” or “$” means a
dollar or other equivalent unit in such coin or currency of the United States of America as at the time shall be legal tender for the payment of public and private debts. 
  
 “DTC” means The Depository Trust Company. 
  
 “Event of Default” has the meaning specified in Section 4.01. 
  
 “Exchange Act” means the Securities Exchange Act of 1934, as
amended, and the rules and regulations promulgated thereunder. 
  
 “Ex-Dividend Time” has the meaning specified in Section 12.04. 
  
 “Existing Notes” shall mean the 4 1/2% Convertible Notes due 2005
issued pursuant to the Existing Note Indenture. 
  
 “Existing Note Indenture” shall mean that certain Indenture, dated as of September 12, 2000, between the Company and State Street Bank and Trust Company. 
  
 “Expiration Time” has the meaning specified in Section 12.04. 
  
 “Government Obligations” means securities that are (i) direct
obligations of the United States of America, for the payment of which its full faith and credit is pledged, or (ii) obligations of a Person controlled or supervised by and acting as an agency or instrumentality of the United 

  

 -4- 

 
States of America, the payment of which is unconditionally guaranteed as a full faith and credit obligation by the United States of America, which is not
callable or redeemable at the option of the issuer thereof, and shall also include a depository receipt issued by a bank or trust company as custodian with respect to any such Government Obligation or a specific payment of interest on or principal
of any such Government Obligation held by such custodian for the account of the holder of a depository receipt, provided that (except as required by law) such custodian is not authorized to make any deduction from the amount payable to the holder of
such depository receipt from any amount received by the custodian in respect of the Government Obligation or the specific payment of interest on or principal of the Government Obligation evidenced by such depository receipt. 
  
 “Holder” means the Person in whose name a Note is registered in the
Note Register. 
  
 “Indemnities” has the meaning
specified in Section 5.07. 
  
 “Indenture” means this
instrument as originally executed or as it may from time to time be supplemented or amended by one or more indentures supplemental hereto entered into pursuant to the applicable provisions hereof. 
  
 “Interest Payment Date” has the meaning specified in Section 3.06.

  
 “Make-Whole Payment” means the interest to be paid
or provided for by the Company upon an Auto-Conversion in an amount equal to two (2) full years of interest on the principal amount of the Notes so converted, less any interest paid or provided for on the principal amount of such Notes so
Auto-Converted prior to the Auto-Conversion Date; provided, however, in no event shall the Make-Whole Payment, if any, be less than an amount equal to one (1) full year of interest on the Notes. For purposes of this definition, interest shall be
computed on the basis of 365 days elapsed over a 360-day year. By way of illustration, “two (2) full years of interest” on a principal amount equal to $1,000 is $110.51 ($1,000 x (730/360) x 5.45%). 
  
 “Material Adverse Effect” has the meaning specified in Section
9.04. 
  
 “Maturity” means the date on which the
principal of the Notes becomes due and payable as therein or herein provided, whether at the Stated Maturity or upon voluntary conversion or Auto-Conversion or by declaration of acceleration, notice of redemption, notice of option to elect repayment
or otherwise. 
  
 “Nasdaq” shall mean The Nasdaq
National Market or, if the Common Stock of the Company is quoted on The Nasdaq SmallCap Market at the time in issue, The Nasdaq SmallCap Market. 
  
 “Note” or “Notes” means any Note or Notes, as the case may be, issued, authenticated and delivered under this Indenture. 

 
 “Note Register” has the meaning specified in Section 3.04.

  

 -5- 

 “Note Registrar” has the meaning specified in Section 3.04. 
  
 “Notice of Default” has the meaning specified in Section 4.01.

  
 “Officers’ Certificate” means a certificate
signed by the Chairman of the Board of Directors, the President or a Vice President and by any of the foregoing or the Treasurer, an Assistant Treasurer, the Secretary or an Assistant Secretary of the Company, and delivered to the Trustee.

  
 “Opinion of Counsel” means a written opinion of
counsel, who may be counsel for the Company or who may be an employee of or other counsel for the Company and who shall be reasonably satisfactory to the Trustee. 
  
 “Optional Redemption” has the meaning specified in Section 10.01. 
  
 “Other Event” has the meaning specified in Section 12.04.

  
 “Outstanding,” when used with respect to Notes,
means, as of the date of determination, all Notes theretofore authenticated and delivered under this Indenture, except: 
  
 (i) Notes theretofore canceled by the Trustee or delivered to the Trustee for cancellation; 
  
 (ii) Notes, or portions thereof, for whose payment or
redemption or repayment at the option of the Holder, money in the necessary amount has been theretofore deposited with the Trustee or any Paying Agent (other than the Company) in trust or set aside and segregated in trust by the Company (if the
Company shall act as its own Paying Agent) for the Holders of such Notes; provided that, if such Notes are to be redeemed, notice of such redemption has been duly given pursuant to this Indenture or provision therefor satisfactory to the Trustee has
been made; 
  
 (iii) Notes that have been paid
pursuant to Section 3.05 or in exchange for or in lieu of which other Notes have been authenticated and delivered pursuant to this Indenture, other than any such Notes in respect of which there shall have been presented to the Trustee proof
satisfactory to it that such Notes are held by a bona fide purchaser in whose hands such Notes are valid obligations of the Company; and 
  
 (iv) Notes voluntarily converted or Auto-Converted pursuant to or in accordance with this Indenture; 
  
 provided, however, that in determining whether the Holders of the requisite principal amount
of the Outstanding Notes have given any request, demand, authorization, direction, notice, consent or waiver hereunder or are present at a meeting of Holders for quorum purposes, and for the purpose of making the calculations required by TIA Section
313, Notes owned by the Company or any other obligor upon the Notes under a supplemental indenture entered into in accordance herewith or any Affiliate of the Company or of such other obligor shall be disregarded and deemed not to be Outstanding,
except that, in determining whether the Trustee shall be protected 

  

 -6- 

 
in making such calculation or in relying upon any such request, demand, authorization, direction, notice, consent or waiver, only Notes that the Trustee
knows to be so owned shall be so disregarded. Notes so owned that have been pledged in good faith may be regarded as Outstanding if the pledgee establishes to the satisfaction of the Trustee the pledgee’s right so to act with respect to such
Notes and that the pledgee is not the Company or any other obligor upon the Notes under a supplemental indenture entered into in accordance herewith or any Affiliate of the Company or of such other obligor. 
  
 “Paying Agent” means any Person (including the Company) authorized
by the Company to pay the principal of (and premium, if any) or interest on any Notes on behalf of the Company. 
  
 “Person” means any individual, corporation, partnership, limited liability company, joint venture, association, joint-stock company, trust,
unincorporated organization or government or any agency or political subdivision thereof. 
  
 “Place of Payment” means the place or places where the principal of (and premium, if any), interest on and the Redemption Prices and the Repurchase Price with respect to the Notes are payable as specified by
Section 9.02. 
  
 “Plus Cash Amount” has the meaning
specified in Section 12.01. 
  
 “Plus Cash Shares” has
the meaning specified in Section 12.01. 
  
 “Predecessor
Note” means, with respect to any Note, every previous Note evidencing all or a portion of the same debt as that evidenced by such Note; and, for the purposes of this definition, any Note authenticated and delivered under Section 3.05 in
exchange for or in lieu of a mutilated, destroyed, lost or stolen Note shall be deemed to evidence the same debt as the mutilated, destroyed, lost or stolen Note. 
  
 “Purchased Shares” has the meaning specified in Section 12.04. 
  
 “Redeemable Capital Stock” has the meaning specified in Section
11.04. 
  
 “Redemption Date,” when used with respect to
any Note to be redeemed, in whole or in part, means the date fixed for such redemption by or pursuant to this Indenture. 
  
 “Redemption Price,” means the Optional Redemption Price as specified in Section 10.01. 
  
 “Reference Date” has the meaning specified in Section 12.04.

  
 “Regular Record Date” for the interest payable on
any Interest Payment Date on the Notes means the date specified for that purpose as contemplated by Section 3.06, whether or not a Business Day. 
  
 “Repurchase Date” has the meaning specified in Section 11.01. 
  

 -7- 

 “Repurchase Price” has the meaning specified in Section 11.01. 
  
 “Repurchase Event” has the meaning specified in Section 11.03.

  
 “Responsible Officer,” when used with respect to the
Trustee, means any senior vice president, any vice president, any assistant vice president, any assistant secretary, or other officer of the Trustee working in its Corporate Trust division, or any other officer of the Trustee working in its
Corporate Trust Division and customarily performing functions similar to those performed by any of the above designated officers and also means, with respect to a particular corporate trust matter, any other officer to whom such matter is referred
because of his knowledge of and familiarity with the particular subject. 
  
 “Securities Act” shall mean the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. 
  
 “Significant Subsidiary” means any Subsidiary that is a “significant subsidiary” (as defined in Article
1, Rule 1-02 of Regulation S-X, promulgated under the Securities Act) of the Company. 
  
 “Special Record Date” for the payment of any Defaulted Interest on the Notes means a date fixed by the Trustee pursuant to Section 3.06. 
  
 “Stated Maturity” means the date specified in the Notes as the fixed date on which the principal of, or interest
on, such Notes is due and payable. 
  
 “Stock
Auto-Conversion” has the meaning specified in Section 12.12(d). 
  
 “Stock Auto-Conversion Notice” has the meaning specified in Section 12.12(f). 
  
 “Stock Substitution Notice” has the meaning specified in Section 12.12(d). 
  
 “Stock Substitution Period” has the meaning specified in Section 12.12(e). 
  
 “Stock Substitution Period Commencement Date” has the meaning
specified in Section 12.12(e). 
  
 “Stock Substitution
Price” has the meaning specified in Section 12.12(g). 
  
 “Stock Substitution Reference Price” has the meaning specified in Section 12.12(d). 
  
 “Subsidiary” means a corporation a majority of the outstanding voting securities of which is owned, directly or indirectly, by the Company or by
one or more other Subsidiaries of the Company, or by the Company and one or more other Subsidiaries. For the purposes of this definition, “voting securities” means shares, interests, participations or other equivalents of corporate stock,
partnership or limited liability company interests or any other participation, right or other interest in the nature of an equity interest that ordinarily have voting power for the election of directors, managers or trustees, whether at all times or
only so long as no senior class of equity interest has such voting power by reason of any contingency. 
  

 -8- 

 “Threshold Price” means $2.61, as adjusted as provided for in Section 12.04. 
  
 “Time of Determination” has the meaning specified in Section 12.04.
“Trading Day” has the meaning specified in Section 12.03. 
  
 “Trust Indenture Act” or “TIA” means the Trust Indenture Act of 1939, and the rules and regulations promulgated thereunder, as in force on the date this Indenture is qualified thereunder; provided, however, that in the
event the Trust Indenture Act of 1939 or such rules and regulations are amended after such date, “Trust Indenture Act” means, to the extent required by any such amendment, the Trust Indenture Act of 1939 and such rules and regulations as
so amended. 
  
 “Trustee” means the Person named as the
“Trustee” in the first paragraph of this Indenture until a successor Trustee shall have become such pursuant to the applicable provisions of this Indenture, and thereafter “Trustee” shall mean or include each Person who is then a
Trustee hereunder. 
  
 “United States” means the United
States of America (including the states and the District of Columbia), its territories, its possessions and other areas subject to its jurisdiction. 
  
 “Valuation Days” has the meaning specified in Section 12.12(e). 
  
 SECTION 1.02. Compliance Certificates and Opinions. Upon any application or request by the Company to the Trustee to
take any action under any provision of this Indenture, the Company shall furnish to the Trustee an Officers’ Certificate stating that all conditions precedent, if any, provided for in this Indenture relating to the proposed action have been
complied with and an Opinion of Counsel stating that in the opinion of such counsel all such conditions precedent, if any, have been complied with, except that in the case of any such application or request as to which the furnishing of such
documents is specifically required by any provision of this Indenture relating to such particular application or request, no additional certificate or opinion need be furnished. 
  
 Every certificate or opinion with respect to compliance with a condition or covenant provided for in this Indenture shall
include: 
  
 (a) a statement that each individual signing such
certificate or opinion has read such condition or covenant and the definitions herein relating thereto; 
  
 (b) a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate
or opinion are based; 
  
 (c) a statement that, in the opinion of
each such individual, he has made such examination or investigation as is necessary to enable him to express an informed opinion as to whether or not such condition or covenant has been complied with; and 
  

 -9- 

 (d) a statement as to whether, in the opinion of each such individual, such condition or covenant has
been complied with. 
  
 SECTION 1.03. Form of Documents
Delivered to Trustee. In any case where several matters are required to be certified by, or covered by an opinion of, any specified Person, it is not necessary that all such matters be certified by, or covered by the opinion of, only one such
Person, or that they be so certified or covered by only one document, but one such Person may certify or give an opinion as to some matters and one or more other such Persons as to other matters, and any such Person may certify or give an opinion as
to such matters in one or several documents. 
  
 Any certificate
or opinion of an officer of the Company may be based, insofar as it relates to legal matters, upon an Opinion of Counsel, or a certificate or representations by counsel, unless such officer knows, or in the exercise of reasonable care should know,
that the opinion, certificate or representations with respect to the matters upon which such certificate or opinion is based are erroneous. Any such Opinion of Counsel or certificate or representations may be based, insofar as it relates to factual
matters, upon a certificate or opinion of, or representations by, an officer or officers of the Company stating that the information as to such factual matters is in the possession of the Company, unless such counsel knows that the certificate or
opinion or representations as to such matters are erroneous. 
  
 Where any Person is required to make, give or execute two or more applications, requests, consents, certificates, statements, opinions or other instruments under this Indenture, they may, but need not, be consolidated and form one
instrument. 
  
 SECTION 1.04. Acts of Holders. (a) Any
request, demand, authorization, direction, notice, consent, waiver or other action provided by this Indenture to be given or taken by Holders of the Outstanding Notes may be embodied in and evidenced by one or more instruments of substantially
similar tenor signed by such Holders in person or by agents duly appointed in writing. Except as herein otherwise expressly provided, such action shall become effective when such instrument or instruments are delivered to the Trustee and, where it
is hereby expressly required, to the Company. Such instrument or instruments (and the action embodied therein and evidenced thereby) are herein sometimes referred to as the “Act” of the Holders signing such instrument or instruments. Proof
of execution of any such instrument or of a writing appointing any such agent, or of the holding by any Person of a Note, shall be sufficient for any purpose of this Indenture and conclusive in favor of the Trustee and the Company and any agent of
the Trustee or the Company, if made in the manner provided in this Section 1.04. 
  
 (b) The fact and date of the execution by any Person of any such instrument or writing may be proved by the affidavit of a witness to such execution or by a certificate of a notary public or other officer authorized
by law to take acknowledgments of deeds, certifying that the individual signing such instrument or writing acknowledged to him the execution thereof. Where such execution is by a signer acting in a capacity other than his individual capacity, such
certificate or affidavit shall also constitute sufficient proof of his authority. The fact and date of the execution of any such instrument or writing, or the authority of the Person executing the same, may also be proved in any other reasonable
manner which the Trustee deems sufficient. 
  

 -10- 

 (c) The ownership of the Notes shall be proved by the Note Register. 
  
 (d) (i) If the Company shall solicit from the Holders any request, demand,
authorization, direction, notice, consent, waiver or other Act, the Company may, at its option, in or pursuant to a Board Resolution, fix in advance a record date for the determination of Holders entitled to effect such request, demand,
authorization, direction, notice, consent, waiver or other Act, but the Company shall have no obligation to do so; provided that the Company shall not be entitled to set a record date for, and the provisions of this paragraph shall not apply with
respect to, the giving or making of any notice, declaration, request or direction referred to in clause 1.04(d)(iii) below. Notwithstanding TIA Section 316(c), such record date shall be the record date specified in or pursuant to such Board
Resolution, which shall be a date not earlier than the date 30 days prior to the first solicitation of Holders generally in connection therewith and not later than the date such solicitation is completed. If such a record date is fixed, such
request, demand, authorization, direction, notice, consent, waiver or other Act may be effected before or after such record date, but only the Holders of record at the close of business on such record date shall be deemed to be Holders for the
purposes of determining whether Holders of the requisite proportion of Outstanding Notes have authorized or agreed or consented to such request, demand, authorization, direction, notice, consent, waiver or other Act, and for that purpose the
Outstanding Notes shall be computed as of such record date; provided that no such authorization, agreement or consent by the Holders on such record date shall be deemed effective unless it shall become effective pursuant to the provisions of this
Indenture not later than eleven months after the record date. 
  
 (ii) Subject to clause 1.04(d)(iii) below, in the absence of any such record date fixed by the Company, regardless as to whether any solicitation of the Holders is occurring on behalf of the Company or any Holder, the
Trustee may, at its option, fix in advance a record date for the determination of such Holders entitled to give such request, demand, authorization, direction, notice, consent, waiver or other Act, but the Trustee shall have no obligation to do so.
Any such record date shall be a date not more than 30 days prior to the first solicitation of Holders generally in connection therewith and no later than the date of such solicitation. 
  
 (iii) The Trustee may set any day as a record date for the purpose of determining the Holders of Outstanding
Notes entitled to join in the giving or making of (A) any notice of default, (B) any declaration of acceleration referred to in Section 4.02, (C) any request to institute proceedings referred to in Section 4.07(b), or (D) any direction referred to
in Section 4.12, and may also set an expiration date by which the relevant Act must be taken. If any record date is set pursuant to this paragraph, the Holders of Outstanding Notes on such record date, and no other Holders, shall be entitled to join
in such notice, declaration, request or direction, whether or not such Holders remain Holders after such record date; provided that no such Act shall be effective hereunder unless taken on or prior to any applicable expiration date by Holders of the
requisite principal amount of Outstanding Notes on such record date. Nothing in this paragraph 

  

 -11- 

 
shall be construed to prevent the Trustee from setting a new record date for any action (whereupon the record date previously set shall automatically and
without any action by any Person be canceled and of no effect), nor shall anything in this paragraph be construed to render ineffective any Act taken by Holders of the requisite principal amount of Outstanding Notes on the date such Act is taken.
Promptly after any record date is set pursuant to this paragraph, the Trustee, at the Company’s expense, shall cause notice of such record date, the proposed Act by Holders and the applicable expiration date to be given to the Company in
writing and to each Holder of Outstanding Notes in the manner set forth in Section 1.06. 
  
 (e) Any request, demand, authorization, direction, notice, consent, waiver or other Act of the Holder of any Note shall bind every future Holder of the same Note and the Holder of every Note issued upon the
registration of transfer thereof or in exchange therefor or in lieu thereof in respect of anything done, omitted or suffered to be done by the Trustee, any Note Registrar, any Paying Agent, any Conversion Agent or the Company in reliance thereon,
whether or not notation of such action is made upon such Note. 
  
 SECTION 1.05. Notices, Etc. to Trustee and Company. Any request, demand, authorization, direction, notice, consent, waiver or other Act of Holders or other notice or communication provided or permitted by this Indenture to be made
upon, given or furnished to, or filed with: 
  
 (a) the Trustee
by any Holder or by the Company shall be sufficient for every purpose hereunder if made, given, furnished or filed in writing to or with the Trustee, delivered in person, mailed by first class mail, postage prepaid, or sent by facsimile or overnight
courier, at its address as follows: if mailed by first class mail, to U.S. Bank National Association, Corporate Trust Services, P.O. Box 778, Boston, MA 02102-0778, Attention: TranSwitch Corporation 5.45% Convertible Plus Cash Notes SM due 2007, or if sent by other means to U.S. Bank National Association, Corporate Trust Services, One Federal Street, 3rd
Floor, Boston, MA 02110, Attention: TranSwitch Corporation 5.45% Convertible Plus Cash Notes SM due 2007 (facsimile:
617-603-6683), or to such other address or facsimile number as the Trustee may designate by written notice from time to time; provided that notices or other communications to the Trustee shall only be deemed given when actually received by the
Trustee, 
  
 (b) the Company by the Trustee or by any Holder shall
be sufficient for every purpose hereunder (unless otherwise herein expressly provided) if in writing and delivered in person, mailed by first class mail, postage prepaid, or sent by facsimile or overnight courier, to the Company addressed to it at
the address of its principal office specified in the first paragraph of this Indenture; provided that the Company may, by notice furnished in writing to the Trustee, designate additional or different addresses for subsequent notices or
communications by the Company; and further provided that notices or other communications to the Company shall only be deemed given when actually received by the Company. 
  
 SECTION 1.06. Notice to Holders; Waiver. Where this Indenture provides for notice of any event to Holders by the
Company or the Trustee, such notice shall be sufficiently given (unless otherwise herein expressly provided) if in writing and deposited in the mail, first-class postage prepaid, to each such Holder affected by such event, at his address as it
appears in the Note 

  

 -12- 

 
Register, not later than the latest date, and not earlier than the earliest date, prescribed for the giving of such notice. Such notice shall be deemed to
have been given when such notice is mailed. In any case where notice to Holders is given by mail, neither the failure to mail such notice, nor any defect in any notice so mailed, to any particular Holder shall affect the sufficiency of such notice
with respect to other Holders given as provided herein. Any notice deposited in the mail to a Holder in the manner herein prescribed shall be conclusively deemed to have been received by such Holder, whether or not such Holder actually receives such
notice. 
  
 If by reason of the suspension of or irregularities in
regular mail service or by reason of any other cause or circumstance it shall be impracticable to give such notice by mail, then such notification to Holders as shall be made with the approval of the Trustee shall constitute a sufficient
notification to such Holders for every purpose hereunder. 
  
 Any
request, demand, authorization, direction, notice, consent, waiver or other Act required or permitted under this Indenture shall be in the English language, except that any published notice may be in an official language of the country of
publication. 
  
 Where this Indenture provides for notice in any
manner, such notice may be waived in writing by the Person entitled to receive such notice, either before or after the event, and such waiver shall be the equivalent of such notice. Waivers of notice by Holders shall be filed with the Trustee, but
such filing shall not be a condition precedent to the validity of any action taken in reliance upon such waiver. 
  
 SECTION 1.07. Effect of Headings and Table of Contents. The Article and Section headings herein and the Table of Contents are for convenience only
and shall not affect the construction hereof. 
  
 SECTION 1.08.
Successors and Assigns. All covenants and agreements in this Indenture by the Company shall bind its successors and assigns, whether so expressed or not. 
  
 SECTION 1.09. Separability Clause. In case any provision in this Indenture or in any Note shall be invalid, illegal or unenforceable, the validity,
legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 
  
 SECTION 1.10. Benefits of Indenture. Nothing in this Indenture or in the Notes, express or implied, shall give to any Person, other than the
parties hereto, any Note Registrar, any Paying Agent, any Conversion Agent and their successors hereunder and the Holders any benefit or any legal or equitable right, remedy or claim under this Indenture. 
  
 SECTION 1.11. Governing Law. This Indenture and the Notes shall be
governed by and construed in accordance with the law of the State of New York without regard to conflict of laws principles. 
  
 SECTION 1.12. Legal Holiday. In any case where any Interest Payment Date, Redemption Date, Repurchase Date, Conversion Date, Auto-Conversion Date,
Stated Maturity or Maturity of any Note or the last date on which a Holder has the right to convert his Notes shall not be a 

  

 -13- 

 
Business Day at any Place of Payment, then (notwithstanding any other provision of this Indenture or any Note), payment of Redemption Price, Repurchase
Price, Make-Whole Payment amount, interest or principal (and premium, if any), or voluntary conversion or Auto-Conversion of the Notes, need not be made at such Place of Payment on such date, but may be made on the next succeeding Business Day at
such Place of Payment with the same force and effect as if made on the Interest Payment Date, Redemption Date, Repurchase Date, Conversion Date, Auto-Conversion Date or at the Stated Maturity or Maturity or on such last day for voluntary conversion
or Auto-Conversion; provided that no interest shall accrue on the amount so payable for the period from and after such Interest Payment Date, Redemption Date, Repurchase Date, Conversion Date, Auto-Conversion Date, Stated Maturity or Maturity or on
such last day for voluntary conversion or Auto-Conversion, as the case may be. 
  
 SECTION 1.13. Personal Immunity from Liability for Incorporators, Stockholders, Etc. No recourse shall be had for the payment of the principal of or premium, if any, or interest, if any, on any Note, or for any
claim based thereon, or otherwise in respect of any Note, or based on or in respect of this Indenture or any indenture supplemental hereto, against any incorporator, or against any past, present or future stockholder, director or officer, as such,
of the Company or of any successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise, all such liability being expressly waived and released as a condition of,
and as consideration for, the execution of this Indenture and the issue of Notes. 
  
 SECTION 1.14. Conflict with Trust Indenture Act. If any provision hereof limits, qualifies or conflicts with a provision of the TIA that is required under such Act to be a part of and govern this Indenture, the
latter provision shall control. If any provision of this Indenture modifies or excludes any provision of the TIA that may be so modified or excluded, the latter provision shall be deemed to apply to this Indenture as so modified or to be excluded,
as the case may be. To the extent that any provision of a Note conflicts with a provision in this Indenture, the provision of this Indenture shall control. 
  
 SECTION 1.15. Execution in Counterparts. This Indenture may be executed in any number of counterparts, each of which shall be an original, but such
counterparts shall together constitute but one and the same instrument. 
  
 ARTICLE 2 
 Note Forms 
  
 SECTION 2.01. Forms of Notes. The Notes shall be in substantially the form of Exhibit A hereto, and shall have notations, legends or endorsements
required by law, stock exchange rule or usage or as otherwise indicated in Exhibit A hereto. 
  

 -14- 

 SECTION 2.02. Form of Trustee’s Certificate of Authentication. The Trustee’s certificate
of authentication shall be in substantially the following form: 
  
 This is one of the Notes described in the within-mentioned Indenture. 
  

	 DATED:
	 	 U.S. BANK NATIONAL
 ASSOCIATION,
 as Trustee

			
	 	 	 By:
  
	 	

	 	 	 	 	     Authorized Signatory

  
 SECTION 2.03. Notes
Issuable in Global Form. Except as otherwise provided in this Section 2.03 or in Section 3.04, the Notes shall be issuable only in global form and deposited with the Trustee, at its Corporate Trust Office (or such other location as it may
determine from time to time for such purpose), as custodian for the depositary or the nominees thereof, and registered in the name of the depositary or the nominees thereof, and any such Note shall represent such of the Outstanding Notes as shall be
set forth in the books and records of the Trustee and may provide that it shall represent the aggregate amount of Outstanding Notes from time to time as adjusted in the books and records of the Trustee, and that the aggregate amount of Outstanding
Notes represented thereby may from time to time be increased or decreased to reflect exchanges. 
  
 Notwithstanding anything to the contrary contained herein, each of the Company’s and any Holder’s obligations or exercise of any right or
procedure described herein shall be made in accordance with and subject to the procedures of the Trustee and the depository or the nominees thereof. Members of, or participants in, the depositary (“Agent Members”) shall have no rights
under this Indenture with respect to any Note in global form held on their behalf by the depositary or by the Trustee as the custodian of the depositary or under such Note in global form, and the depositary may be treated by the Company, the Trustee
and any agent of the Company or the Trustee as the absolute owner of such Note for all purposes whatsoever. Notwithstanding the foregoing, nothing herein shall prevent the Company, the Trustee or any agent of the Company or the Trustee from giving
effect to any written certification, proxy or other authorization furnished by the depositary or impair, as between the depositary and its Agent Members, the operation of customary practices of such depositary governing the exercise of the rights of
a holder of a beneficial interest in any Note held in global form. 
  
 Any adjustment of the aggregate amount of Outstanding Notes represented by a Note in global form to reflect the amount, or any increase or decrease in the amount, of Outstanding Notes represented thereby shall be made by the Trustee in such
manner and upon instructions given by such Person or Persons as shall be specified therein or in the Company Order to be delivered to the Trustee pursuant to Section 3.03. Subject to the provisions of Section 3.03, the Trustee shall, if required,
deliver and redeliver any Note in global form in the manner and upon instructions given by the Person or Persons specified therein or in the applicable Company Order. If a Company Order pursuant to Section 3.03 has been, or simultaneously is,
delivered, any instructions by the Company with respect to endorsement or delivery or redelivery of a Note in global form shall be in writing but need not comply with Section 1.02 and need not be accompanied by an Opinion of Counsel. 
  

 -15- 

 The provisions of the last sentence of Section 3.03 shall apply to any Note represented by a Note in
global form if such Note was never issued and sold by the Company and the Company delivers to the Trustee the Note in global form together with written instructions (which need not comply with Section 1.02 and need not be accompanied by an Opinion
of Counsel) with regard to the reduction in the principal amount of Notes represented thereby, together with the written statement contemplated by the last sentence of Section 3.03. 
  
 Notwithstanding the provisions of Section 3.07, payment of principal of and any premium and interest on any Note in global
form shall be made to the Person or Persons specified in such Note. 
  
 All Notes issued in global form shall bear the following legend: 
  
 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), NEW YORK, NEW YORK, TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF
TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC, AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS
IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC, ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL BECAUSE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 
  
 TRANSFERS OF THIS GLOBAL NOTE SHALL BE LIMITED TO TRANSFERS IN WHOLE, BUT
NOT IN PART, TO NOMINEES OF CEDE & CO. OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S NOMINEE. 
  
 ARTICLE 3 
 The Notes 
  
 SECTION 3.01. Title and Term. The Notes shall be and are hereby
authorized to be designated as “5.45% Convertible Plus Cash Notes SM due 2007,” limited in aggregate
original principal amount up to $114,143,000. The Notes shall mature and the principal thereof shall be due and payable, together with all accrued and unpaid interest thereon, on September 30, 2007. The Notes shall be convertible into shares of
Common Stock as set forth herein. 
  
 SECTION 3.02.
Denominations. The Notes shall be issuable in denominations of $1,000 and any integral multiple thereof. 
  
 SECTION 3.03. Execution, Authentication, Delivery and Dating. The Notes shall be executed on behalf of the Company by the Chief Executive Officer,
the Chief Financial Officer, 

  

 -16- 

 
the Treasurer, the President or a Vice President of the Company. The signature of any of these individuals on the Notes may be a manual or facsimile
signature of such authorized officer and may be imprinted or otherwise reproduced on the Notes. 
  
 Notes bearing the manual or facsimile signatures of an individual who was at any time the proper officer of the Company shall bind the Company,
notwithstanding that such individual shall have ceased to hold such office prior to the authentication and delivery of such Notes or did not hold such office at the date of such Notes. 
  
 At any time and from time to time after the execution and delivery of this Indenture, the Company may deliver Notes,
executed by the Company, to the Trustee for authentication, together with a Company Order for the authentication and delivery of such Notes, and the Trustee in accordance with the Company Order shall authenticate and deliver such Notes. 

 
 Each Note shall be dated the date of its authentication. 
  
 No Note shall be entitled to any benefit under this Indenture or be valid or
obligatory for any purpose unless there appears on such Note a certificate of authentication substantially in the form provided for in Section 2.02, duly executed by the Trustee by manual signature of an authorized signatory, and such certificate
upon any Note shall be conclusive evidence, and the only evidence, that such Note has been duly authenticated and delivered hereunder and is entitled to the benefits of this Indenture. Notwithstanding the foregoing, if any Note shall have been
authenticated and delivered hereunder but never issued and sold by the Company, and the Company shall deliver such Note to the Trustee for cancellation as provided in Section 3.08 together with a written statement (which need not comply with Section
1.02 and need not be accompanied by an Opinion of Counsel) stating that such Note has never been issued and sold by the Company, for all purposes of this Indenture, such Note shall be deemed not to have been authenticated and delivered hereunder and
shall never be entitled to the benefits of this Indenture. 
  
 SECTION 3.04. Registration, Registration of Transfer and Exchange. 
  
 (a) The Company shall cause to be kept at the Corporate Trust Office of the Trustee or in any office or agency of the Company in a Place of Payment a register for the Notes (the “Note Register”) in which,
subject to such reasonable regulations as it may prescribe, the Company shall provide for the registration of the Notes and of transfers of the Notes. The Note Register shall be in written form or any other form capable of being converted into
written form within a reasonable time. The Trustee, at its Corporate Trust Office, is hereby appointed “Note Registrar” for the purpose of registering the Notes and transfers of the Notes on such Note Register as herein provided. In the
event that the Trustee shall cease to be Note Registrar, it shall have the right to examine the Note Register at all reasonable times. 
  
 Subject to the provisions of this Section 3.04 and except as otherwise provided in any Note, including any legend thereon, upon surrender for registration
of transfer of any Note at any office or agency of the Company in a Place of Payment, the Company shall execute, and the Trustee shall authenticate and deliver, in the name of the designated transferee or transferees, one or 

  

 -17- 

 
more new Notes, of any authorized denominations and of a like aggregate principal amount, bearing a number not contemporaneously outstanding, and containing
identical terms and provisions. 
  
 Subject to the provisions of
this Section 3.04, at the option of the Holder, the Notes may be exchanged for other Notes, of any authorized denomination or denominations and of a like aggregate principal amount, containing identical terms and provisions, upon surrender of the
Notes to be exchanged at any such office or agency. Whenever any such Notes are so surrendered for exchange, the Company shall execute, and the Trustee shall authenticate and deliver, the Notes that the Holder making the exchange is entitled to
receive. 
  
 Notwithstanding the foregoing, any global Note shall
be exchangeable only as provided in this paragraph. The depositary for the global Notes shall be DTC, and the global Notes may be transferred, in whole but not in part, only to a nominee of DTC, or by a nominee of DTC to DTC, or to a successor to
DTC for such global Note selected or approved by the Company or to a nominee of such successor to DTC. If at any time DTC notifies the Company that it is unwilling or unable to continue as depositary for the applicable global Note or Notes or if at
any time DTC ceases to be a clearing agency registered under the Exchange Act, if so required by applicable law or regulation, the Company shall appoint a successor depositary with respect to such global Note or Notes. If (x) a successor depositary
for such global Note or Notes is not appointed by the Company within 90 days after the Company receives such notice or becomes aware of such unwillingness, inability or ineligibility, or (y) a Default or an Event of Default has occurred and is
continuing, or (z) the Company, in its sole discretion, executes and delivers to the Trustee and the Note Registrar an Officers’ Certificate stating that definitive Notes may be issued in exchange for interests in a global Note or Notes, then
the Company shall execute, and the Trustee shall authenticate and deliver, definitive Notes of like rank, tenor and terms in definitive form, registered in such names as DTC shall direct and bearing such legends as the Company shall specify in
writing, in an aggregate principal amount equal to the principal amount of such global Note or Notes. If a Note is issued in exchange for any portion of a global Note after the close of business at the office or agency where such exchange occurs on
(i) any Regular Record Date and before the opening of business at such office or agency on the relevant Interest Payment Date or (ii) any Special Record Date and before the opening of business at such office or agency on the related proposed date
for payment of Defaulted Interest, interest or Defaulted Interest, as the case may be, shall not be payable on such Interest Payment Date or proposed date for payment, as the case may be, in respect of such Note, but will be payable on such Interest
Payment Date or proposed date for payment, as the case may be, only to the Person to whom interest in respect of such portion of such global Note is payable in accordance with the provisions of this Indenture. 
  
 All Notes issued upon any registration of transfer or exchange of Notes shall
be the valid obligations of the Company, evidencing the same debt, and entitled to the same benefits under this Indenture, as the Notes surrendered upon such registration of transfer or exchange. 
  
 Every Note presented or surrendered for registration of transfer or for
exchange or redemption shall (if so required by the Company or the Note Registrar) be duly endorsed, or be accompanied by a written instrument of transfer, in form satisfactory to the Company and the Note Registrar, duly executed by the Holder
thereof or his attorney duly authorized in writing. 
  

 -18- 

 No service charge shall be made to a Holder for any registration of transfer or exchange of Notes, but
the Company may require payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in connection with any registration of transfer or exchange of Notes, other than exchanges pursuant to Section 10.07 or 11.02(h)
not involving any transfer. 
  
 The Company or the Trustee, as
applicable, shall not be required (i) to issue, register the transfer of or exchange any Note during a period beginning at the opening of business 15 days before the date of the mailing of a notice of redemption with respect to the Notes to be
redeemed under Section 10.03 and ending at the close of business on the day of the mailing of the relevant notice of redemption, or (ii) to register the transfer of or exchange any Note so selected for redemption in whole or in part, except, in the
case of any Note to be redeemed in part, the portion thereof not to be redeemed, or (iii) to issue, register the transfer of or exchange any Note that has been surrendered for repayment at the option of the Holder, except the portion, if any, of
such Note not to be so repaid. 
  
 (b) At such time as all
interests in the global Note have been redeemed, converted, canceled, repurchased or transferred, the global Note shall be, upon receipt thereof, canceled by the Trustee in accordance with standing procedures and instructions existing between the
depositary and the Custodian. 
  
 SECTION 3.05. Mutilated,
Destroyed, Lost and Stolen Notes. If any mutilated Note is surrendered to the Trustee or the Company, together with such security or indemnity as may be required by the Company or the Trustee to save each of them or any agent of either of them
harmless, the Company shall, at the relevant Holder’s expense, execute and the Trustee shall authenticate and deliver in exchange therefor a new Note of the same principal amount, containing identical terms and provisions and bearing a number
not contemporaneously outstanding. 
  
 If there shall be delivered
to the Company and to the Trustee (i) evidence to their satisfaction of the destruction, loss or theft of any Note and (ii) such security or indemnity as may be required by them to save each of them and any agent of either of them harmless, then, in
the absence of notice to the Company or the Trustee that such Note has been acquired by a bona fide purchaser, the Company, at the relevant Holder’s expense, shall execute, and upon the Company’s request the Trustee shall authenticate and
deliver, in lieu of any such destroyed, lost or stolen Note, a new Note of the same principal amount, containing identical terms and provisions and bearing a number not contemporaneously outstanding, appertaining to such destroyed, lost or stolen
Note. 
  
 Notwithstanding the provisions of the previous two
paragraphs, in case any such mutilated, destroyed, lost or stolen Note has become or is about to become due and payable, the Company in its discretion may, instead of issuing a new Note, pay such Note. 
  
 Upon the issuance of any new Note under this Section, the Company may require
the 

  

 -19- 

 
payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees
and expenses of the Trustee) connected therewith. 
  
 Every new
Note issued pursuant to this Section in lieu of any mutilated, destroyed, lost or stolen Note, shall constitute an original additional contractual obligation of the Company, whether or not the mutilated, destroyed, lost or stolen Note shall be at
any time enforceable by anyone, and shall be entitled to all the benefits of this Indenture equally and proportionately with any and all other Notes duly issued hereunder. 
  
 The provisions of this Section are exclusive and shall preclude (to the extent lawful) all other rights and remedies with
respect to the replacement or payment of mutilated, destroyed, lost or stolen Notes. 
  
 SECTION 3.06. Payment of Interest; Interest Rights Preserved. Except as otherwise provided herein, interest on any Note that is payable, and is punctually paid or duly provided for, semi-annually on any March
31 and September 30 of each year (each such date, an “Interest Payment Date”), shall be paid or duly provided for commencing March 31, 2004 to the Person in whose name that Note (or one or more Predecessor Notes) is registered at the close
of business on the Regular Record Date for such interest at the office or agency of the Company maintained for such purpose pursuant to Section 9.02; provided, however, that each installment of interest on any Note may at the Company’s option
be paid or provided for by (i) mailing a check for such interest, payable to or upon the written order of the Person entitled thereto pursuant to Section 3.07, to the address of such Person as it appears on the Note Register or (ii) if the Trustee
shall have received written bank wire instructions prior to the Regular Record Date for such payment, transfer to an account maintained by the payee located inside the United States; provided, however, that payments to the depositary shall be made
by wire transfer of immediately available funds to the account of the depositary or its nominee. The term “Regular Record Date” with respect to any Interest Payment Date shall mean the March 15 or September 15 preceding March 31 or
September 30, respectively. 
  
 Notwithstanding the foregoing or
anything to the contrary contained herein, interest may be paid or duly provided for in shares of the Company’s Common Stock, solely at the Company’s option; provided, however, that the Company shall not make any payment of interest in
shares of Common Stock unless the daily volume-weighted average price of the Common Stock for the ten (10) Trading Days ending on and including the second Trading Day immediately preceding the applicable Interest Payment Date equals or exceeds the
Threshold Price. If the Company elects to make any payment of or provision for interest in shares of its Common Stock, the shares to be delivered will be valued at 95% of the simple average of the daily volume-weighted average price of the Common
Stock for the ten (10) Trading Days ending on and including the second Trading Day immediately preceding the applicable Interest Payment Date. The Company shall provide the Trustee and the Holders with notice of its intention to pay interest in
Common Stock not later than 12:00 noon (New York City time) on the Trading Day immediately preceding the applicable Interest Payment Date. The Company shall not issue fractional shares of Common Stock or any scrip representing fractional shares of
Common Stock upon such payment of interest. If any fractional share of Common Stock otherwise would be issuable upon the payment 

  

 -20- 

 
of or provision for interest, the Company, at its option, may either make an adjustment therefore in cash at the current market value thereof to the Holder
of the Notes or round the fractional shares up to the nearest whole share, provided that if such Holder holds more than one Note the number of full shares that shall be issuable upon the payment of or provision for interest shall be computed on the
basis of the aggregate principal amount (and the aggregate interest amount payable thereon) of all of the Notes held by such Holder. For these purposes, the current market value of a share of Common Stock shall be the Closing Price on the first
Trading Day immediately preceding the applicable Interest Payment Date and such Closing Price shall be determined as provided in Section 12.03. The Threshold Price and any calculation or determination in respect of the simple average of the daily
volume-weighted average price of the Common Stock shall be adjusted as provided for in Section 12.04. 
  
 Any interest on any Note that is payable, but is not punctually paid or duly provided for, on any Interest Payment Date (herein called “Defaulted
Interest”) shall forthwith cease to be payable to the registered Holder thereof on the relevant Regular Record Date by virtue of having been such Holder, and such Defaulted Interest may be paid by the Company, at its election in each case, as
provided in clause 3.06(a) or 3.06(b) below: 
  
 (a) The Company
may elect to make payment of any Defaulted Interest to the Persons in whose names the Notes (or their respective Predecessor Notes) are registered at the close of business on a Special Record Date for the payment of such Defaulted Interest, which
shall be fixed in the following manner. The Company shall notify the Trustee in writing of the amount of Defaulted Interest proposed to be paid on each Note and the date of the proposed payment (which shall not be less than 30 days after such notice
is received by the Trustee) and at the same time the Company shall deposit with the Trustee an amount of money equal to the aggregate amount proposed to be paid in respect of such Defaulted Interest or shall make arrangements satisfactory to the
Trustee for such deposit on or prior to the date of the proposed payment, such money when deposited to be held in trust for the benefit of the Persons entitled to such Defaulted Interest as in this clause provided. Thereupon the Company shall fix a
Special Record Date for the payment of such Defaulted Interest which shall be not more than 15 days and not less than 10 days prior to the date of the proposed payment. The Company shall promptly notify the Trustee of such Special Record Date and,
in the name and at the expense of the Company, the Trustee shall cause notice of the proposed payment of such Defaulted Interest and the Special Record Date therefor to be mailed, first-class postage prepaid, to each Holder of Notes at his address
as it appears in the Note Register not less than 10 days prior to such Special Record Date. The Trustee may, in its discretion, in the name and at the expense of the Company, cause a similar notice to be published at least once in an Authorized
Newspaper in each Place of Payment, but such publications shall not be a condition precedent to the establishment of such Special Record Date. Notice of the proposed payment of such Defaulted Interest and the Special Record Date therefor having been
mailed as aforesaid, such Defaulted Interest shall be paid to the Persons in whose names the Notes (or their respective Predecessor Notes) are registered at the close of business on such Special Record Date and shall no longer be payable pursuant to
the following clause (b). 
  
 (b) The Company may make payment of
any Defaulted Interest on the Notes in any other lawful manner not inconsistent with the requirements of any securities exchange on which 

  

 -21- 

 
such Notes may be listed, and upon such notice as may be required by such exchange, if, after notice given by the Company to the Trustee of the proposed
payment pursuant to this clause, such manner of payment shall be deemed practicable by the Trustee. 
  
 (c) Subject to the foregoing provisions of this Section, each Note delivered under this Indenture upon registration of transfer of or in exchange for or
in lieu of any other Note shall carry the rights to interest accrued and unpaid, and to accrue, which were carried by such other Note. 
  
 SECTION 3.07. Persons Deemed Owners. Prior to due presentment of a Note for registration of transfer, the Company, the Trustee and any agent of the
Company or the Trustee may treat the Person in whose name such Note is registered as the owner of such Note for the purpose of receiving payment of principal of (and premium, if any), and (subject to Sections 3.04 and 3.06) interest on, such Note
and for all other purposes whatsoever, whether or not such Note is overdue, and neither the Company, the Trustee nor any agent of the Company or the Trustee shall be affected by notice to the contrary. 
  
 None of the Company, the Trustee, any Paying Agent or the Note Registrar
shall have any responsibility or liability for any aspect of the records relating to or payments made on account of beneficial ownership interests of a Note in global form or for maintaining, supervising or reviewing any records relating to such
beneficial ownership interests. 
  
 Notwithstanding the foregoing,
with respect to any global Note, nothing herein shall prevent the Company, the Trustee, or any agent of the Company or the Trustee, from giving effect to any written certification, proxy or other authorization furnished by any depositary, as a
Holder, with respect to such global Note or impair, as between such depositary and owners of beneficial interests in such global Note, the operation of customary practices governing the exercise of the rights of such depositary (or its nominee) as a
Holder of such global Note. 
  
 SECTION 3.08. Cancellation.
All Notes surrendered for payment, redemption, repayment at the option of the Holder, repurchase, voluntary conversion, Auto-Conversion or registration of transfer or exchange shall, if surrendered to any Person other than the Trustee, be delivered
to the Trustee, and any such Notes surrendered directly to the Trustee for any such purpose shall be promptly canceled by it. The Company may at any time deliver to the Trustee for cancellation any Notes previously authenticated and delivered
hereunder that the Company may have acquired in any manner whatsoever, and may deliver to the Trustee (or to any other Person for delivery to the Trustee) for cancellation any Notes previously authenticated hereunder that the Company has not issued
and sold, and all Notes so delivered shall be promptly canceled by the Trustee. If the Company shall so acquire any of the Notes, however, such acquisition shall not operate as a redemption or satisfaction of the indebtedness represented by such
Notes unless and until the same are surrendered to the Trustee for cancellation. No Notes shall be authenticated in lieu of or in exchange for any Notes canceled as provided in this Section, except as expressly permitted by this Indenture. Canceled
Notes held by the Trustee shall be destroyed by the Trustee and the Trustee shall deliver a certificate of such destruction to the Company, unless by a Company Order the Company directs their return to it. 
  

 -22- 

 SECTION 3.09. Computation of Interest. Interest on the Notes shall be computed on the basis of a
360-day year consisting of twelve 30-day months. 
  
 SECTION
3.10. CUSIP Numbers. The Company in issuing the Notes shall use “CUSIP” numbers, and the Trustee shall use CUSIP numbers in notices of redemption as a convenience to Holders; provided however, that any such notice may state that no
representation is made as to the correctness of such numbers either as printed on the Notes or as contained in any notice of a redemption and that reliance may be placed only on the other identification numbers printed on the Notes, and any such
redemption shall not be affected by any defect in or omission of such numbers. The Company shall promptly notify the Trustee of any change in the CUSIP numbers applicable to the Notes. 
  
 ARTICLE 4 
 Remedies 
  
 SECTION 4.01. Events of
Default. “Event of Default,” wherever used herein with respect to the Notes, means any one of the following events (whatever the reason for such Event of Default and whether or not it shall be voluntary or involuntary or be effected by
operation of law or pursuant to any judgment, decree or order of any court or any order, rule or regulation of any administrative or governmental body): 
  
 (a) default in the payment of any interest upon any Note, when such interest becomes due and payable, and continuance of such default for
a period of 30 days; or 
  
 (b) default in the
payment of (i) the principal of (or premium, if any, on) any Note when it becomes due and payable at its Maturity, or (ii) the Redemption Price with respect to any Note when it becomes due and payable; or 
  
 (c) default in the payment of the Repurchase Price in
respect of any Note on the Repurchase Date therefor (whether or not a Person other than the Company has offered to repurchase Outstanding Notes as contemplated by Section 11.02(j)); or 
  
 (d) failure by the Company to give the Company Notice in accordance with Section 11.02(a) to all Holders of
Outstanding Notes and to the Trustee; or 
  
 (e)
failure by the Company to deliver the Base Shares, the Plus Cash Amount, the Plus Cash Shares or the Make-Whole Payment, together with cash or stock in lieu of fractional shares, in each case, as applicable, required to be delivered following
voluntary conversion or Auto-Conversion, as the case may be, of a Note and continuation of such default for a period of 10 days; or 
  
 (f) default in the performance, or breach, of any covenant or warranty of the Company in this Indenture with respect to any Note (other
than a covenant or warranty a default in whose performance or whose breach is elsewhere in this Section specifically dealt with) and continuance of such default or breach for a period of 60 days after there has been given, by 

  

 -23- 

 
registered or certified mail, to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 25% in principal amount of the
Outstanding Notes a written notice specifying such default or breach and requiring it to be remedied and stating that such notice is a “Notice of Default” hereunder; or 
  
 (g) a default under any bonds, debentures, notes or other evidences of indebtedness for money borrowed of
the Company or under any mortgages, indentures or instruments under which there may be issued or by which there may be secured or evidenced any indebtedness for money borrowed by the Company, whether such indebtedness now exists or shall hereafter
be created, which indebtedness, individually or in the aggregate, has a principal amount outstanding in excess of $10,000,000, which default shall have resulted in such indebtedness becoming or being declared due and payable prior to the date on
which it would otherwise have become due and payable, without such indebtedness having been discharged, or such acceleration having been rescinded or annulled, within a period of 60 days after there shall have been given, by registered or certified
mail, to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 25% in principal amount of the Notes then Outstanding, a written notice specifying such default and requiring the Company to cause such indebtedness to
be discharged or cause such acceleration to be rescinded or annulled and stating that such notice is a “Notice of Default” hereunder (unless such default has been cured or waived); or 
  
 (h) the Company or any Significant Subsidiary pursuant to or
within the meaning of any Bankruptcy Law: 
  
 (i)
commences a voluntary case, 
  
 (ii) consents to
the entry of an order for relief against it in an involuntary case, 
  
 (iii) consents to the appointment of a Custodian of it or for all or substantially all of its property, or 
  
 (iv) makes a general assignment for the benefit of its creditors; or 
  
 (i) a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that: 

 
 (i) is for relief against the Company or any Significant
Subsidiary in an involuntary case, 
  
 (ii)
appoints a Custodian of the Company or any Significant Subsidiary or for all or substantially all of the property of any of them, or 
  
 (iii) orders the winding up or liquidation of the Company or any Significant Subsidiary, 
  
 and the order or decree remains unstayed and in effect for 60 days.

  

 -24- 

 As used in this Section 4.01 only, the term “Bankruptcy Law” means title 11, U.S. Code or any
similar Federal or State law for the relief of debtors and the term “Custodian” means any receiver, trustee, assignee, liquidator or other similar official under any Bankruptcy Law. 
  
 SECTION 4.02. Acceleration of Maturity; Rescission and Annulment. If
an Event of Default with respect to Notes at the time Outstanding occurs and is continuing, then and in every such case the Trustee, or the Holders of not less than 25% in principal amount of the Outstanding Notes, may declare the principal of all
the Notes, and accrued interest thereon to the date of such declaration, to be due and payable immediately, by a notice in writing to the Company (and to the Trustee if given by the Holders), and upon any such declaration such principal shall become
immediately due and payable. If an Event of Default specified in Section 4.01(h) or Section 4.01(i) occurs, the principal of, and accrued interest on, all the Notes shall automatically, and without any declaration or other action on the part of the
Trustee or any Holder, become immediately due and payable. 
  
 At
any time after such a declaration of acceleration with respect to the Notes has been made and before a judgment or decree for payment of the money due has been obtained by the Trustee as hereinafter provided in this Article, the Holders of a
majority in principal amount of the Outstanding Notes, by written notice to the Company and the Trustee, may rescind and annul such declaration and its consequences if: 
  
 (a) the Company has paid or deposited with the Trustee a sum sufficient to pay: 
  
 (i) all overdue installments of interest on all Outstanding
Notes, 
  
 (ii) the principal of (and premium, if
any, on) any Outstanding Notes that have become due otherwise than by reason of such declaration of acceleration and interest thereon at the rate or rates borne by or provided for in such Notes, 
  
 (iii) to the extent that payment of such interest is lawful,
interest upon overdue installments of interest at the rate or rates borne by or provided for in such Notes, and 
  
 (iv) all sums paid or advanced by the Trustee hereunder and the reasonable compensation, expenses, disbursements and advances of the
Trustee, its agents and counsel; and 
  
 (b) all Events of
Default with respect to the Notes, other than the nonpayment of the principal of (or premium, if any) or interest on Notes which have become due solely by reason of such declaration of acceleration, have been cured or waived as provided in Section
4.13. 
  
 No such rescission shall affect any subsequent Default
or Event of Default or impair any right in respect thereof. 
  

 -25- 

 SECTION 4.03. Collection of Indebtedness and Suits for Enforcement by Trustee. The Company
covenants that if: 
  
 (a) default is made in the payment of any
installment of interest on any Note when such interest becomes due and payable and such default continues for a period of 30 days, or 
  
 (b) default is made in the payment of the principal of (or premium, if any, on) any Note at its Maturity, then the Company shall, upon demand of the
Trustee, pay to the Trustee, for the benefit of the Holders of such Notes, the whole amount then due and payable on such Notes for principal (and premium, if any) and interest, with interest upon any overdue principal (and premium, if any) and, to
the extent that payment of such interest shall be legally enforceable, upon any overdue installments of interest, at the rate or rates borne by or provided for in such Notes, and, in addition thereto, such further amount as shall be sufficient to
cover the costs and expenses of collection, including the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel. 
  

If the Company fails to pay such amounts forthwith upon such demand, the Trustee, in its own name and as trustee of an express trust, may institute a
judicial proceeding for the collection of the sums so due and unpaid, and may prosecute such proceeding to judgment or final decree, and may enforce the same against the Company or any other obligor upon such Notes under a supplemental indenture
entered into in accordance herewith and collect the moneys adjudged or decreed to be payable in the manner provided by law out of the property of the Company or any other such obligor upon such Notes, wherever situated. 
  
 If an Event of Default occurs and is continuing, the Trustee may in its
discretion proceed to protect and enforce its rights and the rights of the Holders of Notes by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any such rights, whether for the specific
enforcement of any covenant or agreement in this Indenture or in aid of the exercise of any power granted herein, or to enforce any other proper remedy. 
  
 SECTION 4.04. Trustee May File Proofs of Claim. In case of the pendency of any receivership, insolvency, liquidation, bankruptcy, reorganization,
arrangement, adjustment, composition or other judicial proceeding relative to the Company or any other obligor upon the Notes under a supplemental indenture entered into in accordance herewith or the property of the Company or of such other obligor
or the Company’s, or any such other obligor’s, creditors, the Trustee (irrespective of whether the principal of the Notes shall then be due and payable as therein expressed or by acceleration or otherwise and irrespective of whether the
Trustee shall have made any demand on the Company for the payment of overdue principal, premium, if any, or interest) shall be entitled and empowered, by intervention in such proceeding or otherwise: 
  
 (a) to file and prove a claim for the whole amount, or such lesser amount as
may be provided for in the Notes, of principal (and premium, if any) and interest, owing and unpaid in respect of the Notes and to file such other papers or documents as may be necessary or advisable in order to have the claims of the Trustee
(including any claim for the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel) and of the Holders allowed in such judicial proceeding, and 
  
 (b) to collect and receive any moneys or other property payable or
deliverable on any such claims and to distribute the same; and any custodian, receiver, assignee, trustee, liquidator, 

  

 -26- 

 
sequestrator (or other similar official) in any such judicial proceeding is hereby directed by each Holder to make such payments to the Trustee, and in the
event that the Trustee shall request or consent to the making of such payments directly to the Holders, to pay to the Trustee any amount due to it for the reasonable compensation, expenses, disbursements and advances of the Trustee and any
predecessor Trustee, their agents and counsel, and any other amounts due the Trustee or any predecessor Trustee under Section 5.07. 
  
 Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Holder of a Note, any
plan of reorganization, arrangement, adjustment or composition affecting the Notes or the rights of any Holder thereof, or to authorize the Trustee to vote in respect of the claim of any Holder of a Note in any such proceeding; provided however,
that the Trustee may, on behalf of the Holders, vote for the election of a trustee in bankruptcy or similar official and be a member of a creditors’ or other similar committee. 
  
 SECTION 4.05. Trustee May Enforce Claims Without Possession of Notes. All rights of action and claims under this
Indenture or any of the Notes may be prosecuted and enforced by the Trustee without the possession of any of the Notes or the production thereof in any proceeding relating thereto, and any such proceeding instituted by the Trustee shall be brought
in its own name as trustee of an express trust, and any recovery of judgment shall, after provision for the payment of the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, be for the ratable
benefit of the Holders of the Notes in respect of which such judgment has been recovered. 
  
 SECTION 4.06. Application of Money Collected. Any money collected by the Trustee pursuant to this Article shall be applied in the following order, at the date or dates fixed by the Trustee and, in case of the
distribution of such money on account of principal (or premium, if any) or interest, upon presentation of the Notes, or both, as the case may be, and the notation thereon of the payment if only partially paid and upon surrender thereof if fully
paid: 
  
 FIRST: To the payment of all amounts due the
Trustee and any predecessor Trustee under Section 5.07; 
  
 SECOND: To the payment of the amounts then due and unpaid upon the Notes for principal (and premium, if any) and interest payable, and any other amounts due and payable under this Indenture or under the Notes in respect of which or
for the benefit of which such money has been collected, ratably, without preference or priority of any kind, according to the aggregate amounts due and payable on such Notes for principal (and premium, if any) and, interest, respectively; and

  
 THIRD: To the payment of the remainder, if any, to the
Company. 
  

 -27- 

 SECTION 4.07. Limitation on Suits. No Holder of any Note shall have any right to institute any
proceeding, judicial or otherwise, with respect to this Indenture, or for the appointment of a receiver or trustee, or for any other remedy hereunder, unless: 
  

(a) such Holder has previously given written notice to the Trustee of a continuing Event of Default with respect to the Notes; 
  
 (b) the Holders of not less than 25% in principal amount of the Outstanding
Notes shall have made written request to the Trustee to institute proceedings in respect of such Event of Default in its own name as Trustee hereunder; 
  
 (c) such Holder or Holders have offered to the Trustee security or indemnity reasonably satisfactory to the Trustee against the costs, expenses and
liabilities to be incurred in compliance with such request; 
  
 (d) the Trustee for 60 days after its receipt of such notice, request and offer of security or indemnity has failed to institute any such proceeding; and 
  
 (e) no direction inconsistent with such written request has been given to the Trustee during such 60-day period by the
Holders of a majority in principal amount of the Outstanding Notes; 
  
 it being
understood and intended that no one or more of such Holders shall have any right in any manner whatever by virtue of, or by availing of, any provision of this Indenture to affect, disturb or prejudice the rights of any other of such Holders, or to
obtain or to seek to obtain priority or preference over any other of such Holders or to enforce any right under this Indenture, except in the manner herein provided and for the equal and ratable benefit of all such Holders. 
  
 SECTION 4.08. Unconditional Right of Holders to Receive Principal,
Premium, If Any, and Interest. Notwithstanding any other provision in this Indenture, the Holder of any Note shall have the right, which is absolute and unconditional, to receive payment of the principal of, and premium, if any, including the
Redemption Price pursuant to Article 10, the Repurchase Price pursuant to Article 11 and (subject to Sections 3.04 and 3.06) interest on such Note on the respective due dates expressed in such Note (or, in the case of redemption or repurchase, on
the Redemption Date or Repurchase Date, as the case may be) and to convert such Note in accordance with the provisions of this Indenture and to institute suit for the enforcement of any such payment and right to convert, and such rights shall not be
impaired or adversely affected without the consent of such Holder. 
  
 SECTION 4.09. Restoration of Rights and Remedies. If the Trustee or any Holder of a Note has instituted any proceeding to enforce any right or remedy under this Indenture and such proceeding has been discontinued or abandoned for any
reason, or has been determined adversely to the Trustee or to such Holder, then and in every such case, the Company, the Trustee and the Holders of Notes shall, subject to any determination in such proceeding, be restored severally and respectively
to their former positions hereunder and thereafter all rights and remedies of the Trustee and the Holders shall continue as though no such proceeding had been instituted. 
  
 SECTION 4.10. Rights and Remedies Cumulative. Except as otherwise provided with respect to the replacement or payment
of mutilated, destroyed, lost or stolen Notes in the last 

  

 -28- 

 
paragraph of Section 3.05, no right or remedy herein conferred upon or reserved to the Trustee or to the Holders of Notes is intended to be exclusive of any
other right or remedy, and every right and remedy shall, to the extent permitted by law, be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or
employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other appropriate right or remedy. 
  
 SECTION 4.11. Delay or Omission Not Waiver. No delay or omission of the Trustee or of any Holder of any Note to exercise any right or remedy
accruing upon any Event of Default shall impair any such right or remedy or constitute a waiver of any such Event of Default or an acquiescence therein. Every right and remedy given by this Article or by law to the Trustee or to the Holders may be
exercised from time to time, and as often as may be deemed expedient, by the Trustee or by the Holders of Notes, as the case may be. 
  
 SECTION 4.12. Control by Holders of Notes. The Holders of not less than a majority in principal amount of the Outstanding Notes shall have the
right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee or exercising any trust or power conferred on the Trustee with respect to the Notes, provided that: 
  
 (a) such direction shall not be in conflict with any rule of law or with
this Indenture, (b) the Trustee may take any other action deemed proper by the Trustee that is not inconsistent with such direction, and (c) the Trustee need not take any action that might involve it in personal liability or be unduly prejudicial to
the Holders of Notes not joining therein. 
  
 SECTION 4.13.
Waiver of Past Defaults. The Holders of not less than a majority in principal amount of the Outstanding Notes may on behalf of the Holders of all the Notes waive any past Default or Event of Default hereunder with respect to such Notes and its
consequences, except a Default or Event of Default: 
  
 (a) in the payment of the principal of (or premium, if any) or interest on any Note; 
  
 (b) in respect of the conversion by the Company of any Note; 
  
 (c) in the payment of the Redemption Price pursuant to Article 10; 
  
 (d) in the payment of the Repurchase Price pursuant to
Article 11; 
  
 (e) in respect of a covenant or provision hereof
that under Article 8 cannot be modified or amended without the consent of the Holder of each Outstanding Note affected; or 
  
 (f) in respect of a covenant or provision hereof for the personal protection or benefit of the Trustee, without the consent of the Trustee. 
  
 Upon any such waiver, such Default or Event of Default shall cease to exist,
and any Event of Default arising from any such Default shall be deemed to have been cured, for every purpose of this Indenture; but no such waiver shall extend to any subsequent or other Default or Event of Default or impair any right consequent
thereon. 
  

 -29- 

 SECTION 4.14. Waiver of Usury, Stay or Extension Laws. The Company covenants (to the extent that
it may lawfully do so) that it shall not at any time insist upon, or plead, or in any manner whatsoever claim or take the benefit or advantage of, any usury, stay or extension law wherever enacted, now or at any time hereafter in force, which may
affect the covenants or the performance of this Indenture; and the Company (to the extent that it may lawfully do so) hereby expressly waives all benefit or advantage of any such law, and covenants that it shall not hinder, delay or impede the
execution of any power herein granted to the Trustee, but will suffer and permit the execution of every such power as though no such law had been enacted. 
  
 SECTION 4.15. Undertaking for Costs. All parties to this Indenture agree, and each Holder of any Note by his acceptance thereof shall be deemed to
have agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken or omitted by it as Trustee, the filing by any party
litigant in such suit of an undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs, including reasonable attorneys’ fees, against any party litigant in such suit having due regard to the
merits and good faith of the claims or defenses made by such party litigant; but the provisions of this Section shall not apply to any suit instituted by the Trustee, to any suit instituted by any Holder, or group of Holders, holding in the
aggregate more than 10% in principal amount of the Outstanding Notes, or to any suit instituted by any Holder for the enforcement of the payment of the principal of (or premium, if any) or interest on any Note on or after the respective Stated
Maturities expressed in such Note (or, in the case of redemption or repurchase, on or after the Redemption Date or the Repurchase Date, respectively), or the right to convert any Note in accordance with Article 12. 
  
 ARTICLE 5 
 The Trustee 
  
 SECTION 5.01. General. The Trustee, prior to the occurrence of an Event of Default known to a Responsible Officer of the Trustee and after the curing of all Events of Default that may have occurred, undertakes to perform such duties
and only such duties as are specifically set forth in this Indenture. In case an Event of Default has occurred (that has not been cured or waived) and is known to a Responsible Officer of the Trustee, the Trustee shall exercise such of the rights
and powers vested in it by this Indenture, and use the same degree of care and skill in their exercise, as a prudent man would exercise or use under the circumstances in the conduct of his own affairs. 
  
 No provision of this Indenture shall be construed to relieve the Trustee from
liability for its own negligent action, its own negligent failure to act, its own willful misconduct, its own recklessness or its own bad faith. 
  
  

 -30- 

 SECTION 5.02. Certain Rights of Trustee. Subject to TIA Sections 315(a) through (d): 

 
 (a) the Trustee may rely, and shall be protected in acting or refraining
from acting, upon any resolution, certificate, statement, instrument, facsimile transmission, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document believed by
it to be genuine and to have been signed, made or presented by the proper person, and may accept and rely upon the same as conclusive evidence of the truth and accuracy of the statements and opinions contained therein. The Trustee need not
investigate any fact or matter stated in any such document; 
  
 (b) before the Trustee acts or refrains from acting, it may require an Officers’ Certificate or an Opinion of Counsel, which shall conform to Section 1.02. The Trustee shall not be liable for any action it takes or omits to take in
good faith in reliance on such certificate or opinion; 
  
 (c)
the Trustee may consult with counsel, and the written advice of such counsel shall be full and complete authorization and protection with respect to any action taken, suffered or omitted by it hereunder in good faith and in reliance thereon, and may
act through its attorneys and agents and shall not be responsible for the misconduct or negligence of any attorney or agent appointed with due care; 
  
 (d) the Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request or direction of any of
the Holders, unless such Holders shall have offered to the Trustee reasonable security or indemnity against the costs, expenses and liabilities that might be incurred by it in complying with such request or direction; 
  
 (e) the Trustee shall not be liable for any action it takes or omits to take
in good faith that it believes to be authorized or within its rights or powers or for any action it takes or omits to take in accordance with the written direction of the Holders of a majority in principal amount of the Outstanding Notes relating to
the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee, under this Indenture; 
  
 (f) whenever in the administration of this Indenture the Trustee shall deem it desirable that a matter be proved or
established prior to taking, suffering or omitting any action hereunder, the Trustee (unless other evidence be herein specifically prescribed) may, in the absence of bad faith on its part, rely upon an Officers’ Certificate; 
  
 (g) the Trustee shall not be bound to make any investigation into the facts
or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document, but the Trustee, in its
discretion, may make such further inquiry or investigation into such facts or matters as it may see fit, and, if the Trustee shall determine to make such further inquiry or investigation, it shall be entitled to examine the books, records and
premises of the Company personally or by agent or attorney; 
  
 (h) the Trustee shall not be required to take notice or be deemed to have notice of any Default or Event of Default unless the Trustee be specifically notified of such Default or Event of Default in writing by the Company or any Holder, and
in the absence of such notice the Trustee may conclusively assume that there is no Default or event of Default; provided that if the Trustee is acting as Paying Agent, the Trustee shall be required to take and be deemed to have notice of its failure
to receive payments of interest or principal hereunder; 
  

 -31- 

 (i) the Trustee shall have no responsibility with respect to any information in any offering memorandum
or other disclosure material distributed with respect to the Notes, and the Trustee shall have no responsibility for compliance with securities laws in connection with the issuance and sale, resale, transfer or exchange of the Notes; 
  
 (j) in the event the Trustee shall receive inconsistent or conflicting
requests and security or indemnity from two or more groups of Holders, each representing at least 25% (but less than 50%) of the aggregate principal amount of the Notes then Outstanding, the Trustee shall act in accordance with instructions received
by the Holders of the greater percentage thereof; 
  
 (k) except
as otherwise expressly provided by the provisions of this Indenture, the Trustee shall not be obligated, and may not be required to give or furnish any notice, demand, report, request, reply, statement, advice or opinion to any Holder or to the
Company or any other Person, and the Trustee shall not incur any liability for its failure or refusal to give or furnish the same unless obligated or required to do so by the express provisions hereof; 
  
 (l) the Trustee shall not be required to give any bond or surety with
respect to the performance of its duties or the exercise of its powers under this Indenture; and 
  
 (m) any permissive power or authority granted to the Trustee shall not be construed to be a duty. 
  
 SECTION 5.03. Individual Rights of Trustee. The Trustee, any Paying
Agent, Note Registrar or any other agent of the Company, in its individual or any other capacity, may become the owner or pledgee of Notes and may otherwise deal with the Company, its Subsidiaries or its Affiliates with the same rights it would have
if it were not the Trustee, Paying Agent, Note Registrar or such other agent. Any registrar, co-registrar, paying agent, conversion agent or authenticating agent may do the same with like rights. However, upon qualification of this Indenture under
the TIA, the Trustee shall be subject to TIA Sections 310(b) and 311. 
  
 SECTION 5.04. Trustee’s Disclaimer. The Trustee (i) makes no representation as to the validity or adequacy of this Indenture, the Notes or the offering documents relating to the Notes, (ii) shall not be accountable for the
Company’s use or application of the proceeds from the Notes and (iii) shall not be responsible for any statement in the Notes other than its certificate of authentication. 
  
 SECTION 5.05. Notice of Default. If any Event of Default occurs and is continuing and if a Responsible Officer of the
Trustee has actual knowledge of such Event of Default, the Trustee shall mail to each Holder in the manner and to the extent provided in TIA Section 313(c) notice of the Event of Default within 90 days after it occurs, unless such Event of Default
has been cured or waived; provided, however, that, except in the case of a Default in the payment of the principal of (or premium, if any) or interest on any Note, the Trustee shall be protected in withholding such notice if and so long as
Responsible Officers of the Trustee in good faith determine that the withholding of such notice is in the interests of the Holders of the Notes. 
  

 -32- 

 SECTION 5.06. Conflicting Interests of Trustee. If the Trustee has or shall acquire a conflicting
interest within the meaning of the TIA, the Trustee shall either eliminate such interest or resign, to the extent and in the manner provided by, and subject to the provisions of, the TIA and this Indenture. 
  
 SECTION 5.07. Compensation and Indemnity. The Company shall pay to the
Trustee such compensation as shall be agreed upon in writing for its services. The compensation of the Trustee shall not be limited by any law on compensation of a trustee of an express trust. The Company shall reimburse the Trustee upon request for
all reasonable out-of-pocket expenses, disbursements and advances incurred or made by the Trustee in accordance with this Indenture. 
  
 Such expenses shall include the reasonable compensation, expenses, disbursements and advances of the Trustee’s agents and counsel. 
  
 The Company shall indemnify and hold harmless the Trustee and its directors,
agents and employees (including officers) (collectively the “Indemnitees”) against any and all losses, liabilities, obligations, damages, penalties, fines, judgments, actions, suits, proceedings, reasonable costs and expenses (including
reasonable fees and disbursements of counsel) of any kind whatsoever that may be incurred by or imposed on the Indemnitees or any of them arising out of or in connection with the acceptance or administration of the Trustee’s duties under this
Indenture; provided, however, that the Company need not reimburse any expense or indemnify against any loss, obligation, damage, penalty, fine, judgment, action, suit, proceeding, reasonable cost or expense (including reasonable fees and
disbursements of counsel) of any kind whatsoever that may be incurred by Indemnitees or any of them which results from the negligence or willful misconduct of the Indemnitees or any of them. The Trustee shall notify the Company promptly of any claim
for which it may seek indemnity. Failure by the Trustee to so notify the Company shall not relieve the Company of its obligations hereunder, unless the Company is materially prejudiced thereby. The Company shall defend the claim, and the Trustee
shall cooperate in the defense. Unless otherwise set forth herein, the Indemnitees or any of them, may have separate counsel and the Company shall pay the reasonable fees and expenses of such counsel. The Company need not pay for any settlement made
without its consent, which consent shall not be unreasonably withheld. The provisions of this Section 5.07 shall survive the termination of this Indenture and the resignation or removal of the Trustee for any reason, including any termination under
any bankruptcy law. 
  
 To secure the Company’s payment
obligations in this Section 5.07, the Trustee shall have a lien prior to the Notes on all money or property held or collected by the Trustee, in its capacity as Trustee, except money or property held in trust to pay principal of, premium, if any,
and interest on particular Notes. 
  
 If the Trustee incurs
expenses or renders services after the occurrence of an Event of Default specified in Section 4.01(h) or Section 4.01(i), such expenses, and the compensation due to the Trustee for such services, are intended to constitute expenses of administration
under Title 11 of the United States Bankruptcy Code or any applicable federal or state law for the relief of debtors. 
  

 -33- 

 SECTION 5.08. Replacement of Trustee. A resignation or removal of the Trustee and appointment of a
successor Trustee shall become effective only upon the successor Trustee’s acceptance of appointment as provided in this Section 5.08. 
  
 The Trustee may resign at any time by so notifying the Company in writing at least thirty days prior to the date of the proposed resignation. The Holders
of a majority in principal amount of the Outstanding Notes may at any time, by written notice to the Trustee and the Company, remove the Trustee and, with the prior consent of the Company, appoint a successor Trustee. The Company may remove the
Trustee if: (i) the Trustee is no longer eligible under Section 5.10; (ii) the Trustee is adjudged a bankrupt or an insolvent; (iii) a receiver or other public officer takes charge of the Trustee or its property; or (iv) the Trustee becomes
incapable of acting. 
  
 If the Trustee is removed without the
concurrent appointment by the Holders of a successor Trustee, if the Trustee resigns, or if a vacancy exists in the office of Trustee for any other reason, the Company shall promptly appoint a successor Trustee. If no successor Trustee has delivered
its written acceptance required by the next succeeding paragraph of this Section 5.08 within thirty days after the retiring Trustee delivers notice of its resignation or is removed, or after the occurrence of a vacancy in the office of Trustee for
any other reason, the retiring Trustee, the Company or the Holders of a majority in principal amount of the Outstanding Notes may petition any court of competent jurisdiction for the appointment of a successor Trustee. 
  
 A successor Trustee shall deliver a written acceptance of its appointment to
the retiring Trustee and to the Company. Immediately after the delivery of such written acceptance, subject to the lien provided in Section 5.07, (i) the retiring Trustee shall transfer all property held by it as Trustee to the successor Trustee,
(ii) the resignation or removal of the retiring Trustee shall become effective and (iii) the successor Trustee shall have all the rights, powers and duties of the Trustee under this Indenture. A successor Trustee shall mail notice of its succession
to each Holder. 
  
 If the Trustee is no longer eligible under
Section 5.10, any Holder who satisfies the requirements of TIA Section 310(b) may petition any court of competent jurisdiction for the removal of the Trustee and the appointment of a successor Trustee. 
  
 The Company shall give notice of any resignation and any removal of the
Trustee and each appointment of a successor Trustee to all Holders. Each notice shall include the name of the successor Trustee and the address of its Corporate Trust Office. 
  
 Notwithstanding replacement of the Trustee pursuant to this Section 5.08, the Company’s obligations under Section 5.07
shall continue for the benefit of the retiring Trustee. 
  
 SECTION 5.09. Successor Trustee by Merger, Etc. If the Trustee consolidates with, merges or converts into, or transfers all or substantially all of its corporate trust business (including the administration of this Indenture) to,
another corporation or national banking association, the resulting, surviving or transferee corporation or national banking association, without any further act, shall be the successor Trustee with the same effect as if the successor Trustee had
been named as the Trustee herein. 
  

 -34- 

 SECTION 5.10. Eligibility. This Indenture shall always have a Trustee who satisfies the
requirements of TIA Section 310(a)(1). The Trustee (or the bank holding company to which the Trustee is a member) shall have a combined capital and surplus of at least $25 million as set forth in its most recent published annual report of condition.

  
 SECTION 5.11. Money Held in Trust. Subject to the
provisions of Section 9.03, all monies received by the Trustee shall, until used or applied as herein provided, be held in trust for the purposes for which they were received. The Trustee shall not be liable for interest on any money received by it
except as the Trustee may agree with the Company. Money held in trust by the Trustee need not be segregated from other funds except to the extent required by law. 
  
 SECTION 5.12. Preferential Collection of Claims. If and when the Trustee shall be or become a creditor of the Company
(or any other obligor upon the Notes under a supplemental indenture entered into in accordance herewith), the Trustee shall be subject to the provisions of the Trust Indenture Act regarding the collection of the claims against the Company (or any
such other obligor). 
  
 SECTION 5.13. Trustee’s
Application for Instructions from the Company. Any application by the Trustee for written instructions from the Company (other than with regard to any action proposed to be taken or omitted to be taken by the Trustee that affects the rights of
the Holders) may, at the option of the Trustee, set forth in writing any action proposed to be taken or omitted by the Trustee under this Indenture and the date on and/or after which such action shall be taken or such omission shall be effective.
The Trustee shall not be liable for any action taken by, or omission of, the Trustee in accordance with a proposal included in such application on or after the date specified in such application (which date shall not be less than ten Business Days
after the date any officer of the Company actually receives such application, unless any such officer shall have consented in writing to any earlier date) unless prior to taking any such action (or the effective date in the case of an omission), the
Trustee shall have received written instructions in response to such application specifying the action to be taken or omitted. 
  
 ARTICLE 6 
 Holders’ Lists And
Reports By Trustee And Company 
  
 SECTION 6.01. Disclosure
of Names and Addresses of Holders. Every Holder of Notes, by receiving and holding the same, agrees with the Company and the Trustee that none of the Company, the Trustee, any Paying Agent or any Note Registrar, shall be held accountable by
reason of the disclosure of any information as to the names and addresses of the Holders of Notes in accordance with TIA Section 312, regardless of the source from which such information was derived, and that the Trustee shall not be held
accountable by reason of mailing any material pursuant to a request made under TIA Section 312(b). 
  
 SECTION 6.02. Reports by Trustee. Within 60 days after October 15 of each year, commencing with the first October 15 to occur after the
qualification of this Indenture, the 

  

 -35- 

 
Trustee shall transmit by mail to all Holders of Notes as provided in TIA Section 313(c), if required by TIA Section 313(a), a brief report dated as of such
October 15. A copy of each such report shall at the time of such transmission to Holders be filed by the Trustee with the Company. 
  
 SECTION 6.03. Reports by Company. The Company shall: 
  
 (a) file with the Trustee, within 15 days after the Company is required to file the same with the Commission, copies of the annual reports and of the
information, documents and other reports (or copies of such portions of any of the foregoing as the Commission may from time to time by rules and regulations prescribe) that the Company may be required to file with the Commission pursuant to
Sections 13(a) or 13(b) or Section 15(d) of the Exchange Act; or, if the Company is not required to file information, documents or reports pursuant to any of such Sections, then it shall file with the Trustee, in accordance with rules and
regulations prescribed from time to time by the Commission, such of the supplementary and periodic information, documents and reports that may be required pursuant to Section 13 of the Exchange Act in respect of a security listed and registered on a
national securities exchange as may be prescribed from time to time in such rules and regulations; 
  
 (b) file with the Trustee and the Commission, in accordance with rules and regulations prescribed from time to time by the Commission, such additional
information, documents and reports with respect to compliance by the Company with the conditions and covenants of this Indenture as may be required from time to time by such rules and regulations; and 
  
 (c) file with the Trustee and the Commission, if applicable, and transmit by
mail to the Holders, within thirty days after the filing thereof with the Trustee, in the manner and to the extent provided in TIA Section 313(c), such summaries of any information, documents and reports required to be filed by the Company pursuant
to paragraphs (1) and (2) of this Section as may be required by rules and regulations prescribed from time to time by the Commission and sell other information as may be required pursuant to the TIA, at the time and in the manner provided pursuant
to such Act. 
  
 SECTION 6.04. Company to Furnish Trustee Names
and Addresses of Holders. 
  
 (a) The Company shall furnish
or cause to be furnished to the Trustee: 
  
 (i)
semiannually, not later than 10 days after the Regular Record Date for the payment of interest on the Notes, a list, in such form as the Trustee may reasonably require, of the names and addresses of the Holders as of such Regular Record Date; and

  
 (ii) at such other times as the Trustee may
request in writing, within 30 days after the receipt by the Company of any such request, a list of similar form and content as of a date not more than 15 days prior to the time such list is furnished, 
  
 provided, however, that, so long as the Trustee is the Note Registrar, no such list shall be
required to be furnished. (b) The Company shall provide the Trustee with at least thirty days’ prior notice of any change in location of its principal executive offices or other principal place of business. 
  

 -36- 

 ARTICLE 7 
 Consolidation, Merger, Sale, Lease Or Conveyance 
  
 SECTION 7.01. Consolidations and Mergers of Company and Sales, Leases and Conveyances Permitted Subject to Certain Conditions. The Company may consolidate with, or sell, lease, transfer, convey or otherwise
dispose of all or substantially all of its assets to, or merge with or into any other Person, provided however, that in any such case, (1) either the Company shall be the continuing corporation, or the Person (if other than the Company) formed by
such consolidation or into which the Company is merged or the Person (if other than a Subsidiary of the Company) that acquires or leases the Company’s assets substantially as an entirety is a corporation, partnership, limited liability company
or trust organized and existing under the laws of any United States jurisdiction and expressly assumes the due and punctual payment of the principal of (and premium, if any) and any interest payable pursuant to this Indenture on all of the Notes,
according to their tenor, and the due and punctual performance and observance of all of the covenants and conditions of this Indenture to be performed by the Company and shall have provided for conversion rights, as appropriately adjusted, if
applicable, in accordance with the provisions of Article 12 hereof, by supplemental indenture, complying with Article 8 hereof, satisfactory to the Trustee, executed and delivered to the Trustee by such corporation and (2) immediately after giving
effect to such transaction, no Default or Event of Default, shall have occurred and be continuing. For purposes of the foregoing, the transfer (by lease, assignment, sale or otherwise) of the properties and assets of one or more Subsidiaries (other
than to the Company or another Subsidiary), which, if such assets were owned by the Company, would constitute all or substantially all of the properties and assets of the Company, shall be deemed to be the transfer of all or substantially all of the
properties and assets of the Company. 
  
 SECTION 7.02. Rights
and Duties of Successor Corporation. In case of any such consolidation, merger, sale, lease, conveyance or other disposition and upon any such assumption by the successor Person, such successor Person shall succeed to and be substituted for the
Company, with the same effect as if it had been named herein as the party of the first part, and the predecessor corporation, except in the event of a lease, shall be relieved of any further obligation under this Indenture and the Notes. Such
successor Person thereupon may cause to be signed, and may issue either in its own name or in the name of the Company, any or all of the Notes issuable hereunder that theretofore shall not have been signed by the Company and delivered to the
Trustee; and, upon the order of such successor Person, instead of the Company, and subject to all the terms, conditions and limitations in this Indenture prescribed, the Trustee shall authenticate and shall deliver any Notes that previously shall
have been signed and delivered by the officers of the Company to the Trustee for authentication, and any Notes that such successor Person thereafter shall cause to be signed and delivered to the Trustee for that purpose. All the Notes so issued
shall in all respects have the same legal rank and benefit under this Indenture as the Notes theretofore or thereafter issued in accordance with the terms of this Indenture as though all of such Notes had been issued at the date of the execution
hereof. 
  

 -37- 

 In case of any such consolidation, merger, sale, lease, conveyance or other disposition, such changes in
phraseology and form (but not in substance) may be made in the Notes thereafter to be issued as may be appropriate. 
  
 SECTION 7.03. Officers’ Certificate and Opinion of Counsel. Any consolidation, merger, sale, lease, transfer, conveyance or other disposition
permitted under Section 7.01 is also subject to the condition that the Trustee receive an Officers’ Certificate and an Opinion of Counsel to the effect that any such consolidation, merger, sale, lease, transfer, conveyance or other disposition
complies with the provisions of this Article. Such opinion of counsel shall state that any supplemental indenture executed and delivered by a successor Person pursuant to this Article 7 constitutes the legal, valid and binding obligation of such
successor Person, subject to customary and appropriate exceptions. 
  
 ARTICLE 8 
 Supplemental Indentures 
  
 SECTION 8.01. Supplemental Indentures Without Consent of Holders. Without the consent of any Holders of Notes, the
Company, when authorized by or pursuant to a Board Resolution, and the Trustee, at any time and from time to time, may enter into one or more indentures supplemental hereto, in form satisfactory to the Trustee, for any of the following purposes:

  
 (a) to evidence the succession of another Person to the
Company and the assumption by any such successor of the covenants of the Company contained herein and the Notes issued hereunder; 
  
 (b) to add to the covenants of the Company for the equal and ratable benefit of the Holders or to surrender any right, power or option herein conferred
upon the Company; 
  
 (c) to add any Events of Default for the
benefit of the Holders proposed by the Company in a Company Request and, in respect of any such additional Event of Default, such supplemental indenture may provide for a particular period of grace after default (which period may be shorter or
longer than that allowed in the case of other defaults) or may provide for an immediate enforcement upon such Event of Default, or may limit the remedies available to the Trustee upon such Event of Default or limit the right of the Holders of a
majority in aggregate principal amount of those Notes to which such additional Events of Default apply to waive such default, all as set forth in the Company Request; 
  
 (d) to evidence and provide for the acceptance of appointment hereunder by a successor Trustee and to add to or change any
of the provisions of this Indenture as shall be necessary to provide for or facilitate the administration of the trusts hereunder by more than one Trustee; 
  
 (e) to cure any ambiguity or to correct or supplement any provision herein that may be defective or inconsistent with any other provision herein; provided
such provisions shall not adversely affect the interests of the Holders of Notes in any material respect; 
  

 -38- 

 (f) to make any change that does not adversely affect the rights of any Holder of Notes
or to surrender any right, power or option conferred on the Company hereunder; 
  
 (g) to make any change to comply with any requirement of the Commission in connection with the qualification of the Indenture under TIA;
or 
  
 (h) to provide for the issuance of
uncertificated Notes in addition to or in place of certificated Notes; provided, however that the uncertificated Notes are issued in registered form for purposes of Section 163(f) of the Internal Revenue Code of 1986. 
  
 The Company and the Trustee may not enter into a supplemental indenture
pursuant to this Section 8.01 if such supplemental indenture modifies in any respect any Event of Default relating to any covenant in this Indenture in effect immediately prior to the time such supplemental indenture becomes effective. 

 
 SECTION 8.02. Supplemental Indentures with Consent of Holders. With
the consent of the Holders of not less than a majority in principal amount of the Outstanding Notes affected by such supplemental indenture, by Act of said Holders delivered to the Company and the Trustee, the Company, when authorized by or pursuant
to a Board Resolution, and the Trustee may enter into an indenture or indentures supplemental hereto for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Indenture or of modifying in any
manner the rights of the Holders; provided, however, that no such supplemental indenture shall, without the consent of the Holder of each Outstanding Note affected thereby: 
  
 (a) reduce the principal amount, Repurchase Price or Redemption Price with respect to any Note, or extend
the Stated Maturity of any Note or alter the manner of payment or rate of interest on any Note or make any Note (including any Redemption Price or Repurchase Price in respect of such Note) payable in money or Notes other than that stated in the
Note; 
  
 (b) reduce the percentage in principal
amount of the Outstanding Notes the consent of whose Holders is required for any such supplemental indenture or the consent of whose Holders is required for any waiver with respect to Notes (or for any waiver of compliance with certain provisions of
this Indenture or certain Defaults or Events of Default and their consequences); 
  
 (c) make any change that adversely affects the right to convert any Note; 
  
 (d) modify the provisions of the Indenture relating to the ranking of the Notes in a manner adverse to the
Holders of the Notes; or 
  
 (e) impair the right
to institute suit for the enforcement of any payment with respect to, or conversion of, the Notes. 
  
 It shall not be necessary for any Act of Holders under this Section to approve the particular form of any proposed supplemental indenture, but it shall be
sufficient if such Act shall approve the substance thereof. 
  

 -39- 

 SECTION 8.03. Execution of Supplemental Indenture. In executing, or accepting the additional
trusts created by, any supplemental indenture permitted by this Article or the modification thereby of the trusts created by this Indenture, the Trustee shall be entitled to receive, and (subject to Article 5) shall be fully protected in relying
upon, an Opinion of Counsel stating that (i) the execution of such supplemental indenture is authorized or permitted by this Indenture, (ii) all conditions precedent to its execution and delivery have been complied with, and (iii) such supplemental
indenture constitutes the valid and binding obligation of the Company. The Trustee may, but shall not be obligated to, enter into any such supplemental indenture that affects the Trustee’s own rights, duties or immunities under this Indenture
or otherwise. 
  
 SECTION 8.04. Effect of Supplemental
Indentures. Upon the execution of any supplemental indenture under this Article, this Indenture shall be modified in accordance therewith, and such supplemental indenture shall form a part of this Indenture for all purposes; and every Holder of
Notes theretofore or thereafter authenticated and delivered hereunder shall be bound thereby. 
  
 SECTION 8.05. Conformity with Trust Indenture Act. Every supplemental indenture executed pursuant to this Article shall conform to the requirements of the Trust Indenture Act as then in effect. 
  
 SECTION 8.06. Reference in Notes to Supplemental Indentures. Notes
authenticated and delivered after the execution of any supplemental indenture pursuant to this Article may, and shall, if required by the Trustee, bear a notation in form approved by the Trustee as to any matter provided for in such supplemental
indenture. If the Company shall so determine, new Notes so modified as to conform, in the opinion of the Trustee and the Company, to any such supplemental indenture may be prepared and executed by the Company and authenticated and delivered by the
Trustee in exchange for Outstanding Notes. 
  
 ARTICLE 9

 COVENANTS 
  
 SECTION 9.01. Payment of Principal, Premium, If Any, and Interest. The Company covenants and agrees for the benefit of the Holders of Notes that it
shall duly and punctually pay the principal of (and premium, if any), interest on, and the Repurchase Price, the Redemption Price with respect to, the Notes in accordance with the terms of the Notes and this Indenture. At the option of the Company,
all payments of principal with respect to any Note may be paid by check to the registered Holder of the Note or other Person entitled thereto against surrender of such Note. The conversion of any Notes pursuant to Article 12 hereof, together with
the making of any payments required to be made in accordance with the terms of the Notes and this Indenture, shall satisfy the Company’s obligations under this Section 9.01 with respect to such Notes. 
  
 SECTION 9.02. Maintenance of Office or Agency. The Company shall
maintain a Place of Payment for the Notes in the Borough of Manhattan, The City of New York, which shall be an office or agency where the Notes may be presented or surrendered for payment or conversion, 

  

 -40- 

 
exchange or redemption, where the Notes may be surrendered for registration of transfer or exchange and where notices and demands to or upon the Company in
respect of the Notes and this Indenture may be served. The Company initially designates U.S. Bank National Association, U.S. Bank Trust New York, 200 Wall Street, Suite 1600, New York, NY 10005 as such an office or agency of the Company, unless and
until the Company shall designate and maintain some other office or agency for one or more of such purposes. The Company shall give prompt written notice to the Trustee of the location, and any change in the location, of each such office or agency.
If at any time the Company shall fail to maintain any such required office or agency or shall fail to furnish the Trustee with the address thereof, such presentations, surrenders, notices and demands may be made or served at the Corporate Trust
Office of the Trustee, and the Company hereby appoints the Trustee its agent to receive all such presentations, surrenders, notices and demands. 
  
 The Company may from time to time designate one or more other offices or agencies (in or outside of The City of New York) where the Notes may be presented
or surrendered for any or all of such purposes, and may from time to time rescind such designations; provided, however, that no such designation or rescission shall in any manner relieve the Company of its obligation to maintain an office or agency
in accordance with the requirements set forth above for such purposes. The Company shall give prompt written notice to the Trustee of any such designation or rescission and of any change in the location of any such other office or agency.

  
 SECTION 9.03. Money for Notes Payments to Be Held in
Trust. If the Company shall at any time act as its own Paying Agent with respect to any Notes, it shall, on or before each due date of the principal of (and premium, if any), or interest on, the Notes, segregate and hold in trust for the benefit
of the Persons entitled thereto a sum sufficient to pay the principal (and premium, if any) or interest so becoming due until such sums shall be paid to such Persons or otherwise disposed of as herein provided, and shall promptly notify the Trustee
of its action or failure so to act. 
  
 Whenever the Company shall
have one or more Paying Agents for the Notes, it shall, before each due date of the principal of (and premium, if any), or interest on, the Notes, deposit with a Paying Agent a sum sufficient to pay the principal (and premium, if any) or interest,
so becoming due, such sum to be held in trust for the benefit of the Persons entitled to such principal, premium or interest and (unless such Paying Agent is the Trustee) the Company shall promptly notify the Trustee of its action or failure so to
act. 
  
 The Company shall cause each Paying Agent other than the
Trustee to execute and deliver to the Trustee an instrument pursuant to which such Paying Agent shall agree with the Trustee, subject to the provisions of this Section, that such Paying Agent shall: 
  
 (a) hold all sums held by it for the payment of principal of
(and premium, if any,) or interest on the Notes, in trust for the benefit of the Persons entitled thereto, until such sums shall be paid to such Persons or otherwise disposed of as herein provided; 
  
 (b) give the Trustee notice of any default by the Company
(or any other obligor upon the Notes under a supplemental indenture entered into in accordance herewith) in the making of any such payment of principal (and premium, if any) or interest; and 
  

 -41- 

 (c) at any time during the continuance of any such default, upon the written request of
the Trustee, forthwith pay to the Trustee all sums so held in trust by such Paying Agent. 
  
 The Company may at any time, for the purpose of obtaining the satisfaction and discharge of this Indenture or for any other purpose, pay, or by Company Order direct any Paying Agent to pay, to the Trustee all sums
held in trust by the Company or such Paying Agent, such sums to be held by the Trustee upon the same trusts as those upon which such sums were held by the Company or such Paying Agent; and, upon such payment by any Paying Agent to the Trustee, such
Paying Agent shall be released from all further liability with respect to such sums. 
  
 Any money deposited with the Trustee or any Paying Agent, or then held by the Company, in trust for the payment of the principal of (and premium, if any) or interest on any Note and remaining unclaimed for two years
after such principal (and premium, if any) or interest has become due and payable shall be paid to the Company upon Company Request or (if then held by the Company) shall be discharged from such trust; and the Holder of such Note shall thereafter,
as an unsecured general creditor, look only to the Company for payment of such principal of (and premium, if any) or interest on any Note, without interest thereon, and all liability of the Trustee or such Paying Agent with respect to such trust
money, and all liability of the Company as trustee thereof, shall thereupon cease; provided, however, that the Trustee or such Paying Agent, before being required to make any such repayment, may at the expense of the Company cause to be published
once, in an Authorized Newspaper, notice that such money remains unclaimed and that, after a date specified therein, which shall not be less than 30 days from the date of such publication, any unclaimed balance of such money then remaining shall be
repaid to the Company. 
  
 SECTION 9.04. Existence. Subject
to Article 7, the Company shall do or cause to be done all things necessary to preserve and keep in full force and effect the corporate existence of the Company and its Subsidiaries, and their respective rights (charter and statutory) and
franchises, except to the extent that the Board of Directors shall determine that the failure to do so would not have a material adverse effect on the business, assets, financial condition or results of operation of the Company (a “Material
Adverse Effect”); provided, however, that the Company shall not be required to preserve any right or franchise if the Board of Directors shall determine that the preservation thereof is no longer desirable in the conduct of the business of the
Company and that the loss thereof is not disadvantageous in any material respect to the Holders. 
  
 SECTION 9.05. Payment of Taxes and Other Claims. The Company shall pay or discharge, or cause to be paid or discharged, before the same shall
become delinquent, (1) all taxes, assessments and governmental charges levied or imposed upon it or any Subsidiary or upon the income, profits or property of the Company or any Subsidiary, and (2) all lawful claims for labor, materials and supplies
which, if unpaid, might by law become a lien upon the property of the Company or any Subsidiary and have a Material Adverse Effect; provided, however, that the Company shall not be required to pay or discharge or cause to be paid or discharged any
such tax, assessment, charge or claim, the amount, applicability or validity of which is being contested in good faith by appropriate proceedings. 
  

 -42- 

 SECTION 9.06. Statement as to Compliance; Notice of Default. The Company shall deliver to the
Trustee, within 120 days after the end of each fiscal year of the Company, a certificate from the Company’s Chief Executive Officer, Chief Financial Officer or principal accounting officer as to his or her knowledge of the Company’s
compliance with all terms, conditions and provisions under this Indenture and, in the event of any noncompliance, specifying such noncompliance and the nature and status thereof. As of the date hereof, the Company’s fiscal year ends on December
31. For purposes of this Section 9.06, such compliance shall be determined without regard to any period of grace or requirement of notice under this Indenture. The Company, within five Business Days of becoming aware of the occurrence of any Default
or Event of Default, shall deliver written notice to the Trustee of the occurrence thereof. 
  
 SECTION 9.07. Prohibition on Private Transactions Involving Existing Notes. For the eighteen month period commencing on the date hereof and expiring on March 30, 2005, so long as any Notes remain outstanding
during such eighteen-month period, the Company covenants that it shall not engage in any private or open-market repurchases, debt-for-equity swaps, or similar transactions with respect to the Existing Notes. 
  
 SECTION 9.08. Waiver of Certain Covenants. The Company may omit in any
particular instance to comply with any term, provision or condition set forth in Section 9.04, 9.05, or 9.07 if, before the time for such compliance, the Holders of at least a majority in principal amount of the Outstanding Notes, by Act of such
Holders, either waive such compliance in such instance or generally waive compliance with such covenant or condition, but no such waiver shall extend to or affect such covenant or condition except to the extent so expressly waived, and, until such
waiver shall become effective, the obligations of the Company and the duties of the Trustee in respect of any such term, provision or condition shall remain in full force and effect. 
  
 ARTICLE 10 
 REDEMPTION OF NOTES 
  
 SECTION 10.01. Optional
Redemption by the Company. The Notes may be redeemed at the election of the Company, as a whole or from time to time in part, at any time after September 30, 2005 and prior to maturity (an “Optional Redemption”), upon notice as set
forth in Section 10.04, at a redemption price equal to 100% of the principal amount so redeemed, together with accrued and unpaid interest on the principal amount so redeemed, if any, up to but excluding the date fixed for redemption (the
“Optional Redemption Price”). 
  
 SECTION 10.02.
Election to Redeem; Notice to Trustee. The election of the Company to redeem any Notes shall be evidenced by a Board Resolution. In case of any redemption at the election of the Company of all or any part of the Notes pursuant to Section 10.01,
the Company shall, at least 15 days prior to the giving of the notice of redemption in Section 10.04 to the Holders (unless a shorter notice shall be satisfactory to the Trustee), notify the Trustee of the Redemption Date and of the principal amount
of Notes to be redeemed. In the case of any redemption of Notes prior to the expiration of any restriction on such redemption provided in the terms of such Notes or elsewhere in this Indenture, the Company shall furnish the Trustee with an
Officers’ Certificate evidencing compliance with all such restrictions. 
  

 -43- 

 SECTION 10.03. Selection by Trustee of Notes to Be Redeemed. If less than all the Notes are to be
redeemed, the particular Notes to be redeemed shall be selected not more than 60 days and not less than 30 days prior to the Redemption Date by the Trustee, from the Outstanding Notes not previously called for redemption, by lot, pro rata or any
other method that complies with the requirements of any exchange on which the Notes are listed or quoted and that the Trustee shall deem fair and appropriate. 
  

If any Note selected for partial redemption is converted in part before termination of the voluntary conversion right with respect to the portion of
the Note so selected, the converted portion of such Note shall be deemed, solely for purposes of determining the aggregate principal amount of the Notes to be redeemed, to be the portion selected for redemption (provided, however, that the Holder of
such Note so converted and deemed redeemed shall not be entitled to any interest payment as a result of such deemed redemption except for such interest payment as such Holder would have otherwise been entitled to receive upon voluntary conversion of
such Note). Notes that have been voluntarily converted during a selection of Notes to be redeemed may be treated by the Trustee as Outstanding for the purpose of such selection. 
  
 Notes in denominations of $1,000 may only be redeemed in whole. The Trustee may select for redemption portions (equal to
$1,000 or any integral multiple thereof) of the principal of Notes that have denominations larger than $1,000. 
  
 The Trustee shall promptly notify the Company and the Note Registrar (if other than itself) in writing of the Notes selected for redemption and, in the
case of any Notes selected for partial redemption, the principal amount thereof to be redeemed. 
  
 For all purposes of this Indenture, unless the context otherwise requires, all provisions relating to the redemption of Notes shall relate, in the case of
any Note redeemed or to be redeemed only in part, to the portion of the principal amount of such Note which has been or is to be redeemed. 
  
 SECTION 10.04. Notice of Redemption. Notice of redemption shall be given in the manner provided in Section 1.06, at least 30 days, but not more
than 60 days, prior to the Redemption Date; provided, that failure to give such notice in the manner herein provided to the Holder of any Note designated for redemption as a whole or in part, or any defect in the notice to any such Holder, shall not
affect the validity of the proceedings for the redemption of any other such Note or portion thereof. 
  
 All notices of redemption shall state: 
  
 (a) the Redemption Date; 
  
 (b) the Redemption Price; 
  
 (c) if less than all Outstanding Notes are to be redeemed, the identification (and, in the case of partial redemption, the principal amount) of the
particular Notes to be redeemed; 
  

 -44- 

 (d) if any Note is to be redeemed in part only, the portion of the principal amount of such Note to be
redeemed, and the notice that relates to such Note shall state that on and after the Redemption Date, upon surrender of such Note, the Holder shall receive, without a charge, a new Note or Notes of authorized denominations for the principal amount
thereof remaining unredeemed; 
  
 (e) that on the Redemption
Date, the Redemption Price shall become due and payable upon each such Note, or the portion thereof, to be redeemed; 
  
 (f) that the interest on the Note or the portion of the principal amount of the Note to be redeemed accrued to, but excluding, the Redemption Date will be
paid as specified in such notice and that on and after the Redemption Date, interest thereon or on the portion thereof to be redeemed will cease to accrue; 
  
 (g) the Place or Places of Payment where such Notes are to be surrendered for payment of the Redemption Price; 
  
 (h) that Notes called for redemption must be presented and surrendered to
the Paying Agent to collect the redemption price; 
  
 (i) the
then current Conversion Consideration; 
  
 (j) that the Notes
called for redemption may be converted for the Conversion Consideration at any time before the close of business on the last Business Day prior to the Redemption Date; 
  
 (k) the CUSIP number of such Note, if any; and 
  
 (l) that a Holder of Notes who desires to voluntarily convert Notes must satisfy the requirements for voluntary conversion
contained in such Notes. 
  
 Notice of redemption of Notes to be
redeemed shall be given by the Company or, at the Company’s request, by the Trustee in the name and at the expense of the Company. 
  
 SECTION 10.05. Deposit of Redemption Price. Not later than 11:00 a.m. New York City time on the Redemption Date, the Company shall deposit with the
Trustee or with a Paying Agent (or, if the Company is acting as its own Paying Agent, segregate and hold in trust as provided in Section 9.03) an amount of money sufficient to pay, on the Redemption Date, the Redemption Price of all the Notes or
portions thereof that are to be redeemed on that date, other than Notes or portions thereof called for redemption on that date that have been delivered by the Company to the Trustee for cancellation or have been converted. Upon written request, the
Trustee or the Paying Agent, as the case may be, shall return to the Company no later than five Business Days after such request any money not required to pay such Redemption Price. 
  

 -45- 

 SECTION 10.06. Notes Payable on Redemption Date. Notice of redemption having been given as
aforesaid, the Notes so to be redeemed shall, on the Redemption Date, become due and payable at the Redemption Price therein specified, and from and after such date (unless the Company shall default in the payment of the Redemption Price) such Notes
shall cease to bear interest. Upon surrender of any such Note for redemption in accordance with said notice, such Note shall be paid by the Company at the Redemption Price. 
  
 If any Note called for redemption shall not be so paid upon surrender thereof for redemption, the Redemption Price, shall,
until paid, bear interest from the Redemption Date at the rate borne by the Note and such Note shall remain convertible into Common Stock until the Redemption Price, and any such accrued interest, shall have been paid or duly provided for.

  
 SECTION 10.07. Notes Redeemed in Part. Any Note that is
to be redeemed only in part (pursuant to the provisions of this Article) shall be surrendered at a Place of Payment therefor (with, if the Company or the Trustee so requires, due endorsement by, or a written instrument of transfer in form
satisfactory to the Company and the Trustee duly executed by, the Holder thereof or his attorney duly authorized in writing) and the Company shall execute and the Trustee shall authenticate and deliver to the Holder of such Note without service
charge a new Note or Notes, of any authorized denomination as requested by such Holder in aggregate principal amount equal to and in exchange for the unredeemed portion of the principal of the Note so surrendered. 
  
 ARTICLE 11 
 REPURCHASE AT OPTION OF HOLDERS UPON CHANGE IN CONTROL 
  
 SECTION 11.01. Right to Require Repurchase. If, at any time prior to September 30, 2007 there shall occur a Repurchase Event, then each Holder
shall have the right, at such Holder’s option, to require the Company to repurchase all of such Holder’s Notes, or any portion thereof (in principal amounts of $1,000 or integral multiples thereof), on the date (the “Repurchase
Date”) that is forty-five (45) Business Days after the date of the occurrence of a Repurchase Event at a price equal to 100% of the principal amount of Notes such Holder elects to require the Company to repurchase, together with accrued and
unpaid interest on such principal amount, if any, up to but excluding the repurchase date (the “Repurchase Price”). 
  
 SECTION 11.02. Notices; Method of Exercising Repurchase Right, Etc. (a) Unless the Company shall have theretofore called for redemption all of the
Outstanding Notes, on or before the date that is 30 Business Days after the occurrence of a Repurchase Event, the Company shall give notice to all Holders of Outstanding Notes and to the Trustee (the “Company Notice”) of the occurrence of
the Repurchase Event and of the repurchase right set forth herein arising as a result thereof. 
  

 -46- 

 Each Company Notice shall state: 
  
 (i) the date of such Change in Control and, briefly, the events causing such Change in Control; 

 
 (ii) the date by which the Change in Control Purchase
Notice (as defined below) must be delivered; 
  
 (iii) the Repurchase Date; 
  
 (iv) the
Repurchase Price; 
  
 (v) a description of the
procedure that a Holder must follow to exercise a repurchase right; 
  
 (vi) the procedures for withdrawing a Change in Control Purchase Notice; 
  
 (vii) the place or places where such Notes are to be surrendered for payment of the Repurchase Price or for conversion; (viii) briefly,
the conversion rights of Holders of Notes; 
  
 (ix) the Conversion Consideration and any adjustments thereto; and 
  
 (x) that Holders who want to convert Notes must satisfy the requirements set forth in the Notes. 
  
 Promptly after giving the Company Notice to the Holders of Outstanding Notes and to the Trustee, the Company shall cause a copy of the Company Notice to
be published in The Wall Street Journal or another daily newspaper of national circulation and will also post such notice on the Company’s website. 
  
 (b) [Intentionally Omitted] 
  
 (c) To exercise a repurchase right, a Holder must deliver to the Trustee or at the office or agency maintained by the Company for such purpose in the
Borough of Manhattan, The City of New York pursuant to Section 9.02, prior to the close of business on or before the Repurchase Date, (i) written notice of the Holder’s exercise of such right (the “Change in Control Purchase Notice”),
which notice shall set forth (A) the name of the Holder, (B) the certificate numbers of the Notes with respect to which the repurchase right is being exercised, (C) the principal amount of the Notes to be repurchased (and, if any Note is to be
repurchased in part, the portion of the principal amount thereof to be repurchased, which shall be in integral multiples of $1,000) and (D) a statement that an election to exercise the repurchase right is being made thereby pursuant to the
applicable provisions of the Notes and (ii) surrender the Notes subject to the Change in Control Purchase Notice. 
  
 (d) On or prior to the Repurchase Date the Company shall deposit with the Trustee or with the Paying Agent (or, if the Company is acting as its own Paying
Agent, segregate and hold in trust as provided in Section 9.03) an amount of money sufficient to pay the Repurchase Price of the Notes that are to be repaid on the Repurchase Date. On the Repurchase Date, the Trustee, a Paying Agent (or, if the
Company is acting as its own Paying Agent, the Company) shall repurchase all such Notes validly tendered prior to such date. 
  

 -47- 

 (e) In the event that a Holder has previously delivered a Change in Control Purchase Notice, but failed
to surrender the Note with respect to which such Change in Control Purchase Notice relates, then so long as the Trustee or the Paying Agent holds (or, if the Company is acting as its own Paying Agent, the Company segregates and holds in trust as
provided in Section 9.03) money sufficient to pay the Repurchase Price in respect of such Note, then such Note shall cease to be Outstanding for the purposes of this Indenture on the Repurchase Date and all rights of the Holder thereof other than
the right to receive the Repurchase Price shall terminate. 
  
 (f)
All Notes delivered for repurchase shall be delivered to the Trustee to be canceled in accordance with the provisions of Section 3.08. 
  
 (g) If any Note (or portion thereof) surrendered for repurchase shall not have been repurchased on the Business Day following the Repurchase Date, the
Repurchase Price in respect of such Note shall, until paid, bear interest from the Business Day following the Repurchase Date at the rate borne by the Note and such Note shall remain convertible into Common Stock until the Repurchase Price and any
such accrued interest shall have been paid or duly provided for. 
  
 (h) Any Note that is to be repurchased only in part shall be surrendered to the Trustee or any such Paying Agent (or if the Company is acting as its own Paying Agent, the Company) and the Company shall execute, and the Trustee shall
authenticate and deliver to the Holder of such Note without service charge, a new Note or Notes, containing identical terms and conditions, each in an authorized denomination in aggregate principal amount equal to and in exchange for the portion of
the principal of the Note so surrendered that was not repurchased. 
  
 (i) Any Holder that has delivered a Change in Control Purchase Notice shall have the right to withdraw such notice by delivery of a written notice of withdrawal to the Trustee or any such Paying Agent prior to the close of business on the
Repurchase Date. The notice of withdrawal shall state the principal amount and the certificate numbers of the Notes as to which the withdrawal notice relates and the principal amount, if any, that remains subject to the Change in Control Purchase
Notice. A Note in respect of which a Holder has exercised its right to require repurchase upon a Change in Control may thereafter be converted into Common Stock only if, and at such time as, such Holder withdraws its Change in Control Purchase
Notice in accordance with the preceding sentence. 
  
 (j)
Notwithstanding anything to the contrary in this Section 11.02, the Company shall not be required to give the Company Notice following the occurrence of a Change in Control if, in the manner, at the time and otherwise in compliance with the
requirements set forth herein regarding the Company’s obligation to offer to repurchase the Outstanding Notes following the occurrence of a Change in Control, (A) another Person makes an offer to repurchase the Outstanding Notes by giving a
notice containing the information set forth in clauses (i) through (x) of Section 11.02 (a) to the Holders of all Outstanding Notes and to the Trustee, (B) such Person repurchases all Outstanding Notes validly tendered and not withdrawn, and (C)
such Person makes all payments with respect thereto. This Section 11.02(j) shall not relieve the 

  

 -48- 

 
Company of any of its obligations under this Indenture or any Note; provided, however, that if another Person makes the offer to repurchase Outstanding Notes
as set forth in this Section, the Company shall not be obligated to give the Company Notice. 
  
 (k) Absent, and except to the extent of, the Trustee’s receipt of a Company Notice of a Change in Control, the Trustee shall not be under any duty to determine or monitor whether a Change in Control has occurred,
from time to time. 
  
 SECTION 11.03. Certain Definitions.
For purposes of this Article 11: 
  
 (a) the terms
“beneficial owner” and “beneficial ownership” shall be determined in accordance with Rules 13d-3 and 13d-5 promulgated by the Commission pursuant to the Exchange Act, except that a Person shall be deemed to have “beneficial
ownership” of all securities that such Person has the right to acquire, whether such right is exercisable immediately or only after the passage of time; 
  

(b) the term “Person” shall include any syndicate or group that would be deemed to be a “person” under Section 13(d)(3) or Section
14(d)(2) of the Exchange Act; and 
  
 (c) the term
“Repurchase Event” means a Change in Control. 
  
 SECTION 11.04. Change in Control. A “Change in Control” shall be deemed to have occurred at such time after the original issuance of the Notes as: 
  
 (a) any Person acquires the beneficial ownership, directly or indirectly, through a purchase, merger or other acquisition
transaction (other than a transaction described in (b) below), of more than 50% of the total voting power of the total outstanding voting stock of the Company other than an acquisition by the Company, any of its Subsidiaries or any of its employee
benefit plans; 
  
 (b) the Company shall consolidate with, or
merge with or into, another Person or convey, transfer, lease or otherwise dispose of all or substantially all of its assets to any Person, or any Person consolidates with or merges with or into the Company, in any such event pursuant to a
transaction in which the Company’s outstanding voting stock is converted into or exchanged for cash, securities or other property, other than any such transactions where: 
  
 (i) the Company’s voting stock is not converted or exchanged at all (except to the extent necessary to
reflect a change in the Company’s jurisdiction of incorporation) or is converted into or exchanged for voting stock (other than Redeemable Capital Stock) of the surviving or transferee corporation, and 
  
 (ii) immediately after such transaction, no Person, other
than one or more Persons who were the beneficial owner, directly or indirectly, of more than 50% of the total voting power of all of the Company’s voting stock immediately before such transaction, is the beneficial owner, directly or
indirectly, of more than 50% of the total outstanding voting stock of the surviving or transferee corporation; 
  

 -49- 

 (c) during any consecutive two-year period, individuals who at the beginning of such period constituted
the Board of Directors (but not a committee thereof), together with any new directors whose election to such Board of Directors (but not a committee thereof), or whose nomination for election by the Company’s stockholders, was approved by a
vote of a majority of the directors then still in office who were either directors at the beginning of such period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority of the Board of
Directors (but not a committee thereof) then in office; or 
  
 (d) a special resolution is passed by the Company’s stockholders approving a plan of liquidation or dissolution of the Company (other than in a transaction that complies with the provisions described in Article 7), and no additional
approvals of the Company’s stockholders are required under applicable law to cause such a liquidation or dissolution. 
  
 “Redeemable Capital Stock” means any class or series of capital stock that, either by its terms, by the terms of any security into which it is
convertible or exchangeable or by contract or otherwise, is, or upon the happening of an event or passage of time would be, required to be redeemed prior to the Stated Maturity of the Notes or is redeemable at the option of the holder thereof at any
time prior to such Stated Maturity, or is convertible into or exchangeable for debt securities at any time prior to such Stated Maturity; provided, however, that Redeemable Capital Stock shall not include any Common Stock which the holder may cause
the Company to repurchase or redeem upon termination of such holder’s employment. 
  
 ARTICLE 12 
 CONVERSION 
  
 SECTION 12.01. Voluntary Conversion Privilege and Conversion Consideration. 
  
 (a) Subject to and upon compliance with the provisions of this Article 12,
at the option of the Holder thereof, any Note or any portion of the principal amount thereof that is $1,000 or an integral multiple of $1,000 may be voluntarily converted, except as otherwise provided herein, at any time after original issuance
thereof and prior to the close of business on September 30, 2007 into (i) that number of fully-paid and non-assessable shares of the Company’s Common Stock as is equal to 182.71 (the “Base Shares”), plus (ii) $500 (the “Plus Cash
Amount”) for each $1,000 principal amount of Notes so converted. 
  
 Upon the election of any Holder to voluntarily convert any Notes, the Company, at its sole option, may pay the Plus Cash Amount in cash or shares of Common Stock (the “Plus Cash Shares”); provided, however, that the Company shall
not make any payment of the Plus Cash Amount in Plus Cash Shares unless the daily volume-weighted average price of the Common Stock for the ten (10) Trading Days ending on and including the second Trading Day immediately preceding the Conversion
Date (as defined below) equals or exceeds the Threshold Price. The Common Stock deliverable upon voluntary conversion (whether in respect of Base Shares or Plus Cash Shares, as applicable) and any cash delivered in respect of the Plus Cash Amount
are hereinafter referred to in the aggregate as the “Conversion Consideration.” If the Company elects to pay the Plus Cash Amount in Plus Cash Shares, the Plus Cash Shares will be 

  

 -50- 

 
valued at 95% of the simple average of the daily volume-weighted average price of the Common Stock for the ten (10) Trading Days ending on and including the
second Trading Day immediately preceding the Conversion Date, provided that if the Company has delivered an Auto-Conversion Notice (as defined below) the Plus Cash Shares will be valued in the manner set forth in Section 12.01(d) below. The number
of Base Shares and any calculation or determination in respect of the simple average of the daily volume-weighted average price of the Common Stock shall be adjusted as provided for in Section 12.04. 
  
 (b) In case a Note or portion thereof has previously been called for
redemption at the election of the Company, such voluntary conversion right in respect of the Note or portion so called shall expire at the close of business, New York City time, on the last Business Day prior to the Redemption Date, unless the
Company defaults in making the payment due upon redemption. In case a Note or portion thereof is the subject of an Auto-Conversion Notice issued as provided in Section 12.12 below, such voluntary conversion right in respect of such Note or such
portion shall expire at the close of business, New York City time, on the last Business Day prior to the Auto-Conversion Date, unless the Company defaults in making the payment due upon Auto-Conversion. 
  
 (c) A Note in respect of which a Holder has delivered a Change in Control
Purchase Notice (as defined in Article 11 hereof) exercising the option of such Holder to require the Company to purchase such Note may be voluntarily converted only if such notice and the Note is withdrawn by a written notice of withdrawal
delivered by the Holder to the Trustee or any Paying Agent prior to the close of business on the Repurchase Date, in accordance with the terms of this Indenture. 
  
 (d) From and after the delivery by the Company of any Auto-Conversion Notice with respect to any Notes or any portion of the
Notes, Holders shall be entitled to voluntarily convert such Notes or such portion until the close of business, New York City time, on the last Business Day prior to the Auto-Conversion Date, provided that, if in connection with any such voluntary
conversion the Company elects to pay the Plus Cash Amount in Plus Cash Shares, the Plus Cash Shares delivered will be valued with respect to any Note or any portion of the principal amount thereof: 
  
 (1) if the Holder elects to voluntarily convert before the
Auto-Conversion Date and the Company has issued a Stock Auto-Conversion Notice, at the Stock Substitution Price (as defined in Section 12.12(g) below), provided, however, in the case of this Section 12.01(d)(1), the Company may not pay the Plus Cash
Amount in Plus Cash Shares unless the daily volume-weighted average price for the ten (10) Trading Days ending on and including the second Trading Day immediately preceding the Conversion Date equals or exceeds the Threshold Price; 
  
 (2) if the Holder elects to voluntarily convert before the
Auto-Conversion Date and the Company has issued a Cash Auto-Conversion Notice, at 95% of the simple average of the daily volume-weighted average price of the Common Stock for the ten (10) Trading Days ending on and including the second Trading Day
immediately preceding the Conversion Date, provided, however, in the case of this 

  

 -51- 

 
Section 12.01(d)(2), the Company may not pay the Plus Cash Amount in Plus Cash Shares unless the daily volume-weighted average price for the ten (10) Trading
Days ending on and including the second Trading Day immediately preceding the Conversion Date equals or exceeds the Threshold Price; or 
  
 (3) if the Holder elects to voluntarily convert after the Auto-Conversion Date, unless and until a subsequent Auto-Conversion Notice, if
any, has been delivered pursuant to Section 12.12 hereof, at 95% of the simple average of the daily volume-weighted average price of the Common Stock for the ten (10) Trading Days ending on and including the second Trading Day immediately preceding
the Conversion Date, provided, however, in the case of this Section 12.01(d)(3), the Company may not pay the Plus Cash Amount in Plus Cash Shares unless the daily volume-weighted average price for the ten (10) Trading Days ending on and including
the second Trading Day immediately preceding the Conversion Date equals or exceeds the Threshold Price. 
  
 SECTION 12.02. Exercise of Conversion Privilege. In order to exercise the voluntary conversion privilege with respect to any Note in definitive
form, the Holder of any Note to be converted shall surrender such Note, duly endorsed or assigned to the Company or in blank, at any office or agency maintained by the Company pursuant to Section 9.02, accompanied by (a) written notice to the
Company in substantially the form of the conversion notice attached to the form of Note attached as Exhibit A hereto at such office or agency that the Holder elects to voluntarily convert such Note or, if less than the entire principal amount
thereof is to be converted, the portion thereof to be converted, (b) the funds, if any, required by this Section 12.02, and (c) if shares or any portion of such Note not to be converted are to be issued in the name of a Person other than the Holder
thereof, the name of the Person in which to issue such shares and the transfer taxes, if any, required to be paid by the Holder pursuant to Section 12.08. 
  
 In order to exercise the voluntary conversion privilege with respect to any interest in a global Note, the beneficial owner must also complete, or cause
to be completed, the appropriate instruction form for conversion pursuant to the depositary’s book-entry conversion program, deliver, or cause to be delivered, by book-entry delivery, an interest in such global Note, furnish appropriate
endorsements and transfer documents if required by the Company or the Trustee or other agent, and pay the funds, if any, required by this Section 12.02 and any transfer taxes if required pursuant to Section 12.08. 
  
 As promptly as practicable after satisfaction of the requirements for
voluntary conversion set forth above (the date on which such requirements are satisfied being referred to herein as the “Conversion Date”), but in no event later than three Trading Days after the Conversion Date, subject to compliance with
any restrictions on transfer if shares issuable on conversion are to be issued in a name other than that of the Holder (as if such transfer were a transfer of the Note or Notes (or portion thereof) so converted), the Company shall issue and deliver
to such Holder a certificate or certificates for the number of full shares of Common Stock issuable upon the voluntary conversion of such Note or portion thereof in accordance with the provisions of this Article 12 (including any Plus Cash Shares,
if applicable) and a check or cash in respect of the Plus Cash Amount, if applicable, and any payment in respect of a share of Common Stock 

  

 -52- 

 
arising upon such voluntary conversion, as applicable, as provided in Section 12.03. In case any Note of a denomination greater than $1,000 shall be
surrendered for partial voluntary conversion, and subject to Article 2, the Company shall execute, and the Trustee shall authenticate and deliver to the Holder of the Note so surrendered, without charge, a new Note or Notes in authorized
denominations in an aggregate principal amount equal to the unconverted portion of the surrendered Note. 
  
 Each voluntary conversion shall be deemed to have been effected as to any such Note (or portion thereof) on the date on which the requirements set forth
above in this Section 12.02 have been satisfied as to such Note (or portion thereof), and the Person in whose name any certificate or certificates for shares of Common Stock shall be issuable upon such voluntary conversion shall be deemed to have
become on said date the holder of record of the shares represented thereby; provided however that any such surrender on any date when the stock transfer books of the Company shall be closed shall constitute the Person in whose name the certificates
are to be issued as the record holder thereof for all purposes on the next succeeding day on which such stock transfer books are open, but such voluntary conversion shall be for the Conversion Consideration in effect on the date upon which such Note
shall be surrendered. 
  
 Any Note or portion thereof surrendered
for voluntary conversion during the period from the close of business on the record date for any interest payment date to the close of business on the Business Day immediately preceding the following interest payment date that has not been called
for redemption during such period, shall be accompanied by cash payment, in immediately available funds or other funds acceptable to the Company, of an amount equal to the interest otherwise payable on such interest payment date on the principal
amount being converted; provided however that no such payment need be made to the extent any overdue interest shall exist at the time of voluntary conversion with respect to any such Note or portion thereof. For the avoidance of doubt, the
Company’s right to make payment of any interest otherwise payable in shares of its Common Stock pursuant to Section 3.06 shall not be affected by the Holder’s obligation to deliver cash payment as described in the previous sentence.

  
 On voluntary conversion of a Note, that portion of accrued and
unpaid interest, if any, remaining unpaid on such conversion shall not be cancelled, extinguished or forfeited, but rather shall be deemed to be paid in full to the Holder thereof through delivery of the Base Shares and Plus Cash Amount (together
with the cash or stock payment, if any, in lieu of fractional shares) in exchange for the Note being converted pursuant to the provisions hereof. Except as provided above in this Section 12.02, no payment or other adjustment shall be made for
interest accrued on any Note converted or for dividends on any shares issued upon the voluntary conversion of such Note as provided in this Article. 
  
 Upon the voluntary conversion of an interest in a global Note, the Trustee (or other conversion agent appointed by the Company), shall make a notation on
such global Note as to the reduction in the principal amount represented thereby. The Company shall notify the Trustee in writing of any voluntary conversions of Notes effected through any Conversion Agent other than the Trustee. 
  

 -53- 

 SECTION 12.03. Fractional Shares. No fractional shares of Common Stock shall be issued upon
voluntary conversion of Notes (whether in connection with the settlement of Base Shares or Plus Cash Shares, as the case may be). If more than one Note shall be surrendered for voluntary conversion at one time by the same Holder, the number of full
shares that shall be issuable upon voluntary conversion thereof shall be computed on the basis of the aggregate principal amount of the Notes (or specified portions thereof) so surrendered. Subject to Section 12.12(k), instead of any fractional
share of Common Stock that would otherwise be issuable upon voluntary conversion of any Note (or specified portions thereof), the Company shall either, at its sole option, (i) pay a cash adjustment in respect of such fraction in an amount equal to
the same fraction of the Closing Price per share of the Common Stock at the close of business on the Trading Day immediately preceding such day, or (ii) issue an additional whole share in lieu of any fractional share that would otherwise be issuable
upon voluntary conversion of such Note. 
  
 “Trading
Day” shall mean each day on which the primary securities exchange or quotation system or over-the-counter market that is used to determine the volume-weighted average price is open for trading or quotation. 
  
 “Closing Price” of a single share of Common Stock on any Trading
Day shall mean the closing sale price per share for the Common Stock (or if no closing sale price is reported, the average of the bid and ask prices) on such Trading Day on the principal United States national securities exchange on which the Common
Stock is traded or, if the Common Stock is not listed on a United States national securities exchange, as reported by the Nasdaq, or, if the Common Stock is not listed on the Nasdaq, the principal United States regional securities exchange on which
the Common Stock is traded or, if the Common Stock is not listed on a United States regional stock exchange, as reported by the principal over-the-counter market on which the Common Stock is traded, including the Over the Counter Bulletin Board (the
“OTCBB”) or the National Quotation Service Bureau (commonly known as the “Pink Sheets”) or successor markets. 
  
 “daily volume-weighted average price” of a single share of Common Stock on any Trading Day shall mean the daily volume-weighted average price
per share for the Common Stock on such Trading Day on the principal United States national securities exchange on which the Common Stock is traded or, if the Common Stock is not listed on a United States national securities exchange, as reported by
the Nasdaq, or, if the Common Stock is not listed on the Nasdaq, the principal United States regional securities exchange on which the Common Stock is traded or, if the Common Stock is not listed on a United States regional stock exchange, as
reported by the principal over-the-counter market on which the Common Stock is traded, including the OTCBB or the National Quotation Service Bureau or successor markets, in any event, as reported by the Bloomberg L.P. or such other nationally
recognized information source satisfactory to the Trustee. 
  
  

 -54- 

 SECTION 12.04. Adjustment of Conversion Consideration. 
  
 (a) If the Company shall, after the date hereof, pay or make a dividend or
other distribution on its Common Stock exclusively in Common Stock, then, in any such event: 
  
 (i) the number of Base Shares each Holder, upon voluntary conversion or Auto- Conversion, shall be entitled to receive shall be increased
to equal the number of shares of Common Stock it would have been entitled to receive with respect to such Base Shares (prior to any such adjustment) with respect to such dividend or other distribution if such Note had been converted immediately
prior to the earlier of the date of such dividend or distribution or the record date with respect thereto, such adjustment to become effective upon the opening of business on the earlier of the date next following the date of such dividend or
distribution, the date next following the record date with respect thereto or the “ex” date (as hereinafter defined) with respect thereto; 
  
 (ii) each of the Auto-Conversion Price and the Threshold Price shall be reduced by multiplying such price by a fraction, the numerator of
which shall be the number of shares of Common Stock outstanding on the earlier of the date of such dividend or distribution or the record date with respect thereto, and the denominator of which shall be the sum of such number of shares and the total
number of shares constituting such dividend or other distribution, such reduction to become effective upon the opening of business on the earlier of the date next following the date of such dividend or distribution, the date next following the
record date with respect thereto or the “ex” date with respect thereto; and 
  
 (iii) when making any calculation of the simple average of the daily volume-weighted average price, or the simple average of the Closing
Price, of the Common Stock, the daily volume-weighted average price or the Closing Price, as applicable, of the Common Stock on each day prior to the earlier of the date of such dividend or distribution, the record date with respect thereto or the
“ex” date with respect thereto shall be reduced by multiplying such price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding on the earlier of the date of such dividend or distribution or the
record date with respect thereto, and the denominator of which shall be the sum of such number of shares and the total number of shares constituting such dividend or other distribution. 
  
 (b) In case the outstanding shares of Common Stock shall be subdivided or split into a greater number of shares of Common
Stock or combined into a smaller number of shares of Common Stock, then, in any such event: 
  
 (i) the number of Base Shares payable on a voluntary conversion or Auto-Conversion in effect at the opening of business on the day next
following the day upon which such subdivision, split or combination becomes effective shall be proportionately adjusted (i.e., the number of Base Shares payable on a voluntary conversion or Auto-Conversion shall be proportionately increased in
connection with any subdivision or split and proportionately decreased in connection with any combination), any such adjustment to become effective upon the opening of business on the earlier of the day next following the day upon which such
subdivision, split or combination becomes effective or the “ex” date with respect to such subdivision, split or combination; 
  
 (ii) the Auto-Conversion Price and the Threshold Price in effect at the opening of business on the earlier of the day next following the
day upon which such subdivision, 

  

 -55- 

 
split or combination becomes effective or the “ex” date with respect to such subdivision, split or combination shall be proportionately adjusted
(i.e., the Auto-Conversion Price and the Threshold Price shall be proportionately decreased in connection with any subdivision or split and proportionately increased in connection with any combination), any such adjustment to become effective upon
the opening of business on the earlier of the day next following the day upon which such subdivision, split or combination becomes effective or the “ex” date with respect to such subdivision, split or combination; and 
  
 (iii) when making any calculation of the simple average of
the daily volume-weighted average price, or the simple average of the Closing Price, of the Common Stock, the daily volume-weighted average price or the Closing Price, as applicable, of the Common Stock on each day prior to the earlier of the day
upon which such subdivision, split or combination becomes effective or the “ex” date with respect to such subdivision, split or combination shall be proportionately adjusted (i.e., proportionately decreased in connection with any
subdivision or split and proportionately increased in connection with any combination). 
  
 (c) In case the Company shall pay or make a dividend or other distribution on its Common Stock consisting exclusively of, or shall otherwise issue to all holders of its Common Stock, rights, warrants or options
entitling the holders thereof, for a period not exceeding 45 days, to subscribe for or purchase shares of Common Stock at a price per share less than the current market price per share (determined as provided in Section 12.04(g)) of the Common Stock
on the date fixed for the determination of stockholders entitled to receive such rights, warrants or options, then, in any such event: 
  
 (i) the number of Base Shares payable on a voluntary conversion or Auto-Conversion in effect at the opening of business on the day next
following the date fixed for such determination shall be increased by multiplying such number by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding at the close of business on the date fixed for such
determination plus the number of shares of Common Stock so offered for subscription or purchase, and the denominator of which shall be the number of shares of Common Stock outstanding at the close of business on the date fixed for such determination
plus the number of shares of Common Stock which the aggregate price of the total number of shares so offered would purchase at the current market price per share (determined as provided in Section 12.04(g)), such increase to become effective
immediately after the opening of business on the earlier of the day next following the date fixed for such determination or the “ex” date with respect to such dividend or distribution; 
  
 (ii) the Auto-Conversion Price and the Threshold Price shall
be decreased by multiplying such number or price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding at the close of business on the date fixed for such determination plus the number of shares of Common
Stock which the aggregate price of the total number of shares so offered would purchase at the current market price per share (determined as provided in Section 12.04(g)), and the 

  

 -56- 

 
denominator of which shall be the number of shares of Common Stock outstanding at the close of business on the date fixed for such determination plus the
number of shares of Common Stock so offered for subscription or purchase, such decrease to become effective immediately after the opening of business on the earlier of the day next following the date fixed for such determination or the
“ex” date with respect to such dividend or distribution; and 
  
 (iii) when making any calculation of the simple average of the daily volume-weighted average price, or the simple average of the Closing Price, of the Common Stock, the daily volume-weighted average price or the
Closing Price, as applicable. of the Common Stock on each day prior to the earlier of the date fixed for such determination or the “ex” date with respect to such dividend or distribution shall be decreased by multiplying such price by a
fraction, the numerator of which shall the number of shares of Common Stock outstanding at the close of business on the date fixed for such determination plus the number of shares of Common Stock which the aggregate price of the total number of
shares so offered would purchase at the current market price per share (determined as provided in Section 12.04(g)), and the denominator of which shall be the number of shares of Common Stock outstanding at the close of business on the date fixed
for such determination plus the number of shares of Common Stock so offered for subscription or purchase. 
  
 (d) In case the Company shall, by dividend or otherwise, distribute to all holders of its Common Stock evidences of its indebtedness, shares of any class
of capital stock, securities, cash or assets (excluding any rights, warrants or options referred to in Section 12.04(c), any dividend or distribution paid exclusively in cash and any dividend or distribution referred to in Section 12.04(a)), then,
in any such event: 
  
 (i) the number of Base
Shares payable on a voluntary conversion or Auto-Conversion shall be increased by multiplying such number in effect immediately prior to the earlier of such distribution or the determination of stockholders entitled to receive such distribution by a
fraction, the numerator of which shall be the current market price per share (determined as provided in Section 12.04(g)) and the denominator of which shall be such current market price less the fair market value (as determined in good faith by the
Board of Directors, whose determination shall be conclusive and described in a Board Resolution), on the date of such effectiveness, of the portion of the evidences of indebtedness, shares of capital stock, securities, cash and assets so distributed
applicable to one share of Common Stock, such adjustment to become effective immediately prior to the opening of business on the day next following the earlier of (A) the later of (1) the date fixed for the payment of such distribution and (2) the
date 20 days after the notice relating to such distribution is given pursuant to Section 12.06 (such later date of (1) and (2) being referred to as the “Reference Date”) or (B) the “ex” date with respect to such distribution;

  
 (ii) the Auto-Conversion Price and the
Threshold Price shall be decreased by multiplying such price in effect immediately prior to the earlier of such distribution or the determination of stockholders entitled to receive such distribution by a fraction, the 

  

 -57- 

 
numerator of which shall be the current market price per share (determined as provided in Section 12.04(g)) less the fair market value (as determined in good
faith by the Board of Directors, whose determination shall be conclusive and described in a Board Resolution), on the date of such effectiveness, of the portion of the evidences of indebtedness, shares of capital stock, securities, cash and assets
so distributed applicable to one share of Common Stock, and the denominator of which shall be such current market price, such adjustment to become effective immediately prior to the opening of business on the earlier of the day next following the
Reference Date or the “ex” date with respect to such distribution; and 
  
 (iii) when making any calculation of the simple average of the daily volume-weighted average price, or the simple average of the Closing
Price, of the Common Stock, the daily volume-weighted average price or the Closing Price, as applicable, of the Common Stock on each day preceding the earlier of the Reference Date or the “ex” date with respect to such distribution shall
be adjusted by multiplying such price by a fraction, the numerator of which shall be the current market price per share (determined as provided in Section 12.04(g)) less the fair market value (as determined in good faith by the Board of Directors,
whose determination shall be conclusive and described in a Board Resolution), on the date of such effectiveness, of the portion of the evidences of indebtedness, shares of capital stock, securities, cash and assets so distributed applicable to one
share of Common Stock, and the denominator of which shall be such current market price. 
  
 The provisions of this Section 12.04(d) shall not be applicable to an event covered by Section 12.04(k). For purposes of this Section 12.04(d) and Sections 12.04(a) and 12.04(c), any dividend or distribution for which
an adjustment is being made pursuant to this Section 12.04(d) that also includes shares of Common Stock or rights, warrants or options to subscribe for or purchase shares of Common Stock shall be deemed instead to be (A) a dividend or distribution
of the evidences of indebtedness, cash, property, shares of capital stock or securities other than such shares of Common Stock or such rights, warrants or options (making any adjustment to the number of Base Shares payable on a voluntary conversion
or Auto-Conversion, the Auto-Conversion Price, the Threshold Price and any calculation of a simple average of daily volume-weighted average prices, or the simple average of the Closing Price, of a share of Common Stock required by this Section
12.04(d)) immediately followed by (B) a dividend or distribution of such shares of Common Stock or such rights (making any further adjustment to the number of Base Shares payable on a voluntary conversion or Auto-Conversion, the Auto-Conversion
Price, the Threshold Price and any calculation of a simple average of daily volume-weighted average prices, or the simple average of the Closing Price, of a share of Common Stock required by Sections 12.04(a) or 12.04(c)), except (1) the record date
of such dividend or distribution as defined in this Section 12.04(d) shall be substituted as “the date fixed for the determination of stockholders entitled to receive such dividend or other distributions,” “the date fixed for the
determination of stockholders entitled to receive such rights, warrants or options” and “the date fixed for such determination” within the meaning of Sections 12.04(a) and 12.04(c) and (2) any shares of Common Stock included in such
dividend or distribution shall not be deemed “outstanding at the close of business on the date fixed for such determination” within the meaning of this 12.04(d). 
  

 -58- 

 (e) In case the Company shall, by dividend or otherwise, make a distribution to all holders of its Common
Stock exclusively in cash in an aggregate amount that, together with (i) the aggregate amount of any other distributions to all holders of its Common Stock made exclusively in cash within the 12 months preceding the date of payment of such
distribution and in respect of which no adjustment to the number of Base Shares payable on a voluntary conversion or Auto-Conversion, the Auto-Conversion Price, the Threshold Price and any calculation of a simple average of daily volume-weighted
average prices, or the simple average of the Closing Price, of a share of Common Stock pursuant to this Section 12.04(e) has been made and (ii) the aggregate of any cash plus the fair market value (as determined in good faith by the Board of
Directors, whose determination shall be conclusive and described in a Board Resolution), as of the expiration of the tender or exchange offer referred to below, of consideration payable in respect of any tender or exchange offer by the Company or a
Subsidiary for all or any portion of the Common Stock concluded within the 12 months preceding the date of payment of such distribution and in respect of which no adjustment to the number of Base Shares payable on a voluntary conversion or
Auto-Conversion, the Auto-Conversion Price, the Threshold Price and any calculation of a simple average of daily volume-weighted average prices, or the simple average of the Closing Price, of a share of Common Stock pursuant to this Section 12.04(e)
has been made, exceeds 1% of the product of the current market price per share (determined as provided in Section 12.04(g)) of the Common Stock as of the Trading Day immediately preceding the record date fixed for stockholders entitled to receive
such distribution multiplied by the number of shares of Common Stock outstanding on such record date, then, in any such event: 
  
 (i) the number of Base Shares payable on a voluntary conversion or Auto-Conversion shall be increased so that the same shall equal the
number determined by multiplying such number in effect immediately prior to the close of business on the date fixed for the determination of the stockholders of record entitled to such distribution by a fraction of which (i) the denominator shall be
the current market price per share (determined as provided in Section 12.04(g)) on such date less an amount equal to the quotient of (x) the excess of such combined amount over such 10% and (y) the number of shares of Common Stock outstanding on the
record date and (ii) the numerator shall be equal to the current market price on such date, such adjustment to become effective immediately prior to the opening of business on the earlier of the day following the record date fixed for the payment of
such distribution or the “ex” date with respect to such distribution; 
  
 (ii) the Auto-Conversion Price and the Threshold Price shall be decreased so that the same shall equal the price determined by multiplying
such number or price in effect immediately prior to the close of business on the date fixed for the determination of the stockholders of record entitled to such distribution by a fraction of which (i) the numerator shall be the current market price
per share (determined as provided in Section 12.04(g)) on such date less an amount equal to the quotient of (x) the excess of such combined amount over such 10% and (y) the number of shares of Common Stock outstanding on the record date, and (ii)
the denominator shall be equal to the current market price on such date, such adjustment to become effective (A) with respect to the 

  

 -59- 

 
Auto-Conversion Price, immediately prior to the opening of business on the day next following the record date fixed for the payment of such distribution, and
(B) with respect to the Threshold Price, immediately prior to the opening of business on the earlier of the day next following the record date fixed for the payment of such distribution or the “ex” date with respect to such distribution;
and 
  
 (iii) when making any calculation of the
simple average of the daily volume-weighted average price, or the simple average of the Closing Price, of the Common Stock, the daily volume-weighted average price or the Closing Price, as applicable, of the Common Stock on each day prior to the
earlier of the record date fixed for the payment of such distribution or the “ex” date with respect to such distribution shall be decreased so that the same shall equal the price determined by multiplying such price by a fraction of which
(i) the numerator shall be the current market price per share (determined as provided in Section 12.04(g)) on such date less an amount equal to the quotient of (x) the excess of such combined amount over such 10% and (y) the number of shares of
Common Stock outstanding on the record date, and (ii) the denominator shall be equal to the current market price on such date. 
  
 (f) In case a successful tender or exchange offer, other than an odd lot offer, made by the Company or any Subsidiary for all or any portion of the Common
Stock shall involve an aggregate consideration having a fair market value (as determined in good faith by the Board of Directors, whose determination shall be conclusive and described in a Board Resolution) at the last time (the “Expiration
Time”) tenders or exchanges may be made pursuant to such tender or exchange offer (as it may be amended) that, together with (i) the aggregate of the cash plus the fair market value (as determined in good faith by the Board of Directors, whose
determination shall be conclusive and described in a Board Resolution), as of the expiration of the tender or exchange offer, of consideration payable in respect of any other tender or exchange offer by the Company or a Subsidiary for all or any
portion of the Common Stock concluded within the preceding 12 months and in respect of which no adjustment to the number of Base Shares payable on a voluntary conversion or Auto-Conversion, the Auto-Conversion Price, the Threshold Price and any
calculation of a simple average of daily volume-weighted average prices, or the simple average of the Closing Price, of a share of Common Stock pursuant to this Section 12.04(f) has been made and (ii) the aggregate amount of any distributions to all
holders of the Common Stock made exclusively in cash within the preceding 12 months and in respect of which no adjustment to the number of Base Shares payable on a voluntary conversion or Auto-Conversion, the Auto-Conversion Price, the Threshold
Price and any calculation of a simple average of daily volume-weighted average prices, or the simple average of the Closing Price, of a share of Common Stock pursuant to Section 12.04(e) has been made, exceeds 10% of the product of the current
market price per share (determined as provided in Section 12.04(g)) of the Common Stock outstanding (including any tendered shares) on the Expiration Time multiplied by the number of shares of Common Stock outstanding (including any tendered shares)
as of the Expiration Time, then, in each case: 
  
 (i) the number of Base Shares payable on a voluntary conversion or Auto-Conversion, shall be increased by multiplying such number in effect immediately prior to the Expiration Time by a fraction of which (i) the denominator shall be (x) the

  

 -60- 

 
product of the current market price per share (determined as provided in Section 12.04(g)) of the Common Stock on the Trading Day next succeeding the
Expiration Time multiplied by the number of shares of Common Stock outstanding (including any tendered or exchanged shares) at the Expiration Time minus (y) the fair market value (determined as aforesaid) of the aggregate consideration payable to
stockholders based on the acceptance (up to any maximum specified in the terms of the tender or exchange offer) of all shares validly tendered or exchanged and not withdrawn as of the Expiration Time (the shares deemed so accepted, up to any such
maximum, being referred to as the “Purchased Shares”) and (ii) the numerator shall be the product of (x) such current market price per share (determined in accordance with Section 12.04(g)) on the Trading Day next succeeding the Expiration
Time multiplied by (y) such number of outstanding shares at the Expiration Time less the number of Purchased Shares, such increase to become effective immediately prior to the opening of business on the earlier of the day following the Expiration
Time or the “ex” date with respect to such tender or exchange; 
  
 (ii) the Auto-Conversion Price and the Threshold Price shall be decreased by multiplying such price by a fraction of which (i) the denominator shall be the product of (x) the current market price per share (determined
in accordance with Section 12.04(g)) on the Trading Day next succeeding the Expiration Time multiplied by (y) such number of outstanding shares at the Expiration Time less the number of Purchased Shares and (ii) the numerator shall be (x) the
product of the current market price per share (determined as provided in Section 12.04(g)) of the Common Stock on the Trading Day next succeeding the Expiration Time multiplied by the number of shares of Common Stock outstanding (including any
tendered or exchanged shares) at the Expiration Time minus (y) the fair market value (determined as aforesaid) of the aggregate consideration payable to stockholders based on the acceptance of the Purchased Shares, such decrease to become effective
(A) with respect to the Auto-Conversion Price, immediately prior to the opening of business on the day following the Expiration Time, and (B) with respect to the Threshold Price, immediately prior to the opening of business on the earlier of the day
following the Expiration Time or the “ex” date with respect to such tender or exchange; and 
  
 (iii) when making any calculation of the simple average of the daily volume-weighted average price, or the simple average of the Closing
Price, of the Common Stock, the daily volume-weighted average price or the Closing Price, as applicable, of the Common Stock on each day prior to the earlier of the Expiration Time or the “ex” date with respect to such tender or exchange
shall be adjusted by multiplying such price by a fraction of which (i) the denominator shall be the product of (x) such current market price per share (determined in accordance with Section 12.04(g)) on the Trading Day next succeeding the Expiration
Time multiplied by (y) such number of outstanding shares at the Expiration Time less the number of Purchased Shares and (ii) the numerator shall be (x) the product of the current market price per share (determined as provided in Section 12.04(g)) of
the Common Stock on the Trading Day next succeeding the Expiration Time multiplied by the number of shares of Common Stock outstanding (including any tendered or exchanged shares) at the Expiration Time minus 

  

 -61- 

 
(y) the fair market value (determined as aforesaid) of the aggregate consideration payable to stockholders based on the acceptance of the Purchased Shares.

  
 (g) For the purpose of any computation under Sections
12.04(c), (d) and (e), the current market price per share of Common Stock on any date in question shall be deemed to be the average of the daily Closing Prices per share of Common Stock for the ten consecutive Trading Days immediately prior to the
date in question; provided, however, that 
  
 (1)
if the “ex” date (as hereinafter defined) for any event (other than the issuance or distribution requiring such computation) that requires an adjustment to the number of Base Shares payable on a voluntary conversion or Auto-Conversion, the
Auto-Conversion Price, the Threshold Price or any calculation of a simple average of daily volume-weighted average prices, or the simple average of the Closing Prices, of a share of Common Stock, as applicable, pursuant to Section 12.04(a), (b),
(c), (d), (e) or (f) (“Other Event”) occurs on or after the tenth Trading Day prior to the date in question and prior to the “ex” date for the issuance or distribution requiring such computation (the “Current Event”),
the Closing Price for each Trading Day prior to the “ex” date for such Other Event shall be adjusted by multiplying such Closing Price by the reciprocal of the fraction by which the number of Base Shares payable on a voluntary conversion
or Auto-Conversion is so required to be adjusted as a result of such Other Event, 
  
 (2) if the “ex” date for any Other Event occurs after the “ex” date for the Current Event and on or prior to the date
in question, the Closing Price for each Trading Day prior to the “ex” date for such Other Event shall be adjusted by multiplying such Closing Price by the fraction by which the number of Base Shares payable on a voluntary conversion or
Auto-Conversion is so required to be adjusted as a result of such Other Event, 
  
 (3) if the “ex” date for any Other Event occurs on the “ex” date for the Current Event, one of those events shall be
deemed for purposes of clauses (1) and (2) of this proviso to have an “ex” date occurring prior to the “ex” date for the Other Event, and 
  

(4) if the “ex” date for the Current Event is on or after the tenth Trading Day prior to the date in question and prior to
the date in question, after taking into account any adjustment required pursuant to clause (2) of this proviso, the Closing Price for each Trading Day on or after such “ex” date shall be adjusted by adding thereto the amount of any cash
and the fair market value on the date in question (as determined in good faith by the Board of Directors in a manner consistent with any determination of such value for purposes of Section 12.04(d) or (e), whose determination shall be conclusive and
described in a Board Resolution) of the portion of the rights, warrants, options, evidences of indebtedness, shares of capital stock, securities, cash or property being distributed applicable to one share of Common Stock. 
  
 For the purpose of any computation under Section 12.04(f), the current market
price per share of Common Stock on any date in question shall be deemed to be the average of the daily Closing Prices for the five consecutive Trading Days selected by the Company commencing on 

  

 -62- 

 
or after the latest (the “Commencement Date”) of (A) the date 20 Trading Days before the date in question, (B) the date of commencement of the
tender or exchange offer requiring such computation and (C) the date of the last amendment, if any, of such tender or exchange offer involving a change in the maximum number of shares for which tenders are sought or a change in the consideration
offered, and ending not later than the Trading Day next succeeding the Expiration Time of such tender or exchange offer (or, if such Expiration Time occurs before the close of trading on a Trading Day, not later than the Trading Day during which the
Expiration Time occurs); provided, however, that if the “ex” date for any Other Event (other than the tender or exchange offer requiring such computation) occurs on or after the Commencement Date and on or prior to the Trading Day next
succeeding the Expiration Time for the tender or exchange offer requiring such computation, the Closing Price for each Trading Day prior to the “ex” date for such Other Event shall be adjusted by multiplying such Closing Price by the
reciprocal of the same fraction by which the number of Base Shares payable on a voluntary conversion or Auto-Conversion is so required to be adjusted as a result of such other event. For purposes of this paragraph, the term “ex” date, (x)
when used with respect to any issuance or distribution, means the first date on which the Common Stock trades regular way on the relevant exchange or in the relevant market from which the Closing Price was obtained without the right to receive such
issuance or distribution, (y) when used with respect to any subdivision or combination of shares of Common Stock, means the first date on which the Common Stock trades regular way on such exchange or in such market after the time at which such
subdivision or combination becomes effective, and (z) when used with respect to any tender or exchange offer means the first date on which the Common Stock trades regular way on such exchange or in such market after the Expiration Time of such
tender or exchange offer. 
  
 (h) In addition to those required by
paragraphs (a), (b), (c), (d), (e) and (f) of this Section 12.04, to the extent permitted by applicable law, the Company from time to time may increase the number of Base Shares and the Plus Cash Amount payable on a voluntary conversion or
Auto-Conversion, as applicable, by any amount for any period of time if the period is at least twenty (20) days and the Board of Directors shall have made a determination that such increase would be in the best interests of the Company, which
determination shall be conclusive. Whenever the number of Base Shares and the Plus Cash Amount payable on a voluntary conversion or Auto-Conversion, as applicable, is increased pursuant to the preceding sentence, the Company shall give notice of the
increase to the Holders of Notes in the manner provided in Section 1.05 at least fifteen (15) days prior to the date the increased number takes effect, and such notice shall state the increased number of Base Shares and the increased Plus Cash
Amount and the period during which it will be in effect. 
  
 (i)
No adjustment in the number of Base Shares payable on a voluntary conversion or Auto-Conversion, the Auto-Conversion Price, the Threshold Price or any calculation of a simple average of daily volume-weighted average prices, or the simple average of
the Closing Prices, of a share of Common Stock shall be required unless such adjustment would require an increase or decrease of at least 1% in such number or price; provided, however, that any adjustments, which by reason of this Section 12.04(i)
are not required to be made, shall be carried forward and taken into account in any subsequent adjustment. 
  
 (j) Each adjustment made pursuant to this Section 12.04 shall be carried forward and taken into account in any subsequent adjustment pursuant to this
Section 12.04. 
  

 -63- 

 (k) In the event that the Company distributes assets, debt securities, rights, warrants or options (other
than those referred to in Section 12.04(c)) pro rata to holders of Common Stock, and the fair market value of the portion of assets, debt securities, rights, warrants or options applicable to one share of Common Stock distributed to holders of
Common Stock exceeds the Average Sale Price (as defined below) per share of Common Stock, or such Average Sale Price exceeds such fair market value by less than $1.00, then so long as any such assets, debt securities, rights, options or warrants
have not expired or been redeemed by the Company, the Company shall make proper provision so that the Holder of any Note upon voluntary conversion or Auto-Conversion, rather than being entitled to an adjustment in the number of Base Shares will be
entitled to receive upon such voluntary conversion or Auto-Conversion, in addition to the Plus Cash Amount and the shares of Common Stock otherwise issuable upon voluntary conversion or Auto-Conversion, the kind and amount of assets, debt
securities, rights, warrants and options such Holder would have received had such Holder converted its Note immediately prior to the date of determination of the holders entitled to such distribution, assuming for such purposes that the Plus Cash
Amount was paid in cash. 
  
 “Average Sale Price” means
the average of the Closing Prices of the Common Stock for the shorter of (i) 30 consecutive Trading Days ending on the last full Trading Day prior to the Time of Determination (as defined below) with respect to the rights, options, warrants or
distribution in respect of which the Average Sale Price is being calculated, or (ii) the period (x) commencing on the date next succeeding the first public announcement of (a) the issuance of rights, options or warrants or (b) the distribution, in
each case, in respect of which the Average Sale Price is being calculated and (y) proceeding through the last full Trading Day prior to the Time of Determination with respect to the rights, options, warrants or distribution in respect of which the
Average Sale Price is being calculated, or (iii) the period, if any, (x) commencing on the date next succeeding the Ex-Dividend Time (as defined below) with respect to the next preceding (a) issuance of rights, warrants or options or (b)
distribution, in each case, for which an adjustment is required by the provisions of Section 12.04(c) or Section 12.04(j) and (y) proceeding through the last full Trading Day prior to the Time of Determination with respect to the rights, options,
warrants, or distribution in respect of which the Average Sale Price is being calculated. If the Ex-Dividend Time (or in the case of a subdivision, combination or reclassification, the effective date with respect thereto) with respect to a dividend,
subdivision, combination or reclassification to which Section 12.04(a), (b) or (c) applies occurs during the period applicable for calculating “Average Sale Price” pursuant to the definition in the preceding sentence, “Average Sale
Price” shall be calculated for such period in a manner determined in good faith by the Board of Directors to reflect the impact of such dividend, subdivision, combination or reclassification on the Closing Price of the Common Stock during such
period. 
  
 “Time of Determination” means the time and
date of the earlier of (i) the determination of stockholders entitled to receive rights, warrants or options or a distribution, in each case, to which this Section 12.04 applies and (ii) the time (“Ex-Dividend Time”) immediately prior to
the commencement of “ex-dividend” trading for such rights, options, warrants or distribution on the New York Stock Exchange or such other national or regional exchange or market on which the shares of Common Stock are listed or quoted.

  

 -64- 

 SECTION 12.05. Notice of Adjustments. Whenever the number of Base Shares payable on a voluntary
conversion or Auto-Conversion, the Auto-Conversion Price, the Threshold Price or any calculation of a simple average of daily volume-weighted average prices, or the simple average of the Closing Prices, of a share of Common Stock is adjusted as
herein provided, the Company shall compute the adjusted number of Base Shares payable on a voluntary conversion or Auto-Conversion, the Auto-Conversion Price, the Threshold Price or calculation of a simple average of daily volume-weighted average
prices of a share of Common Stock in accordance with Section 12.04 and shall prepare a certificate signed by the Chief Financial Officer of the Company setting forth the adjusted number of Base Shares payable on a voluntary conversion or
Auto-Conversion, the Auto-Conversion Price, the Threshold Price or calculation of a simple average of daily volume-weighted average prices, or the simple average of the Closing Prices, of a share of Common Stock and showing in reasonable detail the
facts upon which such adjustment is based, and such certificate shall forthwith be filed (with a copy to the Trustee or the Conversion Agent) at each office or agency maintained for the purpose of conversion of Notes pursuant to Section 9.02; and
the Company shall forthwith cause a notice setting forth the adjusted number of Base Shares payable on a voluntary conversion or Auto-Conversion, the Auto-Conversion Price or the Threshold Price, to be mailed, first class postage prepaid, to each
Holder of Notes at its address appearing on the Note Register. Unless and until the Trustee (and the Conversion Agent, as the case may be) shall receive such notice, the Trustee (and the Conversion Agent, as the case may be) may assume without
inquiry that the number of Base Shares payable on a voluntary conversion or Auto-Conversion, the Auto-Conversion Price, the Threshold Price or any calculation of a simple average of daily volume-weighted average prices, or the simple average of the
Closing Prices, of a share of Common Stock have not been, and are not required to be, adjusted and that the last number of Base Shares payable on a voluntary conversion or Auto-Conversion, the Auto-Conversion Price, the Threshold Price or
calculation of a simple average of daily volume-weighted average prices, or the simple average of the Closing Prices, of a share of Common Stock of which it has written notice remains in effect. 
  
 SECTION 12.06. Notice of Certain Corporate Action. In case:

  
 (a) the Company shall declare a dividend (or any other
distribution) on its Common Stock that would require an adjustment to the number of Base Shares payable on a voluntary conversion or Auto-Conversion, the Auto-Conversion Price, the Threshold Price or any calculation of a simple average of daily
volume-weighted average prices, or the simple average of the Closing Prices, of a share of Common Stock pursuant to Section 12.04(d) or 12.04(e); or 
  
 (b) the Company shall authorize the granting to all holders of its Common Stock of rights, warrants or options to subscribe for or purchase any shares of
capital stock of any class or of any other rights (excluding rights distributed pursuant to any stockholder rights plan); or 
  
 (c) of any reclassification of the Common Stock of the Company (other than a subdivision or combination of its outstanding shares of Common Stock), or of
any consolidation or merger to which the Company is a party and for which approval of any stockholders of the Company is required, or of the sale or transfer of all or substantially all of the assets of the Company; or 
  

 -65- 

 (d) of the voluntary or involuntary dissolution, liquidation or winding up of the Company; or 

 
 (e) the Company or any Subsidiary of the Company shall commence a tender
or exchange offer for all or a portion of the Company’s outstanding shares of Common Stock (or shall amend any such tender or exchange offer); 
  
 then the Company shall cause to be filed at each office or agency maintained for the purpose of conversion of Notes pursuant to Section 9.02, and shall cause to be mailed
to all Holders at their last addresses as they shall appear in the Note Register, at least 20 days (or 10 days in any case specified in clause 12.06(a) or 12.06(b) above) prior to the applicable record, effective or expiration date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution or granting of rights, warrants or options, or, if a record is not to be taken, the date as of which the holders of Common Stock
of record to be entitled to such dividend, distribution, rights, warrants or options are to be determined, or (y) the date on which such reclassification, consolidation, merger, sale, transfer, dissolution, liquidation or winding up is expected to
become effective, and the date as of which it is expected that holders of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation,
merger, sale, transfer, dissolution, liquidation or winding up, or (z) the date on which such tender offer commenced, the date on which such tender offer is scheduled to expire unless extended, the consideration offered and the other material terms
thereof (or the material terms of any amendment thereto). 
  
 SECTION 12.07. Company’s Obligation Regarding Common Stock. The Company shall at all times reserve and keep available, free from preemptive rights, out of its authorized but unissued Common Stock, solely for the purpose of
effecting the conversion of Notes, the whole number of shares of Common Stock then issuable upon the conversion in full of all Outstanding Notes. 
  
 The Company covenants that if any shares of Common Stock to be provided for the purpose of conversion of Notes hereunder require registration with or
approval of any governmental authority under any federal or state law before such shares may be validly issued upon conversion, the Company shall in good faith and as expeditiously as practicable endeavor to secure such registration or approval, as
the case may be. 
  
 The Company further covenants that so long as
the Common Stock shall be listed or quoted on the New York Stock Exchange, the Nasdaq, or any other national securities exchange, the Company shall, if permitted by the rules of such exchange, list and keep listed so long as the Common Stock shall
be so listed on such market or exchange, all Common Stock issuable upon conversion of the Notes. 
  
 SECTION 12.08. Taxes on Conversions. The Company shall pay any and all stamp, documentary or issuance taxes that may be payable in respect of the
issue or delivery of shares of Common Stock on conversion of Notes pursuant hereto, but shall not pay any taxes measured by 

  

 -66- 

 
net income or otherwise imposed on Holders in connection with a conversion. The Company shall not, however, be required to pay any tax that may be payable in
respect of any transfer involved in the issue and delivery of shares of Common Stock in a name other than that of the Holder of the Note or Notes to be converted, and no such issue or delivery shall be made unless and until the Person requesting
such issue has paid to the Company the amount of any such tax, or has established to the satisfaction of the Company that such tax has been paid. 
  
 SECTION 12.09. Covenant as to Common Stock. The Company covenants that all shares of Common Stock that may be issued upon conversion of Notes shall
upon issue be newly issued (and not treasury shares) and shall be duly authorized, validly issued, fully paid and nonassessable and, except as provided in Section 12.08, the Company shall pay all taxes, liens and charges with respect to the issue
thereof. 
  
 SECTION 12.10. Cancellation of Converted
Notes. All Notes delivered for conversion shall be delivered to the Trustee to be cancelled by or at the direction of the Trustee, which shall dispose of the same as provided in Section 3.08. 
  
 SECTION 12.11. Provisions in Case of Reclassification, Consolidation,
Merger or Sale of Assets. In the event that the Company shall be a party to any transaction (including any (i) recapitalization or reclassification of the Common Stock (other than a change in par value, or from par value to no par value, or from
no par value to par value, or as a result of a subdivision or combination of the Common Stock), (ii) any consolidation of the Company with, or merger of the Company into, any other person, any merger of another person into the Company (other than a
merger that does not result in a reclassification, conversion, exchange or cancellation of outstanding shares of Common Stock of the Company), (iii) any sale, lease, transfer, conveyance or other disposition of all or substantially all of the assets
of the Company or (iv) any compulsory share exchange) pursuant to which the Common Stock is converted into the right to receive other securities, cash or other property, then lawful provision shall be made as part of the terms of such transaction to
the Base Shares and Plus Cash Amount payable upon conversion such that the Holder of any Note upon such conversion will receive upon conversion (subject to funds being legally available for such purpose under applicable law at the time of such
conversion) only the kind and amount of securities, cash and other property receivable upon such transaction by a holder of a number of shares of Common Stock equal to the number of Base Shares into which such Note might have been converted
immediately prior to such transaction, together with the Plus Cash Amount. The Company or the Person formed by such consolidation or resulting from such merger or that acquired such assets or that acquired the Company’s shares of Common Stock,
as the case may be, shall execute and deliver to the Trustee a supplemental indenture, satisfactory to the Trustee, establishing such rights. Such supplemental indenture shall provide for adjustments that, for events subsequent to the effective date
of such supplemental indenture, shall be as nearly equivalent as may be practicable to the adjustments provided for in this Article. The above provisions of this Section 12.11 shall similarly apply to successive transactions of the foregoing type.

  

 -67- 

 SECTION 12.12. Auto-Conversion by the Company. 
  
 (a) Subject to the terms and conditions of this Section 12.12, the Company
may elect, at its sole option, to automatically convert (a “Cash Auto-Conversion”) all of the Notes or any portion of the principal amount thereof that is $1,000 or an integral multiple of $1,000, into the Base Shares and Plus Cash Amount
and pay the Plus Cash Amount in cash, at any time prior to Maturity; provided that the Closing Price of the Company’s Common Stock exceeds $5.47 per share (the “Auto-Conversion Price”) for any 20 Trading Days during any consecutive 25
Trading Day period, ending within one Trading Day prior to the date of any Auto-Conversion Notice (as defined below) provided by the Company; and further provided that the Company shall not carry out a Cash Auto-Conversion during any Stock
Substitution Period. 
  
 In the event that the date on which all or any portion of
the Notes are auto-converted (the “Auto-Conversion Date”) occurs prior to September 30, 2005, the Company will also pay or provide for the Make-Whole Payment in cash on the Auto-Conversion Date. 
  
 (b) Unless the Company shall have previously called for redemption all of the
outstanding Notes, the Company or, at the request and expense of the Company, the Trustee, shall give to all Holders of Notes notice (the “Cash Auto-Conversion Notice”) of a Cash Auto-Conversion seven calendar days prior to the
Auto-Conversion Date, provided that if the seventh calendar day is not a Trading Day the Auto-Conversion Date shall be the next Trading Day. The Company shall also deliver a copy of such Cash Auto-Conversion Notice to the Trustee. 
  
 (c) Each Cash Auto-Conversion Notice shall state: 
  
 (i) the Auto-Conversion Date; 
  
 (ii) the place or places where such Notes are to be
surrendered for Cash Auto-Conversion, if any; 
  
 (iii) the number of Base Shares and Plus Cash Amount then in effect; 
  
 (iv) the Make-Whole Payment amount, if any; and 
  
 (v) the CUSIP number of such Notes, if any. 
  
 (d) Subject to the terms and conditions of this Section 12.12, the Company may elect, at its sole option, to automatically convert (a “Stock
Auto-Conversion”) all of the Notes or any portion of the principal amount thereof that is $1,000 or an integral multiple of $1,000, into the Base Shares and the Plus Cash Amount and pay the Plus Cash Amount in Plus Cash Shares. If the Company
so elects to effect a Stock Auto-Conversion, the Company or, at the request and expense of the Company, the Trustee, shall give to all Holders of Notes notice (a “Stock Substitution Notice”) of a Stock Auto-Conversion with a copy of such
Stock Substitution Notice to be filed with the Commission as an exhibit to a current report on Form 8-K. The Stock Substitution Notice must specify: 
  
 (i) a stock price as selected by the Company, which must be equal to or greater than the Auto-Conversion Price (the “Stock
Substitution Reference Price”); 
  

 -68- 

 (ii) the percentage of the principal amount of the outstanding Notes that the Company
must convert if the conditions described in Section 12.12(e) are met; and 
  
 (iii) the CUSIP number of such Notes, if any. 
  
 (e) Beginning on and including the Stock Substitution Period Commencement Date, as defined below, the Company cannot withdraw or modify the Stock Substitution Notice until the Closing Price of the Company’s
shares of Common Stock for any 20 Trading Days during any consecutive 25 Trading Day period is less than the applicable Stock Substitution Reference Price and only as permitted in this Section 12.12. The period during which a Stock Substitution
Notice cannot be withdrawn or modified is the “Stock Substitution Period.” The first Trading Day (after the Company has given a Stock Substitution Notice) on which the Closing Price of the Company’s shares of Common Stock is greater
than the Stock Substitution Reference Price is the “Stock Substitution Period Commencement Date.” 
  
 During any Stock Substitution Period, if the Closing Price of the Company’s shares of Common Stock for any 20 Trading Days during any consecutive 25
Trading Day period exceeds the Stock Substitution Reference Price, which 20 Trading Days are referred to as the “Valuation Days,” the Company must: 
  

(i) convert the percentage specified in the Stock Substitution Notice of the principal amount of the outstanding Notes and each $1,000
principal amount of Notes so converted shall be converted into Base Shares and the Plus Cash Amount (with any remaining amount less than $1,000 paid as specified in Section 12.12(k)) on the Auto-Conversion Date, which date shall be seven calendar
days after the Company issues a Stock Auto-Conversion Notice (as defined below), provided that if the seventh calendar day is not a Trading Day, the Auto-Conversion Date shall be the next Trading Day; 
  
 (ii) pay the aggregate Plus Cash Amount owing pursuant to
clause (i) above in Plus Cash Shares as described in Section 12.12(g); and 
  
 (iii) pay the Make-Whole Payment, if any, in cash. 
  
 (f) No later than the next Trading Day immediately following the 20th Valuation Day, the Company will notify the Holders of the conversion of the Notes into the shares of the Company’s Common Stock and the
substitution of Plus Cash Shares for the Plus Cash Amount (the “Stock Auto-Conversion Notice”). The Stock Auto-Conversion Notice shall state: 
  
 (i) the Auto-Conversion Date selected by the Company pursuant to 12.12(e)(i); 
  
 (ii) the place or places where such Notes are the be
surrendered for Stock Auto-Conversion, if any; 
  
 (iii) the number of Base Shares and Plus Cash Shares then in effect; 
  
 (iv) the Make-Whole Payment amount, if any; and 
  

 -69- 

 (v) the CUSIP number of such Notes, if any. 
  
 (g) If the Company elects to pay all or any part of the Plus Cash Amount in
Plus Cash Shares, the shares to be delivered will be valued at 95% of the simple average of the Closing Price of the Company’s shares of Common Stock for each of the 20 Valuation Days (the “Stock Substitution Price”). 
  
 (h) For the avoidance of doubt, the Company may elect to carryout a Cash
Auto-Conversion at any time after the issuance of a Stock Substitution Notice and prior to the Stock Substitution Period Commencement Date, including with respect to that percentage of Plus Cash Notes referenced in such Stock Substitution Notice.

  
 After the Stock Substitution Period Commencement Date, the
Company shall not withdraw or modify the Stock Substitution Notice until the Closing Price of the Company’s shares of Common Stock for any 20 Trading Days during any consecutive 25 Trading Days is less than the Stock Substitution Reference
Price then in effect. 
  
 Any notice of the Company’s
withdrawal or modification will be effective upon the Company’s filing of such notice with the Trustee, which notification the Company must also file with the Commission by the close of business of the next Business Day as an exhibit to a
current report on Form 8-K. 
  
 (i) Prior to the Stock
Substitution Period Commencement Date, the Company may withdraw or modify the Stock Substitution Notice at any time. 
  
 (j) Except as provided elsewhere in this Section 12.12, in connection with any Auto-Conversion of any Note or portion thereof, that portion of accrued and
unpaid interest, if any, remaining unpaid on such conversion shall not be cancelled, extinguished or forfeited, but rather shall be deemed to be paid in full to the Holder thereof through delivery of the Base Shares, Plus Cash Amount and any
Make-Whole Payment (together with the cash or stock payment, if any, in lieu of fractional shares) in exchange for the Note or portion thereof being Auto-Converted. Except as provided elsewhere in this Section 12.12, no payment or other adjustment
shall be made for interest accrued on any Note or portion thereof Auto-Converted or for dividends on any shares issued upon the Auto-Conversion of such Note or portion thereof as provided in this Article. Notwithstanding the foregoing, the Holder
shall receive the regular interest payment payable to Holders on a regular record date for such interest payment in connection with any Auto-Conversion effected on or after such record date and prior to the interest payment date. 
  
 (k) In the event of any Auto-Conversion, the Company shall issue and deliver
a certificate or certificates for the number of shares of Common Stock issuable upon Auto-Conversion of the Notes along with any cash or stock due in respect of the Plus Cash Amount or any fractional shares of Common Stock otherwise issuable upon
Auto-Conversion as provided in Section 12.03 hereof for issuance and payment to the Holder as promptly after the Auto-Conversion Date as practicable in accordance with the provisions of this Article 12. In the event of a Stock Auto-Conversion,
instead of any fractional share of Common Stock that would 

  

 -70- 

 
otherwise be issuable upon Auto-Conversion of any Note, the Company shall issue an additional whole share in lieu of any such fractional share (determined
with reference to the aggregate principal amount of all of the Notes held by such Holder). 
  
 (l) All Notes subject to any Auto-Conversion shall be delivered to the Trustee to be canceled at the direction of the Trustee, which shall dispose of the same as provided in Section 3.08 hereof. 
  
 (m) Any Auto-Conversion of less than all of the Notes then outstanding will
be made pro rata with reference to the aggregate principal amount of Notes held by each Holder of Notes relative to the aggregate principal amount of Notes held by all Holders of Notes, in each case as of the Auto-Conversion Date. 
  
 (n) Promptly after the Auto-Conversion Date, the Company will provide notice
to all Holders of outstanding Notes stating the aggregate principal amount of Plus Cash Notes that were Auto-Converted and describing the aggregate consideration paid therefore. A copy of that notice will be promptly filed with the Commission as an
exhibit to a current report on Form 8-K. 
  
 (o) If any provision
of this Section 12.12 are inconsistent with applicable law at the time of such Auto-Conversion, such law shall govern. 
  
 SECTION 12.13. Notification to Trustee. If the Company is obligated to pay any Make-Whole Payment upon Auto-Conversion pursuant to Section
12.12(a), it shall deliver to the Trustee a certificate setting forth the amount of interest actually paid or provided for by the Company with respect to the affected Notes prior to the Auto-Conversion Date. Unless and until the Trustee shall
receive such certificate, it shall not be charged with knowledge of the facts required by this Section 12.13 to be set forth therein. In no event will the Trustee be required to inquire into or verify the information required to be set forth in such
certificate, other than the amount of interest actually paid by the Trustee as paying agent with respect to the affected Notes. The Trustee need not inquire into or confirm any amount of interest “provided for” by the Company, unless such
amount has actually been delivered to the Trustee as paying agent and is being held by the Trustee as paying agent pending distribution to the affected holders. 
  

SECTION 12.14. Company’s Obligation. All calculations, adjustments, conversions and other determinations under this Article 12 shall be the
sole responsibility and obligation of the Company. The Trustee (a) shall have no obligation to review, verify, challenge or contest any such calculation, adjustment, conversion or other determination and (b) shall not be liable for any default or
error by the Company under this Article 12. 
  

 -71- 

 IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed all as of
the day and year first above written. 
  

	 TRANSWITCH CORPORATION

		
	 By:
	 	 /s/ Peter J. Tallian

	 Name:
	 	 Peter J. Tallian

	 Title:
	 	 Senior Vice President and Chief Financial Officer

	
	 U.S. BANK NATIONAL
 ASSOCIATION,
 as Trustee

		
	 By:
	 	 /s/ Chi C. Ma

	 Name:
	 	 Chi C. Ma

	 Title:
	 	 Vice President

  
  

 -72- 

 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY,
A NEW YORK CORPORATION (“DTC”), NEW YORK, NEW YORK, TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED
BY AN AUTHORIZED REPRESENTATIVE OF DTC, AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC, ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS
WRONGFUL BECAUSE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 
  
 TRANSFERS OF THIS GLOBAL NOTE SHALL BE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF CEDE & CO. OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S NOMINEE. 
  

 A-1 

 TRANSWITCH CORPORATION 
  
 5.45% CONVERTIBLE PLUS CASH NOTESM DUE 2007 
  

	 No. 1
	 	 	 	$97,963,000

  
 CUSIP NO.
894065 AC5 
  
 TRANSWITCH CORPORATION, a corporation
duly organized and existing under the laws of the State of Delaware (herein called the “Company,” which term includes any successor entity under the Indenture referred to on the reverse hereof), for value received, hereby promises to pay
to Cede & Co., or registered assigns, the principal sum of ninety-seven million nine hundred sixty-three thousand dollars ($97,963,000) at the office or agency of the Company referred to below, on September 30, 2007 in such coin or currency of
the United States of America as at the time of payment shall be legal tender for the payment of public and private debts, and to pay interest on said principal sum semiannually on March 31 and September 30 of each year, commencing March 31, 2004
(each an “Interest Payment Date”) and beginning to accrue as of the date this Note is first issued, at said office or agency, in like coin or currency, at the rate of 5.45% per annum, until the principal hereof is paid or made available
for payment. The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date shall, as provided in such Indenture, be paid to the Person in whose name this Note (or one or more Predecessor Notes) is registered at the
close of business on the Regular Record Date for such interest, which shall be the March 15 or September 15 (whether or not a Business Day), as the case may be, next preceding such Interest Payment Date. Any such interest not so punctually paid or
duly provided for shall forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this Note (or one or more Predecessor Notes) is registered at the close of business on a Special
Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Notes not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not
inconsistent with the requirements of any securities exchange on which the Notes may be listed, and upon such notice as may be required by such exchange, all as more fully provided in said Indenture. 
  
 The Company may elect, solely at the Company’s option, to pay interest
in shares of the Company’s Common Stock, provided however that the Company shall not make any payment of interest in shares of Common Stock unless the daily volume-weighted average price of the Common Stock for the ten (10) Trading Days ending
on and including the second Trading Day immediately preceding the Interest Payment Date equals or exceeds the Threshold Price (as defined in the Indenture) per share of Common Stock. If the Company elects to make any payment of interest in shares of
Common Stock, the shares to be delivered will be valued at 95% of the simple average of the daily volume-weighted average price of the Common Stock for the ten (10) Trading Days ending on and including the second Trading Day immediately preceding
the Interest Payment Date, as described in the Indenture. 
  
 Except as otherwise described in the Indenture, payment of the principal of, premium, if any, and interest on this Note shall be made at the office or agency of the Company maintained 

  

 A-2 

 
for such purpose, which initially shall be the Corporate Trust Office of the Trustee referred to on the reverse side hereof, in such coin or currency of the
United States of America as at the time of payment is legal tender for payment of public and private debts, provided that the Company may make such payment either by (i) mailing a check in the amount of such payment, payable to or upon the written
order of the Person entitled thereto pursuant to Section 3.07 of the Indenture (as defined therein) or (ii) transfer to an account maintained by the payee located inside the United States. 
  
 Reference is hereby made to the further provisions of this Note set forth on
the reverse hereof, which further provisions shall for all purposes have the same effect as if set forth at this place. 
  
 Unless the certificate of authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature, this Note shall
not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 
  

 A-3 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed. 
  

	 DATED:
                    , 2003
	 	 	 	 TRANSWITCH CORPORATION

					
	 	 	 	 	 	 	 By:
	 	  

	 	 	 	 	 	 	 Name:
	 	  

	 	 	 	 	 	 	 Title:
	 	  

	 	 	 	 	 	 	 	 	 
	 Attest:
	 	 	 	 	 	 
	 	 	 	 	 By:
	 	  

	 	 	 	 	 	 	 Name:
	 	  

	 	 	 	 	 	 	 Title:
	 	  

  
 TRUSTEE’S CERTIFICATE OF
AUTHENTICATION 
  
 This is one of the Notes referred to in the
within-mentioned Indenture. 
  

	 DATED:
                    , 2003
	 	 	 	 U.S. BANK NATIONAL ASSOCIATION,
 as Trustee

	 	 	 	 	 
	 	 	 	 	 	 	 By:
	 	  

	 	 	 	 	 	 	 	 	Authorized Signatory

  

 A-4 

 FORM OF REVERSE OF NOTE 
  
 TranSwitch Corporation 
  
 5.45% CONVERTIBLE PLUS CASH NOTESM DUE 2007 
  
 This Note is one of a
duly authorized issue of Notes of the Company designated as its 5.45% Convertible Plus Cash NotesSM due 2007 (herein
called the “Notes”), limited in aggregate original principal amount to $118,143,000 as adjusted from time to time on the books and records of the Trustee, which may be issued under an Indenture, dated as of September 30, 2003 (the
“Indenture”), between the Company and U.S. Bank National Association, as Trustee for the Holders of Notes issued under said Indenture (herein called the “Trustee”, which term includes any successor trustee under the Indenture),
to which Indenture and all indentures supplemental thereto reference is hereby made for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Notes and of the
terms upon which the Notes are, and are to be, authenticated and delivered. 
  
 Subject to and upon compliance with the provisions of the Indenture, the Holder of this Note is entitled, at its option, at any time on or before maturity of the Notes, or in case this Note or a portion hereof is
called for redemption or is the subject of an Auto-Conversion Notice, then in respect of this Note or such portion hereof until and including, but (unless the Company defaults in making the payment due upon redemption, repurchase or auto-conversion)
not after, the close of business on the Business Day immediately preceding the Redemption Date, Repurchase Date or Auto-Conversion Date, as the case may be, to convert this Note (or any portion of the principal amount hereof which is U.S. $1,000 or
an integral multiple thereof), at the principal amount hereof, or of such portion, into (i) that number of fully-paid and non-assessable shares of the Company’s Common Stock as is equal to 182.71 (the “Base Shares”) plus (ii) $500
cash (the “Plus Cash Amount”). 
  
 At the Company’s
sole option, it may pay or provide for the Plus Cash Amount deliverable upon voluntary conversion in shares of Common Stock (the “Plus Cash Shares”); provided, however, that the Company shall not make any payment of the Plus Cash Amount in
Plus Cash Shares unless the daily volume-weighted average price of the Common Stock for the ten (10) Trading Days ending on and including the second Trading Day immediately preceding the Conversion Date (as defined in the Indenture) equals or
exceeds the Threshold Price per share of Common Stock. The Common Stock deliverable upon voluntary conversion (whether in respect of Base Shares or Plus Cash Shares, as applicable) and any cash delivered in respect of the Plus Cash Amount are
hereafter referred to in the aggregate as the “Conversion Consideration.” If the Company elects to pay the Plus Cash Amount in Plus Cash Shares, the Plus Cash Shares will be valued at 95% of the simple average of the daily volume-weighted
average price of the Common Stock for the ten (10) Trading Days ending on and including the second Trading Day immediately preceding the Conversion Date, provided that if the Company has delivered an Auto-Conversion Notice (as defined in the
Indenture) the Plus Cash Shares will be valued in the manner set forth below. The number of Base Shares and any calculation or determination in respect of the simple average of the daily volume-weighted average price of the Common Stock shall be
adjusted as provided for in Article 12 of the Indenture. 
  

 A-5 

 From and after delivery by the Company of any Auto-Conversion Notice with respect to this Note or any
portion of this Note, the Holder shall be entitled to voluntarily convert this Note or any portion of the principal amount hereof until the close of business, New York City time, on the last Business Day prior to the Auto-Conversion Date, provided
that, if in connection with any such voluntary conversion the Company elects to pay the Plus Cash Amount in Plus Cash Shares, the Plus Cash Shares delivered will be valued: 
  
 (1) if the Holder elects to voluntarily convert before the Auto-Conversion Date (as defined below) and the Company has
issued a Stock Auto-Conversion Notice (as defined below), at the Stock Substitution Price (as defined below), provided, however, that the Company may not pay the Plus Cash Amount in Plus Cash Shares unless the daily volume-weighted average price for
the ten (10) Trading Days ending on and including the second Trading Day immediately preceding the Conversion Date equals or exceeds the Threshold Price; 
  
 (2) if the Holder elects to voluntarily convert before the Auto-Conversion Date and the Company has issued a Cash Auto-Conversion Notice (as defined
below), at 95% of the simple average of the daily volume-weighted average price of the Common Stock for the ten (10) Trading Days ending on and including the second Trading Day immediately preceding the Conversion Date, provided, however, that the
Company may not pay the Plus Cash Amount in Plus Cash Shares unless the daily volume-weighted average price for the ten (10) Trading Days ending on and including the second Trading Day immediately preceding the Conversion Date equals or exceeds the
Threshold Price; or 
  
 (3) if the Holder elects to voluntarily
convert after the Auto-Conversion Date, unless and until a subsequent Auto-Conversion Notice, if any, has been delivered, at 95% of the simple average of the daily volume-weighted average price of the Common Stock for the ten (10) Trading Days
ending on and including the second Trading Day immediately preceding the Conversion Date, provided, however, that the Company may not pay the Plus Cash Amount in Plus Cash Shares unless the daily volume-weighted average price for the ten (10)
Trading Days ending on and including the second Trading Day immediately preceding the Conversion Date equals or exceeds the Threshold Price. 
  
 Holders shall receive the Conversion Consideration after surrender of this Note, duly endorsed or assigned to the Company or in blank, to the Company at
its office or agency maintained for such purpose, accompanied by the conversion notice hereon executed by the Holder hereof evidencing such Holder’s election to convert this Note, or if less than the entire principal amount hereof is to be
converted, the portion hereof to be converted, and, in case such surrender shall be made during the period from the close of business on any Regular Record Date to the opening of business on the corresponding Interest Payment Date (unless this Note
or the portion hereof being converted has been called for redemption on a Redemption Date within such period between and including such Regular Record Date and such Interest Payment Date), also accompanied by payment in funds acceptable to the
Company of an amount equal to the interest payable on such Interest Payment Date on the principal amount of this Note then being converted. Subject to the aforesaid requirement for payment of interest and, in the case of a conversion after the close
of business on any Regular Record Date and on or before the 

  

 A-6 

 
corresponding Interest Payment Date, to the right of the Holder of this Note (or any Predecessor Note) of record at such Regular Record Date to receive an
installment of interest (even if the Note has been called for redemption on a Redemption Date within such period), no payment or adjustment is to be made on conversion for interest accrued hereon or for dividends on the Common Stock issued on
conversion. 
  
 No fractions of shares or scrip representing
fractions of shares will be issued on voluntary conversion, but instead of any fractional interest the Company shall pay a cash adjustment or a whole share in lieu of a fractional share (determined with reference to the aggregate principal amount so
surrendered by such Holder) as provided in Article 12 of the Indenture. In addition, the Indenture provides that in case of certain reclassifications, consolidations, mergers, sales or transfers of assets or other transactions pursuant to which the
Common Stock is converted into the right to receive other securities, cash or other property, the conversion privilege shall be appropriately modified. 
  
 The Company may elect, at its sole option, from time to time as provided in the Indenture, to automatically convert (an “Auto-Conversion”) the
Notes or any portion of the principal amount thereof that is $1,000 or an integral multiple of $1,000 into the Base Shares and the Plus Cash Amount, provided that the Closing Price of the Company’s Common Stock exceeds $5.47 per share (the
“Auto-Conversion Price”) for any twenty (20) Trading Days during a any consecutive twenty-five (25) day Trading Day period, ending within one (1) Trading Day prior to the date of any notification for auto-conversion provided by the Company
(the “Auto-Conversion Notice”). In the event that the date on which all or any portion of the Notes will be auto-converted (the “Auto-Conversion Date”) occurs prior to September 30, 2005, the Company will also pay or provide for
the Make-Whole Payment (as defined in the Indenture) on the Auto-Conversion Date. 
  
 If the Company, in respect of an Auto-Conversion, elects to pay all or any part of the Plus Cash Amount in shares of its Common Stock, the Company must first issue a notice stating a stock substitution reference price
(the “Stock Substitution Reference Price”), and if the Closing Price of the Company’s Common Stock is above that price for any twenty (20) Trading Days out of any consecutive twenty-five (25) Trading Day period, then the subject Notes
will be Auto-Converted and the Plus Cash Amount will be paid in shares of Common Stock valued at 95% of the simple average of the Closing Prices for the twenty (20) days that the Closing Price of the Company’s Common Stock exceeded the Stock
Substitution Reference Price, all in accordance with the provisions of Article 12 of the Indenture. 
  
 No fractions of shares or scrip representing fractions of shares will be issued on Auto-Conversion, but instead of any fractional interest the Company
shall pay a cash adjustment or a whole share in lieu of a fractional share (determined with reference to the aggregate principal amount so surrendered by such Holder) as provided in Article 12 of the Indenture. 
  
 The Notes (other than those Notes that have been converted in accordance with
the terms of the Indenture) are subject to redemption at the option of the Company upon not less than 30 days’ or more than 60 days’ notice by mail, as a whole or from time to time in part, at any time after September 30, 2005 at a
redemption price equal to 100% of the principal amount so redeemed 

  

 A-7 

 
together, in the case of any such redemption, with accrued interest to (but excluding) the Redemption Date (subject to the right of holders of record on the
Regular Record Date to receive interest on the related Interest Payment Date). Any redemption of Notes must be in integral multiples of $1,000. If fewer than all of the Notes are to be redeemed, the Trustee shall select the Notes to be redeemed in
principal amounts at maturity of $1,000 or integral multiples thereof by lot, pro rata or by any other method that complies with the requirements of any exchange on which the Notes are listed or quoted and that the Trustee considers fair and
appropriate. If a portion of a Holder’s Notes is selected for partial redemption and that holder converts a portion of those Notes prior to the redemption, the converted portion shall be deemed, solely for purposes of determining the aggregate
principal amount of the Notes to be redeemed by the Company, to be of the portion selected for redemption. 
  
 In certain circumstances involving a Repurchase Event, each Holder shall have the right to require the Company to repurchase all or part of its Notes at a
repurchase price equal to 100% of the principal amount thereof, together with accrued and unpaid interest through the Repurchase Date (subject to the right of holders of record on the Regular Record Date to receive interest on the related Interest
Payment Date). The repurchase price shall be paid in cash. 
  
 The
Notes do not have the benefit of any sinking fund. 
  
 In the
event of redemption, conversion or repurchase of this Note in part only, a new Note or Notes for the unredeemed, unconverted or unrepurchased portion hereof shall be issued in the name of the Holder hereof upon the cancellation hereof. 

 
 If an Event of Default shall occur and be continuing, the principal of all
the Notes may be declared due and payable in the manner and with the effect provided in Article 4 of the Indenture. 
  
 The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the
Company and the rights of the Holders of the Notes under the Indenture at any time by the Company and the Trustee with (or, in the limited circumstances set forth in the Indenture, without) the consent of the Holders of a majority in aggregate
principal amount of the Notes at the time Outstanding. The Indenture also contains provisions permitting the Holders of a majority in aggregate principal amount of the Notes at the time Outstanding, on behalf of the Holders of all the Notes, to
waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Note shall be conclusive and binding upon such Holder and
upon all future Holders of this Note and of any Note issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Note. 
  
 No reference herein to the Indenture and no provision of this Note or of the
Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of, premium, if any, and interest on this Note at the times, place and rate, and in the coin or currency, herein prescribed or
to convert this Note as provided in the Indenture. 
  

 A-8 

 As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this
Note is registrable in the Note Register, upon surrender of this Note for registration of transfer at the Corporate Trust Office duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Note
Registrar duly executed by, the Holder hereof or his attorney duly authorized in writing, and thereupon one or more new Notes, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or
transferees. 
  
 The Notes are issuable only in registered form
without coupons in denominations of $1,000 and any integral multiple thereof. 
  
 No service charge shall be made to a Holder for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in
connection therewith. 
  
 Prior to due presentment of this Note
for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Note is registered as the owner hereof for all purposes and neither the Company, the Trustee nor any such
agent shall be affected by notice to the contrary. 
  
 Interest on
this Note will accrue from the most recent date to which interest has been paid, or if no interest has been paid, from September 30, 2003. Interest shall be computed on the basis of a 360-day year of twelve 30-day months. In the event that any date
on which interest is payable on the Notes is not a Business Day, then payment of interest payable on such date will be made on the next succeeding day which is a Business Day (and without any interest or other payment in respect of any such delay).

  
 All terms used in this Note which are defined in the Indenture
shall have the meanings assigned to them in the Indenture. 
  
 THE INDENTURE AND THIS NOTE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES. 
  

 A-9 

 FORM OF TRANSFER NOTICE 
  

FOR VALUE RECEIVED, the undersigned registered holder hereby sell(s), assign(s) and transfer(s) unto 
  
 Insert Taxpayer Identification No. 
  
 ______________________________________________________________________________________________ 
 Please print or typewrite name and address
including zip code of assignee 
  
 ______________________________________________________________________________________________ 
 the within Note and all rights thereunder, hereby
irrevocably constituting and appointing __________________________________________ attorney to transfer said Note on the books of the Company with full power of substitution in the premises. 
  
  

 A-10 

 CONVERSION NOTICE 
  
 To: TRANSWITCH CORPORATION 
  
 The undersigned Holder of this Note hereby irrevocably exercises the option to convert this Note, or the portion hereof (which is $1,000 or an integral
multiple thereof) below designated, at any time following the date of original issuance thereof, into shares of Common Stock plus cash in accordance with the terms of the Indenture referred to in this Note, and directs that the shares issuable and
deliverable upon conversion, together with any check in payment for a fractional share and/or the plus cash amount, as applicable, and any Note representing any unconverted principal amount hereof, be issued and delivered to the registered owner
hereof unless a different name has been provided below. If shares or any portion of this Note not converted are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto
and is delivering herewith a certificate in proper form certifying that the applicable restrictions on transfer have been complied with. Any amount required to be paid by the undersigned on account of interest accompanies this Note. 
  

	 Dated:
	 	 By:
	  	  

  

	 	 	 Signature of Registered Holder*

		
	If shares or Notes are to be registered in the name of a Person other than the Holder, please print such Person’s name and address:	 	 Principal amount to be converted
 (if less
than all): $___,000

  

	  

	 Name

	  

	 Social Security or Taxpayer Identification Number

	  

	 Street Address

	  

	 City, State and Zip Code

	*	Signature(s) must be guaranteed by an eligible guarantor institution (banks, stock brokers, savings and loan associations and credit unions with membership in an approved signature
guarantee medallion program) pursuant to Securities and Exchange Commission Rule 17Ad-15 if shares of Common Stock are to be delivered, or unconverted Notes are to be issued, other than to and in the name of the registered owner.

  
  

 1 

 ELECTION OF HOLDER TO REQUIRE REPURCHASE 
  
 (1) Pursuant to Article 11 of the Indenture, the undersigned hereby elects to
have this Note repurchased by the Company. 
  
 (2) The undersigned
hereby directs the Trustee or the Company to pay it or                      an amount in cash equal to 100% of the principal amount to be
repurchased (as set forth below), plus interest accrued to the Repurchase Date, as provided in the Indenture. 
  
 Dated: 
  

	  

	  

	 Signature(s)

  
 Signature(s) must be guaranteed by an
Eligible Guarantor Institution with membership in an approved signature guarantee program pursuant to Rule 17Ad-15 under the Securities Exchange Act of 1934. 
  

	  

	 Signature Guaranteed

	
	 Principal amount to be
 repurchased (at
least U.S.
 $1,000 or an integral
 multiple of $1,000

in excess thereof):             

	  

	
	 Remaining principal
 amount following such
 repurchase (not less than
 U.S. $1,000):

	  

  
 NOTICE: The signature to the
foregoing Election must correspond to the Name as written upon the face of this Note in every particular, without alteration or any change whatsoever.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}]]